|
|
|
Bladder Cancer, January 2025
Retrieve all available abstracts of the following 2207 articles:
|
| Single Articles |
AMEDEO Bladder Cancer is free of charge.
A foundation model with weak experiential guidance in detecting muscle invasive
bladder cancer on MRI.
Cancer Lett. 2025 Jan 2:217438. doi: 10.1016/j.canlet.2025.217438.
Abstract
Combined molecular subclass and immune phenotype correlate to atezolizumab plus
radiation therapy response in invasive bladder cancer: BPT-ART Phase II study.
Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03774.
Abstract
Neutrophils to lymphocytes ratio as a predictor of BCG response in non-muscle
invasive bladder cancer.
Urologia. 2025 Jan 3:3915603241308974. doi: 10.1177/03915603241308974.
Abstract
Comprehensive genomic characterization of early-stage bladder cancer.
Nat Genet. 2025 Jan 3. doi: 10.1038/s41588-024-02030.
Abstract
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a
biomarker of response to BCG.
World J Urol. 2025;43:57.
Abstract
Tumor-colonizing Lachnoclostridium-mediated chemokine expression enhances the
immune infiltration of bladder urothelial carcinoma.
Cancer Immunol Immunother. 2025;74:62.
Abstract
Exploration and validation of a novel reactive oxygen species-related signature
for predicting the prognosis and chemotherapy response of patients with bladder
cancer.
Front Immunol. 2024;15:1493528.
Abstract
Initial experience of 980-nm diode laser treatment for recurrent
non-muscle-invasive bladder cancer.
IJU Case Rep. 2024;8:41-43.
Abstract
Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive
bladder cancer: impact on surgical complications and oncological efficacy.
Acta Oncol. 2025;64:13-21.
Abstract
Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers
for neoadjuvant chemotherapy response in muscle-invasive bladder cancer.
BMC Med Imaging. 2025;25:3.
Abstract
Diagnostic value of dual-layer spectral detector CT parameters for
differentiating high- from low-grade bladder cancer.
Insights Imaging. 2025;16:6.
Abstract
Multiparametric MRI and artificial intelligence in predicting and monitoring
treatment response in bladder cancer.
Insights Imaging. 2025;16:7.
Abstract
Prognostic and clinicopathological value of C-reactive protein in patients with
bladder cancer: a meta-analysis.
Ann Med. 2025;57:2445781.
Abstract
A comprehensive analysis-based study of Di-(2-ethylhexyl) phthalate
(DEHP)-Environmental explanation of bladder cancer progression.
Environ Pollut. 2024;367:125625.
Abstract
Ionizing radiation and photodynamic therapy led to multimodal tumor cell death,
synergistic cytotoxicity and immune cell invasion in human bladder cancer
organoids.
Photodiagnosis Photodyn Ther. 2024 Dec 31:104459.
Abstract
Stage at diagnosis and cancer-specific survival for stomach, lung, colorectal,
and bladder cancers among Armenians in California.
Prev Med. 2024 Dec 31:108214. doi: 10.1016/j.ypmed.2024.108214.
Abstract
Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican
Centers: The ALEBRIJE Study.
JCO Glob Oncol. 2025;11:e2400431.
Abstract
Exploring the potential of the combined diagnostic model of ADC value and bp-MRI
VI-RADS in the evaluation of muscle invasion in bladder Cancer.
Abdom Radiol (NY). 2025 Jan 2. doi: 10.1007/s00261-024-04788.
Abstract
Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with
a high tumor proportion score: a case report.
Front Immunol. 2024;15:1485744.
Abstract
Prognostic Significance of CCDC8 in Bladder Cancer: Insights from Bioinformatics
and Immunohistochemical Analysis.
J Cancer. 2025;16:382-397.
Abstract
Ultrasound irradiation in the presence of microbubbles may enhance the antitumor
effect of chemotherapeutic agents against bladder cancer.
J Cancer. 2025;16:368-381.
Abstract
HPV-Associated Gene Signatures in Bladder Cancer: A Comprehensive Prognostic
Model and its Implications in Immunotherapy.
Int J Med Sci. 2025;22:140-157.
Abstract
Stromal immune cells expression of Siglec-15 is associated with lower T stage and
better prognosis of urinary bladder cancer.
Front Oncol. 2024;14:1437006.
Abstract
Identification and validation of the nicotine metabolism-related signature of
bladder cancer by bioinformatics and machine learning.
Front Immunol. 2024;15:1465638.
Abstract
YWHAG promotes bladder cancer metastasis by regulating TMOD3 to activate ERK1/2
and JNK phosphorylation in the MAPK pathway.
J Transl Med. 2024;22:1159.
Abstract
Programmed cell death 1 inhibitor alone or combined with chemotherapy for
patients with locally advanced or metastatic urothelial carcinoma: a
single-center experience.
BMC Urol. 2024;24:289.
Abstract
Anesthetic approaches and 2-year recurrence rates in non-muscle invasive bladder
cancer: a randomized clinical trial.
Reg Anesth Pain Med. 2024 Dec 31:rapm-2024-105949. doi: 10.1136/rapm-2024-105949
Abstract
Tertiary Lymphoid Structures are Linked to Enhanced Antitumor Immunity and Better
Prognosis in Muscle-Invasive Bladder Cancer.
Adv Sci (Weinh). 2024 Dec 30:e2410998. doi: 10.1002/advs.202410998.
Abstract
Causes and Consequences of Delayed Presentation of Muscle Invasive Urinary
Bladder Carcinoma.
Mymensingh Med J. 2025;34:98-105.
Abstract
Identifying optimal candidates for active surveillance in low-grade
intermediate-risk non-muscle invasive bladder cancer.
World J Urol. 2024;43:52.
Abstract
Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder
cancer treated with neoadjuvant chemotherapy: a prospective validation study.
Eur Radiol. 2024 Dec 31. doi: 10.1007/s00330-024-11327.
Abstract
AI allows pre-screening of FGFR3 mutational status using routine histology slides
of muscle-invasive bladder cancer.
Nat Commun. 2024;15:10914.
Abstract
RNA-seq profiling identified a three-lncRNA panel in serum as potential biomarker
for muscle-invasive bladder cancer.
Front Oncol. 2024;14:1451009.
Abstract
Case report: Long-term response to a combination of immune checkpoint inhibitors
as a single treatment for multiple synchronous cancers: a case study.
Front Immunol. 2024;15:1487227.
Abstract
Prognostic value of the triglyceride-glucose index in non-muscle-invasive bladder
cancer: a retrospective study.
Front Nutr. 2024;11:1472104.
Abstract
Predicting distant metastasis of bladder cancer using multiple machine learning
models: a study based on the SEER database with external validation.
Front Oncol. 2024;14:1477166.
Abstract
Improved epirubicin delivery selectivity to bladder cancer achieved by
functionalized hydroxyethyl starch-based prodrug.
Int J Biol Macromol. 2024;293:139275.
Abstract
circICMT upregulates and suppresses the malignant behavior of bladder cancer.
Transl Oncol. 2024;52:102262.
Abstract
RUNX2 enhances bladder cancer progression by promoting glutamine metabolism.
Neoplasia. 2024;60:101120.
Abstract
NSUN2-Mediated R-loop Stabilization as a Key Driver of Bladder Cancer Progression
and Cisplatin Sensitivity.
Cancer Lett. 2024 Dec 26:217416. doi: 10.1016/j.canlet.2024.217416.
Abstract
Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive
Bladder Cancer Prognosis.
Clin Genitourin Cancer. 2024;23:102286.
Abstract
Corrigendum to "p85alpha Inactivates MMP-2 and Suppresses Bladder Cancer Invasion by
Inhibiting MMP-14 Transcription and TIMP-2 Degradation" [Neoplasia (2019) 21,
908-920].
Neoplasia. 2024;60:101095.
Abstract
Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen
receptor binding in bladder cancer oncogenesis.
Clin Transl Med. 2025;15:e70153.
Abstract
Allelic variants in xenobiotic metabolism genes predict susceptibility and worse
prognosis of urothelial bladder cancer.
Pathol Res Pract. 2024;266:155767.
Abstract
A pilot study of the value of micronucleus count in urinary cytology samples in
the follow-up of patients with urothelial carcinoma: Implications for diagnosis
and prognosis.
Cancer Cytopathol. 2025;133:e22923.
Abstract
A review of the performance of urinary cytology with a focus on atypia, upper
tract and updates on novel ancillary testing.
J Am Soc Cytopathol. 2025;14:23-35.
Abstract
Case Series of Thermal Cautery Artifact in Urine Cytology: An Uncommon Finding
but a Potential Pitfall.
Diagn Cytopathol. 2025;53:72-75.
Abstract
A Comparative Study of the Paris System and Common Reporting System for Urine
Cytology With Cyto-Histology Correlation: A Study of 829 Urine Cytology
Specimens.
Diagn Cytopathol. 2025;53:51-57.
Abstract
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial
Carcinoma.
N Engl J Med. 2025;392:45-55.
Abstract
Suppressing the progression of bladder cancer using cyclovirobuxine D based on
network pharmacology and bioinformatics approaches.
Naunyn Schmiedebergs Arch Pharmacol. 2025.
Abstract
Training the synergy between Bacillus Calmette-Guerin and immune
checkpoint-blocking antibodies in bladder cancer.
Cancer Commun (Lond). 2025 Jan 10. doi: 10.1002/cac2.12647.
Abstract
Point-Based Prediction Model for Bladder Cancer Risk in Diabetes: A Random
Survival Forest-Guided Approach.
J Clin Med. 2024;14:4.
Abstract
Artificial Intelligence-Based Classification and Segmentation of Bladder Cancer
in Cystoscope Images.
Cancers (Basel). 2024;17:57.
Abstract
CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer.
Diagnostics (Basel). 2024;15:59.
Abstract
SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis
and pentose phosphate pathway.
Commun Biol. 2025;8:36.
Abstract
Deep learning-based lymph node metastasis status predicts prognosis from
muscle-invasive bladder cancer histopathology.
World J Urol. 2025;43:65.
Abstract
Detection of Human Bladder Epithelial Cancerous Cells with Atomic Force
Microscopy and Machine Learning.
Cells. 2024;14:14.
Abstract
Successful Treatment of Non-invasive Bladder Cancer During Pregnancy: Diagnostic
and Management Challenges.
Cureus. 2024;16:e75417.
Abstract
Construction and validation of prognosis and treatment outcome models based on
plasma membrane tension characteristics in bladder cancer.
PeerJ. 2025;13:e18816.
Abstract
Transcriptome-wide association study identifies genes associated with bladder
cancer risk.
Sci Rep. 2025;15:1390.
Abstract
Environmental Exposures and Canine Bladder Cancer: A Case Control Study Using
Silicone Passive Samplers.
Environ Sci Technol. 2025 Jan 9. doi: 10.1021/acs.est.4c09271.
Abstract
Short-term outcomes after robot-assisted versus open radical cystectomy for
bladder cancer in patients with diabetes mellitus: an analysis of the United
States Nationwide Inpatient Sample of 2005-2018.
Int J Med Sci. 2025;22:409-416.
Abstract
FKBP10 Promotes the Muscle Invasion of Bladder Cancer via Lamin A Dysregulation.
Int J Biol Sci. 2025;21:758-771.
Abstract
Integrating gene therapy into the treatment paradigm for non-muscle invasive
bladder cancer.
Expert Opin Biol Ther. 2025 Jan 9:1-11. doi: 10.1080/14712598.2024.2445674.
Abstract
The Role of SWI/SNF Complex in Bladder Cancer.
J Cell Mol Med. 2025;29:e70348.
Abstract
Do the inflammatory markers have a prognostic role in an elderly patient
population diagnosed with non-muscle invasive bladder cancer?
Cir Cir. 2025 Jan 8. doi: 10.24875/CIRU.23000278.
Abstract
Panel containing three serum microRNAs: a promising biomarker for early detection
of bladder cancer.
Front Oncol. 2024;14:1470457.
Abstract
Prognostic value and immune landscapes of disulfidptosis?related lncRNAs in
bladder cancer.
Mol Clin Oncol. 2024;22:19.
Abstract
Efficacy and safety of office-based diode laser ablation for recurrent low-grade
non-muscle-invasive bladder cancer under local anaesthesia: A pilot study.
Arab J Urol. 2024;23:70-74.
Abstract
Impact of late effects after treatment for bladder cancer with radical cystectomy
on Quality of life: a case-control study.
Acta Oncol. 2025;64:27-33.
Abstract
A nomogram for predicting lymph node metastases in nonmetastatic muscle-invasive
bladder cancer: a SEER-based investigation.
Int J Surg. 2025 Jan 8. doi: 10.1097/JS9.0000000000002222.
Abstract
AL16431.1 is identified as a biomarker for bladder cancer progression and
immunotherapy response.
Sci Rep. 2025;15:1170.
Abstract
Sex differences in the risk of bladder cancer among kidney transplant recipients
and patients with kidney failure receiving hemodialysis: a nationwide cohort
study.
Am J Nephrol. 2025 Jan 7:1-16. doi: 10.1159/000543298.
Abstract
New Challenges in Bladder Cancer Diagnosis: How Biosensing Tools Can Lead to
Population Screening Opportunities.
Sensors (Basel). 2024;24:7873.
Abstract
Correction: Hong et al. Anti-Proliferative and Pro-Apoptotic Effects of
Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human
Bladder Cancer Cells. Int. J. Mol. Sci. 2019, 20, 3820.
Int J Mol Sci. 2024;25:13595.
Abstract
Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report.
Int J Mol Sci. 2024;25:13315.
Abstract
Loss of Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Tumor
Microenvironment and Response to BCG Immunotherapy in a Murine Orthotopic Model
of Bladder Cancer.
Int J Mol Sci. 2024;25:13296.
Abstract
Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio
on Survival in Patients with Metastatic Bladder Carcinoma Treated with
Immunotherapy.
Medicina (Kaunas). 2024;60:2103.
Abstract
Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation
Sequencing-Preliminary Data.
J Clin Med. 2024;13:7701.
Abstract
Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A
Study from a Single Institution.
Life (Basel). 2024;14:1670.
Abstract
Microsatellite Instability in Urine: Breakthrough Method for Bladder Cancer
Identification.
Biomedicines. 2024;12:2726.
Abstract
The Potential for Lifestyle Intervention Among Patients Undergoing Transurethral
Resection of Bladder Tumour Based on Patient Needs Including Smoking and Other
Risky Lifestyle Factors: A Cross-Sectional Study.
Int J Environ Res Public Health. 2024;21:1633.
Abstract
Gasdermin D (GSDM D) as a Potential Diagnostic Biomarker in Bladder Cancer: New
Perspectives in Detection.
Cancers (Basel). 2024;16:4213.
Abstract
Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and
Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer:
Updated Systematic Review and Meta-Analysis.
Cancers (Basel). 2024;16:4125.
Abstract
Hedyotis diffusa injection modulates the ferroptosis in bladder cancer via
CAV1/JUN/VEGFA.
Int Immunopharmacol. 2025;147:113925.
Abstract
Beta-human chorionic gonadotropin, carbohydrate antigen 19-9, cancer antigen 125,
and carcinoembryonic antigen as prognostic and predictive biological markers in
bladder cancer.
Front Oncol. 2024;14:1479988.
Abstract
Perivascular Epithelioid-Cell Tumour of the Bladder: A Case Report.
Arch Esp Urol. 2024;77:1211-1215.
Abstract
[Efficacy and Adverse Events of Low-Dose Intravesical BCG Therapy for
Non-Muscle-Invasive Bladder Cancer].
Hinyokika Kiyo. 2024;70:445-450.
Abstract
The N(1)-methyladenosine methyltransferase TRMT61A promotes bladder cancer
progression and is targetable by small molecule compounds.
Clin Transl Med. 2025;15:e70137.
Abstract
[Detection and interpretation of PD-L1 in urologic neoplasms].
Zhonghua Bing Li Xue Za Zhi. 2025;54:11-15.
Abstract
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients
with urothelial carcinoma with MDM2 amplification or overexpression.
J Immunother Cancer. 2025;13:e010964.
Abstract
Unveiling ADAMTS12: A Key Driver of Bladder Cancer Progression via
COL3A1-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway.
J Biol Chem. 2025 Jan 4:108155. doi: 10.1016/j.jbc.2025.108155.
Abstract
Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma.
J Am Anim Hosp Assoc. 2025;61:12-14.
Abstract
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive
Biomarker in Advanced Urothelial Cancer.
JCO Precis Oncol. 2025;9:e2400472.
Abstract
Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle
Invasive Bladder Cancer.
Curr Urol Rep. 2025;26:24.
Abstract
Spatially-resolved analyses of muscle invasive bladder cancer microenvironment
unveil a distinct fibroblast cluster associated with prognosis.
Front Immunol. 2024;15:1522582.
Abstract
Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention.
Cancer Prev Res (Phila). 2025;18:7-9.
Abstract
Development of point-of-care tests for urinary bladder cancer - an historic
review and view to future prospectives.
Urol Oncol. 2025 Jan 4:S1078-1439(24)01043-3. doi: 10.1016/j.urolonc.2024.
Abstract
Anticancer potentialsof chaga and notoginseng against dog bladder cancer
organoids.
J Vet Med Sci. 2025 Jan 3. doi: 10.1292/jvms.24-0258.
Abstract
Inhibition of SIRT4 promotes bladder cancer progression and immune escape via
attenuating CD8(+) T cells function.
Int Immunopharmacol. 2025;147:113906.
Abstract
Electrical impedance-based tissue classification for bladder tumor
differentiation.
Sci Rep. 2025;15:825.
Abstract
Preferred labels and language to improve communication about lesions at low risk
of progressing to cancer: qualitative interviews with patients and physicians.
BMJ Open. 2025;15:e087484.
Abstract
Genetic polymorphisms, methylation, and expression levels in the GSTP1 and MGMT
genes in urothelial bladder tumors.
Gene. 2025;939:149158.
Abstract
Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR)
tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma.
Pharmacol Res. 2025;211:107543.
Abstract
TE-RPA: One-tube telomerase extension recombinase polymerase amplification-based
electrochemical biosensor for precise diagnosis of urothelial carcinoma.
Biosens Bioelectron. 2025;271:117042.
Abstract
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of
anti-PD-L1 plus mTOR inhibitors.
Mol Oncol. 2025;19:151-172.
Abstract
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic
Urothelial Carcinoma: An Application of Multidimensional Thresholding.
Patient. 2025;18:77-87.
Abstract
Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence.
Nat Rev Urol. 2025;22:46-54.
Abstract
SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor
activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid
synthase.
Lipids Health Dis. 2025;24:14.
Abstract
Non-thermal plasma as promising anti-cancer therapy against bladder cancer by
inducing DNA damage and cell cycle arrest.
Sci Rep. 2025;15:2334.
Abstract
The incidence and risk factor for febrile urinary tract infection after
robot-assisted laparoscopic radical cystectomy in bladder cancer patients.
J Infect Chemother. 2025 Jan 15:102624. doi: 10.1016/j.jiac.2025.102624.
Abstract
Non-coding RNAs in urinary bladder cancer microenvironment: Diagnostic,
therapeutic, and prognostic perspective.
Pathol Res Pract. 2025;266:155815.
Abstract
Circ-ITCH inhibits bladder cancer progression through miR-184/FOXO3 axis.
Am J Transl Res. 2024;16:7911-7923.
Abstract
Robotic Laparoscopy and Endoscopy Cooperative Surgery for Primary Appendiceal
Mucinous Carcinoma Masquerading as Bladder Cancer: A Case Report.
Asian J Endosc Surg. 2025;18:e70021.
Abstract
Circ-NMNAT1 Drives Tumor Progression in Bladder Cancer by Modulating the
miR-370-3p/ATXN2L Axis.
Appl Biochem Biotechnol. 2025 Jan 16. doi: 10.1007/s12010-024-05162.
Abstract
A multicenter study of perioperative and functional outcomes of open vs. robot
assisted uretero-enteric reimplantation after radical cystectomy.
World J Urol. 2025;43:74.
Abstract
Matrix Metalloproteinase-9 is associated with tumor microenvironment remodeling
of bladder cancer.
Biol Direct. 2025;20:8.
Abstract
Development of TAR-200: A novel targeted releasing system designed to provide
sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol. 2025 Jan 15:S1078-1439(24)01044.
Abstract
Comprehensive Genetic Profile of Chinese Muscle-Invasive Bladder Cancer Cohort.
Clin Genitourin Cancer. 2024;23:102280.
Abstract
Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive
different survival benefit from platinum chemotherapy.
J Pathol Clin Res. 2025;11:e70017.
Abstract
Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and
prognosis of bladder cancer.
Theranostics. 2025;15:1272-1284.
Abstract
Validation of clinical T stages and of prognostic negative markers in patients
with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer
Registry vs. data from a detailed research database.
Transl Androl Urol. 2024;13:2757-2770.
Abstract
Construction of a disulfidptosis-associated lncRNA signature to predict prognosis
in bladder cancer.
Transl Androl Urol. 2024;13:2705-2723.
Abstract
Long non-coding RNAs as prognostic biomarkers in non-muscle invasive bladder
cancer: A systematic review.
Narra J. 2024;4:e1233.
Abstract
Diagnostic accuracy of urinary cytokeratin fragment-19 (CYFRA21-1) for bladder
cancer.
Narra J. 2024;4:e1142.
Abstract
Neuroendocrine tumour of the urinary bladder.
BMJ Case Rep. 2025;18:e263265.
Abstract
Molecular profiling of bladder cancer xenografts defines relevant molecular
subtypes and provides a resource for biomarker discovery.
Transl Oncol. 2025;52:102269.
Abstract
Clinical outcome of BCG treatment for patients with urothelial carcinoma of the
prostatic urethra: Implications for early cystectomy.
World J Urol. 2025;43:71.
Abstract
PIN1 prolyl isomerase promotes initiation and progression of bladder cancer
through the SREBP2-mediated cholesterol biosynthesis pathway.
Cancer Discov. 2025 Jan 14. doi: 10.1158/2159-8290.CD-24-0866.
Abstract
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes
KMT2A-menin to bivalent promoters.
Nat Genet. 2025;57:165-179.
Abstract
The MCM6-c-Myc positive feedback loop mediates bladder cancer progression and
cisplatin resistance.
Int J Biol Macromol. 2025;296:139777.
Abstract
Comparative evaluation of PD-L1 expression and tumor immune microenvironment in
molecular subtypes of muscle-invasive bladder cancer and its correlation with
survival outcomes.
Am J Clin Pathol. 2025 Jan 13:aqae176. doi: 10.1093.
Abstract
Study of urine-based mRNA biomarkers for early detection of nonmuscle invasive
bladder cancer (NMIBC).
Urol Oncol. 2025 Jan 11:S1078-1439(24)01050.
Abstract
[Impacts of curcumin on proliferation, migration and cisplatin resistance of
bladder cancer cells by regulating LKB1-AMPK-LC3 signaling pathway].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2025;41:9-16.
Abstract
Research progress of near-infrared fluorescence imaging in accurate theranostics
in bladder cancer.
Photodiagnosis Photodyn Ther. 2025 Jan 9:104480.
Abstract
Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging
After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for
Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024;23:102290.
Abstract
[Enfortumab vedotin and pembrolizumab : Management of side effects during first
line combined treatment for advanced or metastatic urothelial carcinoma].
Urologie. 2025;64:60-74.
Abstract
Differential Diagnosis of Urinary Cancers by Surface-Enhanced Raman Spectroscopy
and Machine Learning.
Anal Chem. 2025;97:27-32.
Abstract
Membrane palmitoylated protein MPP1 inhibits immune escape by regulating the
USP12/ CCL5 axis in urothelial carcinoma.
Int Immunopharmacol. 2025;146:113802.
Abstract
Upper Extremity Mass as First Presentation of Metastatic Urothelial Carcinoma.
Orthopedics. 2025;48:e52-e55.
Abstract
Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in
Metastatic Urothelial Carcinoma.
Oncology. 2025;103:11-21.
Abstract
Extracellular vesicles-a new player in the development of urinary bladder cancer.
Ther Adv Med Oncol. 2025;17:17588359241297529.
Abstract
Incidence and Outcomes of Secondary Bladder Cancer Following Radiation Therapy
for Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2025 Jan 22:S2405-4569(24)00262.
Abstract
Roadmap for the transition to robotic radial cystectomy for patients with bladder
cancer in a tertiary urology unit: planning for change.
BMJ Lead. 2025 Jan 22:leader-2024-001044. doi: 10.1136/leader-2024-001044.
Abstract
Association of Prehabilitation in the Precystectomy Pathway in Patients With
Bladder Cancer on Postoperative Outcomes.
Clin Genitourin Cancer. 2024;23:102297.
Abstract
Interaction between opium use and cigarette smoking on bladder cancer: An inverse
probability weighting approach based on a multicenter case-control study in Iran.
Glob Epidemiol. 2024;9:100182.
Abstract
Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A
Prospective, Single-centre Trial.
Eur Urol Open Sci. 2024;71:172-179.
Abstract
Bacillus Calmette-Guerin (BCG) infections following intravesical BCG
immunotherapy: a systematic review protocol.
Syst Rev. 2025;14:21.
Abstract
Ethnicity and race as modifiers of the association between patient sex and stage
at diagnosis of bladder cancer.
Cancer Epidemiol. 2025;95:102749.
Abstract
Combining a Risk Factor Score Designed From Electronic Health Records With a
Digital Cytology Image Scoring System to Improve Bladder Cancer Detection:
Proof-of-Concept Study.
J Med Internet Res. 2025;27:e56946.
Abstract
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential
Censoring.
JAMA Netw Open. 2025;8:e2455630.
Abstract
The combination treatment of RC48 and STAT3 inhibitor acts as a promising
therapeutic strategy for basal bladder cancer.
Front Immunol. 2025;15:1432586.
Abstract
AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review
with study strengths and weaknesses.
Front Oncol. 2025;14:1509362.
Abstract
Impact of race-based calculations of eGFR on the management of muscle invasive
bladder cancer.
Am J Clin Exp Urol. 2024;12:389-398.
Abstract
A novel therapeutic strategy utilizing EpCAM aptamer-conjugated gemcitabine for
targeting bladder cancer and cancer stem cells.
Biomater Sci. 2025 Jan 21. doi: 10.1039/d4bm01471.
Abstract
Methyltransferase-like 7B participates in bladder cancer via ACSL3 m(6)A
modification in a ferroptosis manner.
Biol Direct. 2025;20:9.
Abstract
"Delta" Delta neobladder: a novel stentless simplified totally intracorporeal robotic
technique.
Minerva Urol Nephrol. 2024;76:773-781.
Abstract
Blue light cystoscopy- as an improvised diagnostic modality for bladder tumours.
J Pak Med Assoc. 2025;75:84-90.
Abstract
[SUCCESSFUL TREATMENT WITH mFOLFOX6 FOR URACHAL ADENOCARCINOMA WITH MULTIPLE LUNG
METASTASIS: A CASE REPORT].
Nihon Hinyokika Gakkai Zasshi. 2024;115:28-32.
Abstract
[EFFICACY AND SAFETY OF ENFORTUMAB VEDOTIN IN ADVANCED UROTHELIAL CARCINOMA
TREATMENT: AN INITIAL EXPERIENCE IN A SINGLE INSTITUTION].
Nihon Hinyokika Gakkai Zasshi. 2024;115:21-27.
Abstract
Unusual recurrence in advanced ovarian cancer after interval cytoreductive
surgery and HIPEC.
BMJ Case Rep. 2025;18:e262137.
Abstract
Utilizing vaginal natural orifice to facilitate bowel manipulation during totally
intracorporeal ileal conduit construction: a retrospective cohort study.
Ann Med. 2025;57:2453827.
Abstract
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3,
MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2025;23:102284.
Abstract
Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated
Meta-Analysis of Randomized Controlled Trials.
Clin Genitourin Cancer. 2025;23:102288.
Abstract
A French Multicenter Real-Life Study on the Biological and Clinical Parameters
Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line
Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration
at the Time
Clin Genitourin Cancer. 2025;23:102283.
Abstract
Evaluation of Gemcitabine and Carboplatin Dosing in Patients With
Cisplatin-Ineligible Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer. 2025;23:102279.
Abstract
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial
Cancer: An Austrian Multicentre Study.
Clin Genitourin Cancer. 2025;23:102278.
Abstract
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally
Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance
Avelumab.
Clin Genitourin Cancer. 2025;23:102270.
Abstract
Chitosan/polyvinyl alcohol-based magnetic hydrogel microspheres with controlled
retention and regulated drug release for intravesical instillation.
Int J Biol Macromol. 2025;287:138412.
Abstract
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced
Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
Clin Genitourin Cancer. 2025;23:102261.
Abstract
Robot-Assisted Cystectomy in Patients With Previous Pelvic Irradiation: A
Comprehensive Systematic Review and Single-Arm Meta-Analysis.
Clin Genitourin Cancer. 2025;23:102259.
Abstract
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With
Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361
Trial.
Clin Genitourin Cancer. 2025;23:102248.
Abstract
TC-Sniffer: A Transformer-CNN Bibranch Framework Leveraging Auxiliary VOCs for
Few-Shot UBC Diagnosis via Electronic Noses.
ACS Sens. 2025;10:213-224.
Abstract
Neoadjuvant chemotherapy for bladder cancer: Two decades on.
Indian J Urol. 2025;41:1-2.
Abstract
Prospective comparative study of quality of life in patients with bladder cancer
undergoing cystectomy with ileal conduit or bladder preservation.
BMJ Oncol. 2024;3:e000435.
Abstract
Epithelial cell diversity and immune remodeling in bladder cancer progression:
insights from single-cell transcriptomics.
J Transl Med. 2025;23:135.
Abstract
Photochemical bomb: Precision nuclear targeting to activate cGAS-STING pathway
for enhanced bladder cancer immunotherapy.
Biomaterials. 2025;318:123126.
Abstract
Current and Future Role of Circulating DNA in the Diagnosis and Management of
Urothelial Carcinoma.
Am Soc Clin Oncol Educ Book. 2025;45:e471912.
Abstract
Sonodynamic Therapy by Reactive Oxygen Species Generation-Responsive
Pseudo-Semiconducting Polymer Nanoparticles Combined with a Fibroblast Growth
Factor Receptor Inhibitor for Enhancing Immunotherapy in Bladder Cancer.
ACS Appl Mater Interfaces. 2025 Jan 30. doi: 10.1021/acsami.4c20545.
Abstract
Urinary DNA Methylation Test for Bladder Cancer Diagnosis.
JAMA Oncol. 2025 Jan 30. doi: 10.1001/jamaoncol.2024.6160.
Abstract
Exploring the influence of health and digital health literacy on quality of life
and follow-up compliance in patients with primary non-muscle invasive bladder
cancer: a prospective, single-center study.
World J Urol. 2025;43:94.
Abstract
Natural compounds as modulators of miRNAs: a new frontier in bladder cancer
treatment.
Med Oncol. 2025;42:56.
Abstract
Utility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected
patients: a systematic review.
World J Urol. 2025;43:95.
Abstract
A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic
Quinolones with Adjuvant Bacillus Calmette-Guerin Instillation for
Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 Jan 28:S2588-9311(24)00296.
Abstract
Correlation between TCF7 and bladder cancer and feasibility of Erlotinib
targeting in bladder cancer: Molecular mechanism and expression of TCF7
recombinant protein.
Int J Biol Macromol. 2025 Jan 27:140438. doi: 10.1016/j.ijbiomac.2025.140438.
Abstract
A novel bladder cancer surveillance schedule using bladder Cx for patients on
annual surveillance.
BJUI Compass. 2025;6:e468.
Abstract
Transcriptional signature of CD56(bright) NK cells predicts favourable prognosis
in bladder cancer.
Front Immunol. 2025;15:1474652.
Abstract
Development and Validation of a Competitive Risk Model in Elderly Patients with
Transitional Cell Bladder Carcinoma.
Med Sci Monit. 2025;31:e946332.
Abstract
Comparison of treatments for preventing lower urinary tract symptoms after BCG
immunotherapy of bladder tumors : a systematic review and network meta-analysis.
BMC Urol. 2025;25:19.
Abstract
Does Bladder Outlet Obstruction Releated to Recurrence In Low Risk Ta Low Grade
Non Muscle Invasive Bladder Cancer?
Clin Genitourin Cancer. 2024;23:102296.
Abstract
Immunohistochemical evaluation of SOX-10 in patients with urinary bladder cancer.
Wiad Lek. 2024;77:2481-2486.
Abstract
Immunohistochemical evaluation of GATA-3 in patients with urinary bladder cancer.
Wiad Lek. 2024;77:2381-2387.
Abstract
Identification of multicohort-based predictive signature for NMIBC recurrence
reveals SDCBP as a novel oncogene in bladder cancer.
Ann Med. 2025;57:2458211.
Abstract
Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer
Patients Treated with Bladder-Preservation Comprehensive Therapy.
Biol Proced Online. 2025;27:2.
Abstract
The usage of the paris classification system in urine cytology in the diagnosis
of non-muscle-invasive bladder cancer: a retrospective single-center study.
Discov Oncol. 2025;16:95.
Abstract
[Erratum to: Novel systemic treatment options for advanced bladder cancer].
Urologie. 2025 Jan 27. doi: 10.1007/s00120-024-02499.
Abstract
Exploring the role of transcription factor TWIST1 in bladder cancer progression.
Cancer Genet. 2025;292-293:44-48.
Abstract
Predictive value of Bladder EpiCheck((R)) in detecting residual tumor before second
TUR for non-muscle-invasive bladder cancer.
World J Urol. 2025;43:89.
Abstract
Development and external validation of a model to predict recurrence in patients
with non-muscle invasive bladder cancer.
Front Immunol. 2025;15:1467527.
Abstract
Development and validation of a glycolysis-associated gene signature for
predicting the prognosis, immune landscape, and drug sensitivity in bladder
cancer.
Front Immunol. 2025;15:1430583.
Abstract
Nanoparticle Therapies: Targeted Treatment for Bladder Cancer With Reduced Side
Effects [Letter].
Int J Nanomedicine. 2025;20:989-990.
Abstract
Preoperative myosteatosis and perioperative serum chloride levels predict 180 day
major complications after radical cystectomy.
Sci Rep. 2025;15:3184.
Abstract
Computed tomography-based nomogram for estimating progression-free survival
probability in bladder cancer patients undergoing partial cystectomy.
Abdom Radiol (NY). 2025 Jan 25. doi: 10.1007/s00261-024-04747.
Abstract
Insights into the Mode of Action of Novel Morpholinated Curcumin Derivatives
Exhibiting Potent Antitumor Activity in Bladder Cancer Cells In Vitro.
Molecules. 2025;30:295.
Abstract
New Trends and Future Perspectives in the Diagnosis of Urothelial Carcinoma: A
Comprehensive Review of the Literature.
Medicina (Kaunas). 2025;61:71.
Abstract
Squamous Cell Bladder Cancer: A Rare Histological Variant with a Demand for
Modern Cancer Therapeutics.
Cancers (Basel). 2025;17:169.
Abstract
Symptoms and Side Effects of Bacille Calmette-Guerin Therapy for Non-Muscle
Invasive Bladder Cancer as Reported by Patients: A Systematic Review.
Cancers (Basel). 2025;17:160.
Abstract
Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard
Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG
Tokyo172 Strain.
Biomedicines. 2025;13:174.
Abstract
Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer
Patients Treated with M. bovis BCG or Other Therapies.
Biomedicines. 2025;13:156.
Abstract
Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of
Advanced Bladder Cancer: From Etiology to Current Development.
Biomedicines. 2025;13:86.
Abstract
Effects of Different Voided Urine Sample Storage Time, Temperature, and
Preservatives on Analysis with Multiplex Bead-Based Oncuria Bladder Cancer
Immunoassay.
Diagnostics (Basel). 2025;15:138.
Abstract
Clinicopathological study and molecular subtyping of muscle-invasive bladder
cancer (MIBC) using dual immunohistochemical (IHC) markers.
Diagn Pathol. 2025;20:10.
Abstract
Risk factors for lymphatic leakage following radical cystectomy and pelvic lymph
node dissection in patients with muscle-invasive bladder cancer.
World J Surg Oncol. 2025;23:23.
Abstract
CDCA4 promotes bladder cancer progression by JAK/STAT signaling pathway.
J Cancer Res Clin Oncol. 2025;151:46.
Abstract
Bibliometric analysis of photodynamic research in bladder cancer: trends and
future directions.
Photodiagnosis Photodyn Ther. 2025 Jan 22:104494.
Abstract
Histone lactylation regulates PRKN-Mediated mitophagy to promote M2 Macrophage
polarization in bladder cancer.
Int Immunopharmacol. 2025;148:114119.
Abstract
Acidic Microenvironment Enhances Cisplatin Resistance in Bladder Cancer via Bcl-2
and XIAP.
Curr Issues Mol Biol. 2025;47:43.
Abstract
Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and
Safety of Intravesical Bacillus Calmette-Guerin in Patients with
Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital
Centers in Greece.
Curr Oncol. 2024;32:18.
Abstract
Growth differentiation factor 15 is a glucose-downregulated gene acting as the
cross talk between stroma and cancer cells of the human bladder.
Am J Physiol Cell Physiol. 2025;328:C557-C573.
Abstract
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic
Strategies.
Target Oncol. 2025;20:1-11.
Abstract
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma:
An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.
Target Oncol. 2025;20:57-69.
Abstract
[Urinary bladder: tumor precursors and non-invasive carcinoma].
Pathologie (Heidelb). 2025;46:21-26.
Abstract
Pathological Extramural Venous Invasion in High-stage Urothelial Carcinoma of the
Bladder has Shorter Locoregional Recurrence-free Survival.
Int J Surg Pathol. 2025;33:41-48.
Abstract
Localized Urinary Bladder Amyloidosis as Urothelial Cancer Mimicker: A Case
Series Examining Cystoscopic, Histologic, and Cytologic Findings.
Arch Pathol Lab Med. 2025;149:191-194.
Abstract
Outcome Analysis of a Series of Mixed-Grade, Non-muscle Invasive, Papillary
Carcinomas of the Bladder.
Int J Surg Pathol. 2025;33:19-25.
Abstract
Pseudoprogression Shown on (18)F-FDG PET/CT After Pembrolizumab Treatment in a
Case of Metastatic Bladder Cancer.
Mol Imaging Radionucl Ther. 2025;34:70-72.
Abstract
Prognostic role of prognostic nutritional index in patients with bladder cancer:
a systematic review and meta-analysis.
Front Oncol. 2025;14:1486389.
Abstract
Elevated expression of ANTXR1 gene in tumors is a poor prognostic biomarker for
patients with bladder cancer.
Front Mol Biosci. 2025;11:1520223.
Abstract
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present,
and Future of Antibody-Drug Conjugate Development in Advanced Urothelial
Carcinoma.
Am Soc Clin Oncol Educ Book. 2025;45:e471924.
Abstract
Pelvic Lymph Node Dissection Before Versus After Radical Cystectomy: A Systematic
Review and Meta-Analysis.
Int Braz J Urol. 2025;51:e20240490.
Abstract
Redefining bladder cancer treatment: innovations in overcoming drug resistance
and immune evasion.
Front Immunol. 2025;16:1537808.
Abstract
Amyloids in bladder cancer hijack cancer-related proteins and are positive
correlated to tumor stage.
Sci Rep. 2025;15:4393.
Abstract
Re: Akihiro Matsukawa, Takafumi Yanagisawa, Marcin Miszczyk, et al. Trimodality
Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A
Systematic Review and Meta-analysis of Matched Cohort Studies. Eur Urol Focus. In
press. https://do
Eur Urol Focus. 2025 Feb 4:S2405-4569(25)00016-1. doi: 10.1016/j.euf.2024.
Abstract
Perioperative Durvalumab in Bladder Cancer. Reply.
N Engl J Med. 2025;392:619.
Abstract
Perioperative Durvalumab in Bladder Cancer.
N Engl J Med. 2025;392:618-619.
Abstract
Urachal Carcinomas: A Comprehensive Systematic Review and Meta-analysis.
Int Braz J Urol. 2025;51:e20240665.
Abstract
Multicenter Retrospective Registry Study on BCG Use in Non-Muscle Invasive
Bladder Cancer in Latin America: BLATAM (Bladder Cancer in Latin America) Group.
Int Braz J Urol. 2025;51:e20240615.
Abstract
Urease-Driven Janus Nanomotors for Dynamic Enrichment and Multiplexed Detection
of Bladder Cancer MicroRNAs in Urine.
ACS Sens. 2025 Feb 5. doi: 10.1021/acssensors.4c02996.
Abstract
COTI-2 suppresses the malignancy of bladder cancer by inducing apoptosis via the
AMPK-mTOR signaling pathway.
Iran J Basic Med Sci. 2025;28:240-246.
Abstract
Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic
and glucose-deprived bladder cancer cells.
iScience. 2025;28:111758.
Abstract
Cost-reduction strategy to culture patient derived bladder tumor organoids.
Sci Rep. 2025;15:4223.
Abstract
Innovative logic "AND" gate gene circuits for bladder cancer treatment:
preclinical study.
Int J Surg. 2025 Feb 4. doi: 10.1097/JS9.0000000000002270.
Abstract
[The Case of Solitary Adrenal Metastasis of Urothelial Carcinoma].
Hinyokika Kiyo. 2025;71:5-8.
Abstract
2025 Canadian Urological Association Expert Report: Muscle-invasive bladder
cancer.
Can Urol Assoc J. 2025;19:E1-E16.
Abstract
Genome-wide association study and Mendelian randomization analyses reveal
insights into bladder cancer etiology.
JNCI Cancer Spectr. 2025 Feb 3:pkaf014. doi: 10.1093.
Abstract
Evaluation of Melanoma and Bladder Cancers in New Hampshire to Identify Registrar
Training Needs.
J Registry Manag. 2024;51:121-123.
Abstract
Journal of Registry Management Continuing Education Quiz-FALL 2024: EVALUATION OF
MELANOMA AND BLADDER CANCERS IN NEW HAMPSHIRE TO IDENTIFY REGISTRAR TRAINING
NEEDS.
J Registry Manag. 2024;51:128.
Abstract
TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy
resistance.
Theranostics. 2025;15:1966-1986.
Abstract
Best evidence for rehabilitation management of urinary incontinence in patients
with bladder cancer following orthotopic neobladder reconstruction.
Asia Pac J Oncol Nurs. 2024;12:100647.
Abstract
S100A8 promotes the proliferation, migration and invasion in bladder cancer
cells.
J Cancer. 2025;16:1066-1077.
Abstract
An Unusual Presentation of Bladder Carcinoma in a Visceral Hernia: A Case Report
and Literature Review.
Cancer Rep (Hoboken). 2025;8:e70128.
Abstract
Blood lead levels and bladder cancer among US participants: NHANES 1999-2018.
BMC Public Health. 2025;25:416.
Abstract
Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling
of ARID1A loss in bladder cancer reveals therapeutic molecular targets.
Cancer Lett. 2025 Jan 29:217506. doi: 10.1016/j.canlet.2025.217506.
Abstract
Investigating the Potential to Offer Reproductive Organ Preserving Radical
Cystectomy to More Female Bladder Cancer Patients.
Clin Genitourin Cancer. 2025;23:102303.
Abstract
Sex-specific differences in recurrence and progression following cytostatic
intravesical chemotherapy for non-muscle invasive urothelial bladder cancer
(NMIBC).
J Cancer Res Clin Oncol. 2025;151:59.
Abstract
Novel combination therapy for platinum-eligible patients with locally advanced or
metastatic urothelial carcinoma: a systematic review and network meta-analysis.
Cancer Immunol Immunother. 2025;74:76.
Abstract
Feasibility of enzalutamide on patients with recurrent non-muscle-invasive
bladder cancer with marker tumors: phase I study.
BMC Res Notes. 2025;18:47.
Abstract
Proteomic profiling identifies muscle-invasive bladder cancers with distinct
biology and responses to platinum-based chemotherapy.
Nat Commun. 2025;16:1240.
Abstract
Molecular Classification of Urothelial Carcinoma.
Surg Pathol Clin. 2025;18:41-51.
Abstract
Mesenchymal Neoplasms of the Bladder and Male Genital Tract, including the
Perineum and Scrotum.
Surg Pathol Clin. 2025;18:229-247.
Abstract
Tissue-Based Biomarkers Important for Prognostication and Management of
Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations.
Surg Pathol Clin. 2025;18:175-189.
Abstract
Loss of YTHDC1 m(6)A reading function promotes invasiveness in urothelial
carcinoma of the bladder.
Exp Mol Med. 2025;57:118-130.
Abstract
VI steps to achieve VI-RADS assessment.
Eur J Radiol. 2025;183:111868.
Abstract
[Antibioprophylaxis failure with BCG therapy for bladder neoplasia].
Rev Mal Respir. 2025;42:75-80.
Abstract
Variations in the diagnostic performance of transurethral resection of bladder
tumor with photodynamic diagnosis according to surgical experience: A
retrospective, single-center study.
Photodiagnosis Photodyn Ther. 2025;51:104429.
Abstract
Single-cell RNA sequencing analysis reveals the dynamic changes in the tumor
microenvironment during NMIBC recurrence.
Apoptosis. 2025;30.
Abstract
Comparison of fluorescence intensity of protoporphyrin IX as observed on the
screen of different cystoscopic systems.
Photodiagnosis Photodyn Ther. 2025;51:104425.
Abstract
Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase
III Multicenter Randomized Controlled Trial.
Int J Radiat Oncol Biol Phys. 2025;121:728-736.
Abstract
Image-Guided Brachytherapy for Pediatric Bladder and/or Prostate
Rhabdomyosarcoma: Toward an Increased Personalization of Treatment.
Int J Radiat Oncol Biol Phys. 2025;121:658-666.
Abstract
KRT18 as a Novel Biomarker of Urothelial Papilloma while Evaluating Low-Grade
Papillary Urothelial Neoplasms: Bi-Center Analysis.
Pathobiology. 2025;92:28-39.
Abstract
Clinical and pathological risk factors for tumour recurrence and upstaging in
second TURBT for patients with NMIBC: a systematic review and meta-analysis.
Aktuelle Urol. 2025;56:30-40.
Abstract
Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial
Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.
Cancer Med. 2025;14:e70636.
Abstract
[A Case of Sigmoid Colon Cancer with Bladder Invasion Successfully Treated with
Chemotherapy with mFOLFOX6+Cetuximab].
Gan To Kagaku Ryoho. 2024;51:1797-1799.
Abstract
[A Case of Rectal Cancer Resection with Total Cystectomy That Avoided a Double
Stoma].
Gan To Kagaku Ryoho. 2024;51:1758-1760.
Abstract
[A Case of Bladder Preservation by Neoadjuvant Chemotherapy for Sigmoid Colon
Cancer with Bladder Invasion].
Gan To Kagaku Ryoho. 2024;51:1434-1436.
Abstract
[Three Cases of Sigmoid Colon Cancer with Bladder Invasion That Were Treated with
Neoadjuvant Chemotherapy, Allowing Radical Resection and Bladder Preservation].
Gan To Kagaku Ryoho. 2024;51:1408-1410.
Abstract
[A Case of Bladder Metastasis from Invasive Ductal Carcinoma of the Breast-A Case
Report].
Gan To Kagaku Ryoho. 2024;51:1345-1347.
Abstract
Plasma tsRNA Signatures Serve as a Novel Biomarker for Bladder Cancer.
Cancer Sci. 2025 Feb 13. doi: 10.1111/cas.70003.
Abstract
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for
superficial recurrence following bladder-sparing therapy of muscle invasive
bladder cancer: A retrospective study.
Urol Oncol. 2025 Feb 12:S1078-1439(25)00013.
Abstract
Urinary Diversion and Quality of Life: A Six-Year Follow-Up Study of Bladder
Cancer Surgery.
Actas Urol Esp (Engl Ed). 2025 Feb 11:501699. doi: 10.1016/j.acuroe.2025.501699.
Abstract
Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With
Urothelial Nonmetastatic Muscle-Invasive Bladder Cancer in the United States.
Cancer Med. 2025;14:e70644.
Abstract
Impact of finasteride on modulating the risk and clinical outcomes of bladder
cancer: insights from a comprehensive meta-analysis.
Front Pharmacol. 2025;16:1471442.
Abstract
Association between pioglitazone use and bladder cancer: A systematic review.
Bladder (San Franc). 2024;11:e21200023.
Abstract
Molecular classification using Lund University algorithm and clinical
correlations in muscle-invasive bladder cancer: Insights from a retrospective
study.
Bladder (San Franc). 2024;11:e21200019.
Abstract
Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer
based on microarray differential expression profiling.
Int J Biol Markers. 2025 Feb 13:3936155251317551. doi: 10.1177/03936155251317551
Abstract
Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis
of Eligibility, Utilization, and Outcomes.
Cancers (Basel). 2025;17:505.
Abstract
Long-Term Outcomes of Intravesical Mitomycin C Administered via Electromotive
Drug Administration or Conductive Chemo-Hyperthermia in Non-Muscle-Invasive
Bladder Cancer.
Cancers (Basel). 2025;17:453.
Abstract
Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving
Immunotherapy.
J Clin Med. 2025;14:879.
Abstract
The effect of different adipose tissue measurements on clinical prognosis in
bladder cancer patients undergoing radical cystectomy: preliminary results.
Abdom Radiol (NY). 2025 Feb 13. doi: 10.1007/s00261-025-04838.
Abstract
pH-Responsive Triplex DNA Nanoswitches: Surface Plasmon Resonance Platform for
Bladder Cancer-Associated microRNAs.
ACS Nano. 2025 Feb 12. doi: 10.1021/acsnano.4c16396.
Abstract
Expanding frontiers in liquid biopsy-discovery and validation of circulating
biomarkers in renal cell carcinoma and bladder cancer.
Int Rev Cell Mol Biol. 2025;391:135-197.
Abstract
Oncological outcomes of patients with node positive disease following neoadjuvant
chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A
multicenter observational study of the EAU Young Academic Urologists (YAU)
urothelial carcinoma
Actas Urol Esp (Engl Ed). 2025 Feb 10:501701. doi: 10.1016/j.acuroe.2025.501701.
Abstract
Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1)
nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle
invasive bladder cancer.
Tissue Cell. 2025;93:102783.
Abstract
Dermatological findings in bladder cancer: relationship between clinical and
paraneoplastic syndromes.
Arch Dermatol Res. 2025;317:389.
Abstract
Socioeconomic disparities in survival of patients with non-muscle invasive
urothelial carcinoma.
World J Urol. 2025;43:120.
Abstract
Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in
Non-Muscle Invasive Bladder Cancer.
Pathol Int. 2025 Feb 12. doi: 10.1111/pin.70002.
Abstract
Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes
in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical
Cystectomy.
Eur Urol Open Sci. 2025;73:24-30.
Abstract
Nucleotide variation in Foxp3 gene and prognosis of bladder cancer: a
case-control study.
Front Oncol. 2025;15:1506900.
Abstract
Case report: Successful perioperative intervention with efgartigimod in a patient
in myasthenic crisis.
Front Immunol. 2025;16:1524200.
Abstract
Urine-Stable Aptamer-Conjugated Gold Nanorods for the Early Detection of
High-Grade Bladder Cancer Residual Disease.
Adv Healthc Mater. 2025 Feb 11:e2403314. doi: 10.1002/adhm.202403314.
Abstract
Efficacy of curative radiotherapy for the treatment of elderly patients with
muscle-invasive bladder cancer: a systematic review.
BMC Urol. 2025;25:26.
Abstract
New Treatment Options for Non-Muscle-Invasive Bladder Cancer.
Am Soc Clin Oncol Educ Book. 2025;45:e471942.
Abstract
Review of BCG immunotherapy for bladder cancer.
Clin Microbiol Rev. 2025 Feb 11:e0019423. doi: 10.1128/cmr.00194.
Abstract
New biomarkers for diagnosis of bladder cancer: a bibliometric analysis.
Arch Ital Urol Androl. 2025 Feb 11:13396. doi: 10.4081/aiua.2025.13396.
Abstract
Serum Matrix Metalloproteinases and Risk of Urologic Cancers: A Bidirectional
Mendelian Randomization Study.
Am J Mens Health. 2025;19:15579883241311229.
Abstract
Occupational health topics series on the effects of chemicals: epidemiological
and toxicological risk assessments of ortho-toluidine on bladder cancer.
J Occup Health. 2025 Feb 11:uiaf005. doi: 10.1093.
Abstract
TAR-200: Investigational intravesical drug delivery system for bladder cancer.
Urologia. 2025 Feb 10:3915603251319133. doi: 10.1177/03915603251319133.
Abstract
The importance of data transformation in RNA-Seq preprocessing for bladder cancer
subtyping.
BMC Res Notes. 2025;18:61.
Abstract
IVC treatment between primary and second TURBT may improve the prognosis of
high-risk NMIBC patients receiving BCG treatment.
Sci Rep. 2025;15:4874.
Abstract
Machine Learning Accurately Predicts Muscle Invasion of Bladder Cancer Based on
Three miRNAs.
J Cell Mol Med. 2025;29:e70361.
Abstract
Internal Hernia Beneath the Obturator Nerve After Robot-Assisted Radical
Cystectomy and Pelvic Lymphadenectomy: A Case Report With Literature Review.
Asian J Endosc Surg. 2025;18:e70030.
Abstract
Temporal patterns of major postoperative events after radical cystectomy:
analysis of 90-day morbidity.
World J Urol. 2025;43:111.
Abstract
Discrepancies between physician-assessed and patient-reported complications after
cystectomy - a prospective analysis.
World J Urol. 2025;43:115.
Abstract
Evaluation of six novel biomarkers for predicting recurrence of non-muscle
invasive bladder cancer after endoscopic resection- a prospective observational
study.
World J Urol. 2025;43:114.
Abstract
Durable response to treatment of an atypical desmoplastic small round cell tumor
with enfortumab-vedotin.
J Cancer Res Clin Oncol. 2025;151:73.
Abstract
Comment to: "Identifying optimal candidates for active surveillance in low-grade
intermediate-risk non-muscle invasive bladder cancer".
World J Urol. 2025;43:113.
Abstract
Mechanistic insights into PROS1 inhibition of bladder cancer progression and
angiogenesis via the AKT/GSK3beta/beta-catenin pathway.
Sci Rep. 2025;15:4748.
Abstract
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus
Calmette-Guerin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing
Bladder-sparing Therapies.
Eur Urol Focus. 2025 Feb 7:S2405-4569(25)00001-X. doi: 10.1016/j.euf.2025.
Abstract
Reply to: Francesco Montorsi, Francesco Montorsi, Giuseppe Rosiello, Marco
Moschini, Andrea Salonia, and Alberto Briganti's letter to the Editor re: Akihiro
Matsukawa, Takafumi Yanagisawa, Marcin Miszczyk, et al. Trimodality Therapy
Versus Radical Cys
Eur Urol Focus. 2025 Feb 7:S2405-4569(25)00020-3. doi: 10.1016/j.euf.2025.
Abstract
Understanding regional anesthesia's impact on non-muscle invasive bladder cancer
oncological outcomes.
Reg Anesth Pain Med. 2025 Feb 8:rapm-2025-106433. doi: 10.1136/rapm-2025-106433.
Abstract
Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding
Tumor Biology and Developing Personalized Treatment.
Adv Sci (Weinh). 2025 Feb 7:e2414558. doi: 10.1002/advs.202414558.
Abstract
Impact of dialysis on intravesical recurrence and survival outcomes in upper
tract urothelial cancer patients undergoing radical nephroureterectomy.
Ren Fail. 2025;47:2458762.
Abstract
Urinary Diversion Versus Adverse In-Hospital Outcomes After Radical Cystectomy.
Ann Surg Oncol. 2025;32:2233-2240.
Abstract
Evaluation of Diagnostic Accuracy of the Paris System (TPS 2.0) in Urine Cytology
Specimens: An Institutional Experience From a Large Cohort of a Tertiary Care
Centre.
Cytopathology. 2025;36:140-149.
Abstract
The Value of Multi-directional High b-Value DWI in the Assessment of Muscular
Invasion in Bladder Urothelial Carcinoma: In Comparison with VI-RADS.
Acad Radiol. 2025;32:844-854.
Abstract
Improved bladder diagnostics using multiparametric ultrasound.
Abdom Radiol (NY). 2025;50:1240-1253.
Abstract
Investigating the association between blue light cystoscopy utilization and
social determinants of health.
Urologia. 2025;92:44-50.
Abstract
En-bloc resection of non-muscle invasive urinary bladder tumors using low power
Holmium laser-A new promise.
Urologia. 2025;92:39-43.
Abstract
Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients
with Hematuria.
Eur Urol Oncol. 2025;8:87-93.
Abstract
Author Correction: Proteomic profiling identifies muscle-invasive bladder cancers
with distinct biology and responses to platinum-based chemotherapy.
Nat Commun. 2025;16:1855.
Abstract
Chorioretinitis following Bacillus Calmette-Guerin Treatment for Bladder Cancer.
Retin Cases Brief Rep. 2025 Feb 14. doi: 10.1097/ICB.0000000000001736.
Abstract
Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and
miRNAs.
Front Immunol. 2025;16:1518144.
Abstract
Transcriptomic Profiles for Elucidating Response of Bladder Intracavitary
Hyperthermic Perfusion Chemotherapy in High-Risk Nonmuscular Invasive Bladder
Cancer.
Cancer Med. 2025;14:e70672.
Abstract
CDCA3-MYC positive feedback loop promotes bladder cancer progression via
ENO1-mediated glycolysis.
J Exp Clin Cancer Res. 2025;44:63.
Abstract
GATA3 amplification is associated with high grade disease in non-invasive
urothelial bladder cancer but unrelated to patient prognosis.
BMC Urol. 2025;25:37.
Abstract
Ectopic prostate tissue presenting as a bladder tumor in a young man- a case
report.
BMC Urol. 2025;25:36.
Abstract
Predicting immunotherapy response of advanced bladder cancer through a
meta-analysis of six independent cohorts.
Nat Commun. 2025;16:1213.
Abstract
Innovative applications of natural polysaccharide polymers in intravesical
therapy of bladder diseases.
Carbohydr Polym. 2025;354:123307.
Abstract
Mechanical modulation of docetaxel-treated bladder cancer cells by various
changes in cytoskeletal structures.
J Mech Behav Biomed Mater. 2025;165:106952.
Abstract
Sonodynamic activated nanoparticles with Glut1 inhibitor and cystine-containing
polymer stimulate disulfidptosis for improved immunotherapy in bladder cancer.
Biomaterials. 2025;319:123178.
Abstract
Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle
Invasive Bladder Cancer.
Curr Oncol Rep. 2025 Feb 20. doi: 10.1007/s11912-025-01645.
Abstract
Concomitant medications in patients with metastatic urothelial carcinoma
receiving enfortumab vedotin: real-world data from the ARON-2(EV) study.
Clin Exp Metastasis. 2025;42:18.
Abstract
Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus
Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive
Urothelial Carcinoma: A Real-World Study.
Cancer Med. 2025;14:e70661.
Abstract
Balancing risks and benefits in the treatment of patients with Bacillus
Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.
Transl Androl Urol. 2025;14:1-3.
Abstract
Efficacy of cystectomy in single-site oligometastatic bladder cancer: a
Surveillance, Epidemiology, and End Results (SEER) study of 1,381 patients.
Transl Androl Urol. 2025;14:81-90.
Abstract
Long-term efficacy of two sequential induction courses of Bacillus
Calmette-Guerin in patients with high-risk non-muscle-invasive bladder cancer.
Transl Androl Urol. 2025;14:4-7.
Abstract
A novel nomogram for predicting post-operative recurrence for patients with
intermediate and high-risk non-muscle invasive bladder cancer after thulium laser
resection of bladder tumors or conventional transurethral resection of bladder
tumors followe
Transl Androl Urol. 2025;14:91-102.
Abstract
A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.
ACS Pharmacol Transl Sci. 2025;8:286-307.
Abstract
Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder
Cancer: A Phase 2 Trial-Results of Secondary Endpoints.
Eur Urol Focus. 2025 Feb 18:S2405-4569(25)00042.
Abstract
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive
antigen-presenting cells.
J Pathol Clin Res. 2025;11:e70021.
Abstract
Neutrophil Extracellular Traps and Reactive Oxygen Species: Predictors of
Prognosis in Bladder Cancer.
Immunol Lett. 2025 Feb 17:106991. doi: 10.1016/j.imlet.2025.106991.
Abstract
Effects of pterostilbene on inducing apoptosis in normal bladder and bladder
cancer cells.
Tissue Cell. 2025;94:102794.
Abstract
Predictive role of lactylation-related gene signature in the prognosis and
immunotherapy response in bladder cancer.
Arch Ital Urol Androl. 2025 Feb 17:13516. doi: 10.4081/aiua.2025.13516.
Abstract
Contrast-enhanced ultrasound enables precision diagnosis of preoperative muscle
invasion in bladder cancer: a prospective study.
MedComm (2020). 2025;6:e70106.
Abstract
Retracted: IC-2 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer
Cells via the Wnt/beta-Catenin Pathway.
Med Sci Monit. 2025;31:e948581.
Abstract
High-Dimensional Variable Selection With Competing Events Using Cooperative
Penalized Regression.
Biom J. 2025;67:e70036.
Abstract
Evaluating biparametric MRI for diagnosing muscle-invasive bladder cancer with
variant urothelial histology: a multicenter study.
Cancer Imaging. 2025;25:15.
Abstract
Outcomes of radical cystectomy in a resource-limited setting: a pilot study.
BMC Urol. 2025;25:31.
Abstract
Impact of upper tract urothelial carcinoma history on patients with non-muscle
invasive bladder cancer undergoing intravesical chemotherapy.
Sci Rep. 2025;15:5977.
Abstract
Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I
IFN signaling.
J Clin Invest. 2025 Feb 18:e186648. doi: 10.1172/JCI186648.
Abstract
Case report: Successful treatment of hyperbaric oxygen for radiation-induced
hemorrhagic cystitis in a 95-year-old patient with bladder cancer.
Front Oncol. 2025;15:1410148.
Abstract
Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its
nomogram.
Front Oncol. 2025;15:1406585.
Abstract
Transcriptional Regulation of NUPR1 by MYH11 Activates PI3 K/AKT and Promotes
Bladder Cancer Progression Through Ferroptosis and M2 Polarization of
Macrophages.
Technol Cancer Res Treat. 2025;24:15330338241305434.
Abstract
CircST6GALNAC6 Inhibits Glycolysis of Bladder Cancer by Regulating PRKN/HK1
Signaling Pathway.
Mol Carcinog. 2025 Feb 17. doi: 10.1002/mc.23894.
Abstract
Cancer Cell and Cancer-Associated Fibroblast Communication-Mediated Molecular
Subtypes Portray Non-Inflamed Tumor Microenvironment and Guide the Precision
Treatment of Bladder Cancer.
Adv Biol (Weinh). 2025 Feb 17:e2400434. doi: 10.1002/adbi.202400434.
Abstract
Analysis of local and systemic side effects of bacillus Calmette-Guerin
immunotherapy in bladder cancer: a retrospective study in Turkiye.
PeerJ. 2025;13:e18870.
Abstract
EXPOSURE TO ARSENIC IN DRINKING WATER AND RISK OF BLADDER CANCER.
Acta Clin Croat. 2024;63:55-64.
Abstract
Comparison of neoadjuvant chemotherapy and combined chemotherapy with
immunotherapy for muscle-invasive bladder cancer: a propensity score-matched
analysis.
Am J Transl Res. 2025;17:125-143.
Abstract
Systemic Bacillus Calmette-Guerin (BCG) Infection in a Patient With
Non-Muscle-Invasive Bladder Cancer: A Case Report.
Cureus. 2025;17:e77558.
Abstract
RETRACTION: CAB39 Modulates Epithelial-Mesenchymal Transition Through NF-kappaB
Signaling Activation, Enhancing Invasion, and Metastasis in Bladder Cancer.
Environ Toxicol. 2025 Feb 16. doi: 10.1002/tox.24498.
Abstract
[A Case of Laparoscopic Sigmoidectomy for Sigmoid Colon Cancer after Open Total
Cystectomy].
Gan To Kagaku Ryoho. 2025;52:76-78.
Abstract
Tumor-derived exosomal KPNA2 activates fibroblasts and interacts with KIFC1 to
promote bladder cancer progression, a process inhibited by miR-26b-5p.
Cell Mol Biol Lett. 2025;30:20.
Abstract
Comparison of Post-Radical Cystectomy Renal Function and Ileal Conduit-Related
Complications Between Extracorporeal and Robot-Assisted Intracorporeal
Urinary Diversion: A Single-Center Experience.
Asian J Endosc Surg. 2025;18:e70033.
Abstract
Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on
outcomes and changes after BCG exposure.
Urol Oncol. 2025 Feb 15:S1078-1439(25)00014.
Abstract
Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by
promoting macrophage polarization.
Cancer Cell Int. 2025;25:48.
Abstract
Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing
apoptosis, and suppressing metastasis in bladder cancer cells through
EGFR/ERK/P38/NF-kappaB signaling inactivation.
Cancer Cell Int. 2025;25:47.
Abstract
Recent animal models of bladder cancer and their application in drug discovery:
an update of the literature.
Expert Opin Drug Discov. 2025 Feb 17:1-21. doi: 10.1080/17460441.2025.2465373.
Abstract
IC/BPS is not associated with bladder cancer: a nationwide propensity score
matched cohort study in Taiwan.
World J Urol. 2025;43:123.
Abstract
Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients
With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2025 Jan 23:102306. doi: 10.1016/j.clgc.2025.102306.
Abstract
Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review.
Actas Urol Esp (Engl Ed). 2025 Feb 12:501717. doi: 10.1016/j.acuroe.2025.501717.
Abstract
The oncological impact of complete transurethral resection before neoadjuvant
chemotherapy in muscle-invasive bladder cancer.
Actas Urol Esp (Engl Ed). 2025 Feb 12:501712. doi: 10.1016/j.acuroe.2025.501712.
Abstract
In Vivo Time-Resolved Single-Cell RNA-Seq Reveals Chemotherapy-Induced
Transcriptional Dynamics in Tumor Infiltrating Lymphocytes.
Anal Chem. 2025;97:3438-3448.
Abstract
Non-invasive diagnosis for urothelial carcinoma using a dual-target DNA
methylation biomarker panel.
Clin Chim Acta. 2025;569:120164.
Abstract
Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin
in patients with metastatic urothelial carcinoma.
Int J Clin Oncol. 2025;30:524-531.
Abstract
Treatment of metastatic urothelial carcinoma in the United Kingdom, France,
Germany, Italy, and Spain.
Future Oncol. 2025;21:569-578.
Abstract
Advancements in the front-line treatment of metastatic urothelial carcinoma.
Eur Urol Focus. 2024;10:972-974.
Abstract
The Impact of Second Opinion Expert Pathology Review in Patient Management at the
Time of Transurethral Resection of the Bladder.
Eur Urol Focus. 2024;10:1043-1048.
Abstract
Enhancing RECK Expression Through miR-21 Inhibition: A Promising Strategy for
Bladder Carcinoma Control.
Biochem Genet. 2025;63:817-831.
Abstract
Single-cell Analysis Highlights Anti-apoptotic Subpopulation Promoting Malignant
Progression and Predicting Prognosis in Bladder Cancer.
Cancer Inform. 2025;24:11769351251323569.
Abstract
BIN1 inhibited tumor growth, metastasis and stemness by ALDH1/NOTCH pathway in
bladder carcinoma.
Hereditas. 2025;162:29.
Abstract
Identification of E3 ubiquitin ligase-based molecular subtypes and prognostic
signature regarding prognosis and immune landscape in bladder cancer.
Cancer Cell Int. 2025;25:70.
Abstract
SFRP2 mediates Epstein-Barr virus and bladder cancer risk: a Mendelian
randomization study and colocalization analysis.
Sci Rep. 2025;15:7118.
Abstract
Aspartate Isomerization Regulates in Situ Assembly of Peptides into
Supramolecular Probes for Detection of Protein Carboxyl Methyltransferase in
Bladder Cancer.
Nano Lett. 2025 Feb 27. doi: 10.1021/acs.nanolett.4c06452.
Abstract
Association of pickled food consumption with non-digestive system cancers: a
systematic review and meta-analysis.
BMJ Open. 2025;15:e082786.
Abstract
[Intravesical treatment of non-muscle-invasive bladder cancer].
Urologie. 2025 Feb 27. doi: 10.1007/s00120-025-02522.
Abstract
DGKalpha Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney
Disease.
Cancer Med. 2025;14:e70710.
Abstract
Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients
with advanced or metastatic urothelial carcinoma who are ineligible for
platinum-based chemotherapy: a meta-analysis.
Front Immunol. 2025;16:1430673.
Abstract
Immunoproteasome subunits are novel signatures for predicting efficacy of
immunotherapy in muscle invasive bladder cancer.
J Transl Med. 2025;23:228.
Abstract
A conditionally replicative adenovirus vector containing the synNotch receptor
gene for the treatment of muscle-invasive bladder cancer.
Cancer Gene Ther. 2025 Feb 26. doi: 10.1038/s41417-025-00879.
Abstract
Analysis the diagnostic performance of H4C6/SOX1-OT gene methylation in bladder
cancer based on urine sample.
Sci Rep. 2025;15:6961.
Abstract
Imipramine-induced Apoptosis and Metastasis Inhibition in Human Bladder Cancer
T24 Cells Through EGFR/ERK/NF-kappaB Pathway Suppression.
In Vivo. 2025;39:669-682.
Abstract
Prognostic significance of PD-1, PD-L1, PD-L2 and FGFR3 mRNA expression in
bladder cancer.
Pathobiology. 2025 Feb 26:1-19. doi: 10.1159/000544733.
Abstract
Factors influencing smoking cessation in Lebanese patients with bladder cancer: A
cross sectional study.
Cancer Treat Res Commun. 2025;43:100879.
Abstract
CHRONIC INFECTION WITH SCHISTOSOMA HAEMATOBIUM LEADS TO THE DEVELOPMENT OF
SQUAMOUS CELL CARCINOMA OF THE BLADDER.
Georgian Med News. 2024;:99-103.
Abstract
Tracing the Evolution of Sex Hormones and Receptor-Mediated Immune
Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic
Development to Disease.
Adv Sci (Weinh). 2025 Feb 25:e2407715. doi: 10.1002/advs.202407715.
Abstract
Novel Hydrogel-Mediated Lentiviral Gene Delivery via Intravesical Administration
for Bladder Cancer Treatment.
Pharmaceutics. 2025;17:143.
Abstract
Phytochemical Profile and Anticancer Potential of Helichrysum arenarium Extracts
on Glioblastoma, Bladder Cancer, and Breast Cancer Cells.
Pharmaceuticals (Basel). 2025;18:144.
Abstract
Pro-Tumorigenic Effect of Continuous Cromolyn Treatment in Bladder Cancer.
Int J Mol Sci. 2025;26:1619.
Abstract
Liquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning.
Diagnostics (Basel). 2025;15:492.
Abstract
Therapeutic Advances in Bladder Preservation for BCG-Unresponsive Non-Muscle
Invasive Bladder Cancer.
Cancers (Basel). 2025;17:636.
Abstract
The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2025;17:628.
Abstract
Association between antibiotics and treatment efficacy in metastatic urothelial
carcinoma patients.
BMC Med. 2025;23:117.
Abstract
Predicting 90-day risk of urinary tract infections following urostomy in bladder
cancer patients using machine learning and explainability.
Sci Rep. 2025;15:6807.
Abstract
RETRACTION: Comparing Surgical Site Wound Infection After Laparoscopic and Open
Radical Cystectomies in Patients with Bladder Cancer.
Int Wound J. 2025;22:e70263.
Abstract
Blockade of the STAT3/BCL-xL Axis Leads to the Cytotoxic and
Cisplatin-Sensitizing Effects of Fucoxanthin, a Marine-Derived Carotenoid, on
Human Bladder Urothelial Carcinoma Cells.
Mar Drugs. 2025;23:54.
Abstract
Correction: Singh et al. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder
Cancer Cell Survival in 3D Tumor Models. Cells 2024, 13, 1463.
Cells. 2025;14:299.
Abstract
Construction and verification of a prognostic model for bladder cancer based on
disulfidptosis-related angiogenesis genes.
PeerJ. 2025;13:e18911.
Abstract
Solvent exposure, genetic susceptibility, and risk of bladder cancer.
Cancer Prev Res (Phila). 2025 Feb 25. doi: 10.1158/1940-6207.CAPR-24-0434.
Abstract
Comparative diagnostic performance of VI-RADS based on biparametric and
multiparametric MRI in predicting muscle invasion in bladder cancer.
BMC Med Imaging. 2025;25:60.
Abstract
HOXA13 promotes immune evasion in bladder cancer by suppressing antigen
processing and presentation, and phagosome pathways.
Funct Integr Genomics. 2025;25:44.
Abstract
Radical Cystectomy with Elective Indication to Cutaneous Ureterostomy:
Single-Center Comparative Analysis Between Open and Robotic Surgery in Frail
Patients.
Int Braz J Urol. 2025;51:e20240556.
Abstract
Integrative multi-omics and machine learning identify a robust signature for
discriminating prognosis and therapeutic targets in bladder cancer.
J Cancer. 2025;16:1479-1503.
Abstract
DARS2 Promotes Bladder Cancer Progression by Enhancing PINK1-Mediated Mitophagy.
Int J Biol Sci. 2025;21:1530-1544.
Abstract
Mycobacterium bovis Infections Following Intravesical Bacillus Calmette-Guerin
Instillation for Bladder Cancer in Western Australia: A 22-Year Retrospective
Review.
Open Forum Infect Dis. 2025;12:ofaf070.
Abstract
DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through
MYC stabilization.
Theranostics. 2025;15:2375-2392.
Abstract
STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder
cancer.
Mol Clin Oncol. 2025;22:33.
Abstract
LRP8 inhibits bladder cancer cell ferroptosis by activating the
Wnt/beta-catenin-SCD1 positive feedback loop.
Hum Mol Genet. 2025 Feb 24:ddaf024. doi: 10.1093.
Abstract
Non-invasive and rapid diagnosis of low-grade bladder cancer via SERSomes of
urine.
Nanoscale. 2025 Feb 24. doi: 10.1039/d4nr05306.
Abstract
Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer:
A systematic review and meta-analysis.
Urol Oncol. 2025 Feb 21:S1078-1439(25)00011.
Abstract
Natural history of bladder cancer: Validation of the multiple pathway model in
multi-omics era.
Urol Oncol. 2025;43:88-93.
Abstract
Change of the guards-Looking back at Michael Droller: Visionary and supporter-The
perspective of the International Bladder Cancer Network.
Urol Oncol. 2025;43:129-131.
Abstract
Interferon-gamma/Janus kinase 1/STAT1 Signaling Represses Forkhead Box A1 and Drives
a Basal Transcriptional State in Muscle-Invasive Bladder Cancer.
Am J Pathol. 2025 Feb 20:S0002-9440(25)00068.
Abstract
Cystectomy in Metastatic Bladder Cancer: Feasibility, Safety and Outcomes.
Exp Oncol. 2025;46:345-250.
Abstract
Quality of Life Assessed by the Questionnaire MOS SF-36 in Bladder Cancer
Patients Depending on the Method of Surgical Treatment.
Exp Oncol. 2025;46:351-357.
Abstract
Primary sarcomas of the bladder and prostate: A genomic landscape study.
Pathol Res Pract. 2025;267:155840.
Abstract
The spatial landscape of cancer hallmarks reveals patterns of tumor ecological
dynamics and drug sensitivity.
Cell Rep. 2025;44:115229.
Abstract
CD105-microvessel density analysis and its clinical value in urothelial carcinoma
of bladder patients.
Biomarkers. 2025;30:23-36.
Abstract
[Establishment of a German ICCR dataset : Translation and integration of SNOMED
CT using the example of TUR-B].
Pathologie (Heidelb). 2025;46:108-114.
Abstract
Saudi urologists' treatment pattern for high-risk Bacillus Calmette-Guerin naive
and Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer.
Urol Ann. 2025;17:58-63.
Abstract
Competing Risk Analysis for Diabetes Mellitus Mortality in Bladder Cancer
Patients: A Population-based Study.
Curr Cancer Drug Targets. 2025 Mar 7. doi: 10.2174/0115680096356675250217074915.
Abstract
Comparison of Perioperative and Postoperative Outcomes in Patients with Urinary
Diversions: Direct Cutaneous Ureterostomy versus Bricker Ileal Conduit Technique
Following Radical Cystectomy.
Chirurgia (Bucur). 2025;120:103-116.
Abstract
Two Cases of Revisional Urinary Diversion from Ureterocutaneostomy to Ileal
Conduit: A Staged Urinary Diversion Strategy for Patients with Bladder Cancer in
the Targeted and Immunotherapy Era.
Am J Case Rep. 2025;26:e946924.
Abstract
Selectivity and anti-tumor immune elevation by vascular-targeted photodynamic
therapy of mouse orthotopic bladder cancer model.
Photochem Photobiol. 2025 Mar 6. doi: 10.1111/php.14048.
Abstract
Corrigendum to "Protein profile in urinary extracellular vesicles is a marker of
malignancy and correlates with muscle invasiveness in urinary bladder cancer"
[Cancer Lett. 609 (2025) 217352].
Cancer Lett. 2025 Mar 5:217592. doi: 10.1016/j.canlet.2025.217592.
Abstract
Efficacy of scheduled intravenous acetaminophen administration for
catheter-related bladder discomfort in patients after transurethral resection of
bladder tumors: A prospective randomized pilot study.
Investig Clin Urol. 2025;66:144-151.
Abstract
Intracorporeal Versus Extracorporeal Urinary Diversion Following Robotic-Assisted
Radical Cystectomy for Bladder Cancer in Patients >/= 65 Years of Age: A Systematic
Review and Meta-Analysis.
Cureus. 2025;17:e78406.
Abstract
RBPMS inhibits bladder cancer metastasis by downregulating MYC pathway through
alternative splicing of ANKRD10.
Commun Biol. 2025;8:367.
Abstract
The effect of chronic kidney disease on adverse in-hospital outcomes after
radical cystectomy with ileal conduit urinary diversion.
World J Urol. 2025;43:149.
Abstract
Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive
Bladder Cancer in a National Registry.
Clin Genitourin Cancer. 2025 Feb 10:102316. doi: 10.1016/j.clgc.2025.102316.
Abstract
[Value of whole-lesion apparent diffusion coefficient histogram parameters in
preoperative differentiation of histological grade of bladder urothelial
carcinoma].
Zhonghua Yi Xue Za Zhi. 2025;105:753-759.
Abstract
Development of a technique for diagnosis and screening of superficial bladder
cancer by cell-pellet DNA from urine sample.
Lab Invest. 2025 Mar 3:104124. doi: 10.1016/j.labinv.2025.104124.
Abstract
Association between drinking water disinfection byproducts exposure and human
bladder cancer: A time-updated meta-analysis of trihalomethanes.
J Hazard Mater. 2025;490:137833.
Abstract
The interplay between angiogenesis-associated genes and molecular, clinical, and
immune features in bladder cancer.
Discov Oncol. 2025;16:265.
Abstract
Real-world treatment patterns and clinical outcomes in patients with locally
advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE
study.
J Cancer Res Clin Oncol. 2025;151:100.
Abstract
[Report on the 15th symposium of the German Research Association for Bladder
Cancer (DFBK) on 24 and 25 January 2025 in Jena].
Urologie. 2025 Mar 5. doi: 10.1007/s00120-025-02556.
Abstract
Trends in the global, regional, and national burden of bladder cancer from 1990
to 2021: an observational study from the global burden of disease study 2021.
Sci Rep. 2025;15:7655.
Abstract
Multiparametric MRI for Bladder Cancer: A Practical Approach to the Clinical
Application of VI-RADS.
Radiology. 2025;314:e233459.
Abstract
RETRACTION: Role of miR-490-3p in Blocking Bladder Cancer Growth Through
Targeting the RNA-Binding Protein PCBP2.
Kaohsiung J Med Sci. 2025 Mar 4:e70009. doi: 10.1002/kjm2.70009.
Abstract
Repeat TURBT in large volume high-grade non-invasive bladder cancer.
Bladder Cancer. 2024;10:270-277.
Abstract
Achieving health equity in bladder cancer care: Addressing disparities through
collaborative research and evidence-based strategies.
Bladder Cancer. 2024;10:264-269.
Abstract
North American study and meta-analysis evaluating performance of Bladder
EpiCheck((R)), a FDA cleared test, in non-muscle invasive bladder cancer
recurrence.
Bladder Cancer. 2025;10:278-289.
Abstract
BCG therapy for bladder cancer: Exploring patient experiences and concerns
through artificial intelligence-based social media analysis.
Bladder Cancer. 2024;10:290-299.
Abstract
Muscle invasive bladder cancer treated with gemcitabine plus cisplatin as
neoadjuvant chemotherapy during the second trimester of pregnancy.
IJU Case Rep. 2025;8:138-141.
Abstract
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer:
Current status and future perspectives.
Bladder Cancer. 2025;11:23523735251322017.
Abstract
Management of bladder cancer in kidney transplant recipients: A narrative review.
Bladder Cancer. 2025;11:23523735251321986.
Abstract
Summary from the NCI clinical trials planning meeting on next generation of
clinical trials in non-muscle invasive bladder cancer().
Bladder Cancer. 2025;11:23523735251319185.
Abstract
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC)
payloads in bladder cancer.
Bladder Cancer. 2025;11:23523735251317865.
Abstract
Practice patterns and outcomes of conventional versus split-dose cisplatin in
neoadjuvant ddMVAC in bladder cancer.
Bladder Cancer. 2025;11:23523735241310388.
Abstract
Urachal adenocarcinoma presenting as pseudomyxoma peritonei: an unusual bladder
tumour.
BMJ Case Rep. 2025;18:e258115.
Abstract
123I-MIBG SPECT/CT in Evaluating Symptomatic Urinary Bladder Pheochromocytoma.
Clin Nucl Med. 2025;50:e211-e213.
Abstract
Single Cell RNA-sequencing of BCG naive and recurrent non-muscle invasive bladder
cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.
bioRxiv [Preprint]. 2025 Feb 17:2025.02.13.638074.
Abstract
Clinical utility of liquid biopsy in bladder cancer: The beginning of a new era.
J Liq Biopsy. 2024;6:100271.
Abstract
Nutraceutical Evaluation of Trigonelline's Therapeutic Potential by Targeting
Bladder Cancer Stem Cells and Cancer-Associated Fibroblasts via Downregulation of
TGFbeta3/GLI2/YAP1 Signaling Hub.
Int J Med Sci. 2025;22:1194-1207.
Abstract
Emerging drivers of female bladder cancer: a pathway to precision prevention and
treatment.
Front Oncol. 2025;15:1497637.
Abstract
Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A
case report.
Respir Med Case Rep. 2025;54:102179.
Abstract
An unfolded protein response (UPR)-signature regulated by the NFKB-miR-29b/c axis
fosters tumor aggressiveness and poor survival in bladder cancer.
Front Mol Biosci. 2025;12:1542650.
Abstract
Prognostic and predictive role of circulating tumor DNA detection in patients
with muscle invasive bladder cancer: a systematic review and meta-analysis.
Cancer Cell Int. 2025;25:75.
Abstract
Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance
in bladder cancer by binding to IGF2BP2.
J Exp Clin Cancer Res. 2025;44:80.
Abstract
TCF7 functions as a prognostic biomarker in bladder cancer by strengthening EMT
and stemness associated with TGF-beta/SMAD3 signaling.
Mol Cell Biochem. 2025 Mar 1. doi: 10.1007/s11010-025-05241.
Abstract
STAG2 expression imparts distinct therapeutic vulnerabilities in muscle-invasive
bladder cancer cells.
Oncogenesis. 2025;14:4.
Abstract
Discovery of new aphidicolin diterpenoids from the deep-sea-derived fungus
Botryotinia fuckeliana with cytotoxic activity against human bladder cancer
cells.
Bioorg Chem. 2025;157:108311.
Abstract
In vitro Evaluation of Zinc Oxide-Metformin Folic Acid Nanocomposite as a
Targeted Drug Delivery System for Cancer Therapy.
Asian Pac J Cancer Prev. 2025;26:443-452.
Abstract
Association of metabolic syndrome and chronic kidney disease with nonmuscle
invasive bladder cancer recurrence and progression.
Urol Oncol. 2025 Feb 27:S1078-1439(25)00032.
Abstract
Gold nanoparticles/Cu decorated metal-organic frameworks for synergistic
photodynamic/ferroptosis cancer therapy.
Biomed Mater. 2025;20.
Abstract
Primary adenocarcinoma of the urinary tract and its precursors: Diagnostic
criteria and classification.
Hum Pathol. 2025;155:105734.
Abstract
Epidemiology, resource use, and treatment patterns of locally advanced or
metastatic urothelial carcinoma in France.
Future Oncol. 2025;21:665-679.
Abstract
Relationship between intraoperative intestinal cultures and postoperative urinary
infection in radical cystectomy with ileal diversion patients.
Actas Urol Esp (Engl Ed). 2025;49:501703.
Abstract
The value of magnetic resonance imaging in predicting vesicovaginal fistula in
cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Gynecol Oncol. 2025;193:136-140.
Abstract
"Three-in-one" Analysis of Proteinuria for Disease Diagnosis through
Multifunctional Nanoparticles and Machine Learning.
Adv Sci (Weinh). 2025;12:e2410751.
Abstract
Concomitant antihistamine administration is associated with improved survival
outcomes in patients with locally advanced or metastatic urothelial carcinoma
treated with atezolizumab. Analysis of individual participant data from
IMvigor210 and IMvigor2
Urol Oncol. 2025;43:188.
Abstract
Single-Cell RNA Sequencing Reveals the Tumor Heterogeneity and Immunosuppressive
Microenvironment in Urothelial Carcinoma.
Cancer Sci. 2025;116:710-723.
Abstract
Retrospective analysis of partial cystectomy in patients with muscle-invasive
urothelial carcinoma: A German single-center experience.
Urol Oncol. 2025;43:188.
Abstract
Real-world survival and economic burden among patients with locally advanced or
metastatic urothelial carcinoma in the United States.
Urol Oncol. 2025;43:189.
Abstract
The role of intravesical chemotherapy following nephroureterectomy in upper tract
urothelial carcinoma: A systematic review and meta-analysis.
Urol Oncol. 2025;43:191.
Abstract
Development of a new radical cystectomy surveillance protocol and nurse-led
cystectomy follow-up clinic in Australia.
ANZ J Surg. 2025;95.
Abstract
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A
systematic review and meta-analysis of randomized clinical trials.
Urol Oncol. 2025;43:156-163.
Abstract
8-Methoxy-alpha-lapachone and lawsone: antiproliferative effects on bladder tumour
cells.
Nat Prod Res. 2025;39:1058-1064.
Abstract
Enhancing Drug Repositioning Through Local Interactive Learning With Bilinear
Attention Networks.
IEEE J Biomed Health Inform. 2025;29:1644-1655.
Abstract
Niacin Ester Derivative of Brefeldin A as a Potential Dual-Target Arf1/BMX
Inhibitor for Bladder Cancer.
J Nat Prod. 2025 Mar 14. doi: 10.1021/acs.jnatprod.5c00086.
Abstract
Radiotherapy can significantly improve survival outcomes in patients with
muscle-invasive bladder cancer who are unsuitable for cystectomy or
chemoradiotherapy.
Am J Cancer Res. 2025;15:723-736.
Abstract
Inhibition of Cyclin D1 by Novel Biguanide Derivative YB-004 Increases the
Sensitivity of Bladder Cancer to Olaparib via Causing G0 / G1 Arrest.
Int J Biol Sci. 2025;21:1984-1998.
Abstract
IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by
enhancing the mRNA stability of CDK6 in an m6A dependent manner.
Int J Biol Sci. 2025;21:2048-2066.
Abstract
Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a
comparative analysis of efficacy and safety in muscle-invasive bladder cancer.
Front Immunol. 2025;16:1549647.
Abstract
Chlorination by-products in drinking water - association with bladder cancer
risk.
Nat Rev Urol. 2025 Mar 13. doi: 10.1038/s41585-025-01017.
Abstract
Novel Computational Pipeline Enables Reliable Diagnosis of Inverted Urothelial
Papilloma and Distinguishes It From Urothelial Carcinoma.
JCO Clin Cancer Inform. 2025;9:e2400059.
Abstract
Life Experience of Patients Living With Urostomy: A Meta-Synthesis of Qualitative
Research.
Psychooncology. 2025;34:e70096.
Abstract
Pulsed TM-YAG laser (Thulio(R)): a new weapon in endourologists' hand in the
conservative management of imperative cases of Upper Tract Urothelial Carcinoma
(UTUC).
Int Braz J Urol. 2025;51:e20240653.
Abstract
Quadratus lumborum block is feasible alternative to epidural block for
postoperative analgesia after open radical cystectomy: surgical and oncological
outcomes of a randomised clinical trial.
Scand J Urol. 2025;60:59-65.
Abstract
The Impact of the Localization of Metastasis in Bladder Cancer Patients with
Recurrence After Cystectomy.
Cancers (Basel). 2025;17:867.
Abstract
Serum Tumor Markers for Muscle-Invasive Bladder Cancer in Clinical Practice: A
Narrative Review.
Cancers (Basel). 2025;17:728.
Abstract
Factors predicting local or systemic side effects related to intravesical BCG
(Bacillus Calmette-Guerin) therapy: a retrospective observational study.
BMC Urol. 2025;25:49.
Abstract
Exosomes containing miR-152-3p targeting FGFR3 mediate SLC7A7-induced
angiogenesis in bladder cancer.
NPJ Precis Oncol. 2025;9:71.
Abstract
Starvation-induced HBP metabolic reprogramming and STAM2 O-GlcNAcylation
facilitate bladder cancer metastasis.
Sci Rep. 2025;15:8480.
Abstract
Association of radiotherapy with secondary pelvic cancers in male patients with
rectal cancer.
Int J Colorectal Dis. 2025;40:65.
Abstract
A machine learning-based prognostic signature utilizing MSC proteomics for
predicting bladder cancer prognosis and treatment response.
Transl Oncol. 2025;54:102349.
Abstract
Feasibility, Safety, and Patient Satisfaction of Transurethral Bladder Tumor
Resection in an Outpatient Setting.
Cancer Rep (Hoboken). 2025;8:e70120.
Abstract
Metabolic landscape in bladder cancer.
Curr Opin Oncol. 2025 Mar 12. doi: 10.1097/CCO.0000000000001137.
Abstract
Outcomes of total cystectomy with medical treatment in canine urothelial
carcinoma of the bladder trigone.
Can Vet J. 2025;66:318-326.
Abstract
Real-World Treatment Patterns and Outcomes in Patients With Bacillus
Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A
Multicountry Medical Chart Review.
Clin Genitourin Cancer. 2025;23:102313.
Abstract
Neoadjuvant Chemotherapy and Partial Cystectomy for Muscle-Invasive Bladder
Cancer - 20-year bladder-preserved survival.
Urol Pract. 2025 Mar 11:101097UPJ0000000000000807.
Abstract
Intracorporeal versus extracorporeal neobladder in robot-assisted radical
cystectomy: perioperative, oncological, and functional outcomes from a
single-institutional experience.
World J Urol. 2025;43:160.
Abstract
[Association of glitazones and bladder cancer: a rapid review].
Urologie. 2025 Mar 11. doi: 10.1007/s00120-025-02557.
Abstract
Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial
Carcinoma: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2025;8:e250250.
Abstract
Regulation of Apoptosis, Autophagy, and Metastasis by Luteolin in Human Bladder
Cancer EJ138 Cells: An Experimental Study.
Iran J Pharm Res. 2024;23:e153408.
Abstract
A CT-based interpretable deep learning signature for predicting PD-L1 expression
in bladder cancer: a two-center study.
Cancer Imaging. 2025;25:27.
Abstract
Health-related quality of life after radical cystectomy for bladder cancer in
elderly patients with ileal orthotopic neobladder, ureterocutaneostomy or ileal
conduit: cross-sectional study using validated questionnaires.
BMC Urol. 2025;25:46.
Abstract
A histopathological snapshot of bladder cancer: a Johannesburg experience of 1480
histopathology reports.
World J Urol. 2025;43:159.
Abstract
A qualitative study exploring the experiences of nurses delivering bacillus
Calmette-Guerin therapy.
Br J Nurs. 2025;34:S4-S8.
Abstract
Comparing oncological outcomes and safety between photodynamic diagnosis-assisted
and white-light transurethral resection in elderly patients with non-muscle
invasive bladder cancer.
Jpn J Clin Oncol. 2025 Mar 10:hyaf047. doi: 10.1093.
Abstract
Prognostic Factors Influencing Postoperative Survival in Patients With
Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Cancer Med. 2025;14:e70758.
Abstract
PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1/S
Progression and Epithelial-Mesenchymal Transition.
Cancer Med. 2025;14:e70749.
Abstract
Updated review on novel therapies and ongoing clinical trials for high-risk
non-muscle invasive bladder cancer.
Front Oncol. 2025;15:1519428.
Abstract
Sex-specific associations of sex hormone binding globulin and risk of bladder
cancer.
Open Med (Wars). 2025;20:20251163.
Abstract
Neoantigen immunotherapy: a novel treatment for bladder cancer.
Explor Target Antitumor Ther. 2025;6:1002288.
Abstract
ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using
[(64)Cu]Cu-NOTA-Trodelvy.
Mol Pharm. 2025 Mar 9. doi: 10.1021/acs.molpharmaceut.5c00069.
Abstract
A systematic review and meta-analysis of intracorporeal versus extracorporeal
urinary diversion after robotic-assisted radical cystectomy in elderly patients
with malignancy.
J Robot Surg. 2025;19:106.
Abstract
Optimal energy source selection strategies for en bloc resection in non-muscle
invasive bladder cancer: a systematic review and network meta-analysis.
World J Urol. 2025;43:155.
Abstract
ENPP1 promotes immune suppression, drug resistance, and adverse outcomes in
bladder cancer: Potential for targeted therapy.
Cancer Genet. 2025;294-295:1-14.
Abstract
Comprehensive pan-cancer single-cell analysis reveals glycolysis-related
signatures as predictive biomarkers for immunotherapy response and their role in
bladder Cancer.
Int Immunopharmacol. 2025;152:114381.
Abstract
Efficacy and safety of disitamab vedotin in combination with immune checkpoint
inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
World J Urol. 2025;43:154.
Abstract
Antioxidant Properties of Aronia melanocarpa and Morinda citrifolia Juices and
their Impact on Bladder Cancer Cell Lines.
Med Sci Monit. 2025;31:e945120.
Abstract
Disulfidptosis related immune genes drive prognostic model development and tumor
microenvironment characterization in bladder urothelial carcinoma.
Sci Rep. 2025;15:8130.
Abstract
Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures
for bladder cancer.
Nat Commun. 2025;16:2292.
Abstract
Correlation of noninvasive imaging of tumour-infiltrating lymphocytes with
survival and BCG immunotherapy response in patients with bladder cancer: a
multicentre cohort study.
Int J Surg. 2025;111:920-931.
Abstract
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients
With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and
KEYNOTE-361 Trials.
Clin Genitourin Cancer. 2025;23:102273.
Abstract
Isolated Urinary Tract Persistence or Progression in Patients Treated With
Immunotherapy for Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2025;23:102312.
Abstract
Mapping the initial effects of carcinogen-induced oncogenic transformation in the
mouse bladder.
Exp Cell Res. 2025;446:114452.
Abstract
Predicting cancer survival at different stages: Insights from fair and
explainable machine learning approaches.
Int J Med Inform. 2025;197:105822.
Abstract
An accurate and trustworthy deep learning approach for bladder tumor segmentation
with uncertainty estimation.
Comput Methods Programs Biomed. 2025;263:108645.
Abstract
Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy
in metastatic urothelial cancer.
JCI Insight. 2025;10:e186062.
Abstract
Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment
Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA
Study).
Clin Genitourin Cancer. 2025;23:102301.
Abstract
Efficacy and safety of enfortumab vedotin in older patients with metastatic
urothelial carcinoma: A multicenter retrospective study.
J Geriatr Oncol. 2025;16:102183.
Abstract
FOXP3/TLS; a prognostic marker in patients with bladder carcinoma without muscle
invasion.
Urol Oncol. 2025;43:268.
Abstract
Long-term oncologic outcomes and complications of robot-assisted radical
cystectomy for the treatment of urothelial carcinoma of the bladder.
Urol Oncol. 2025;43:267.
Abstract
Tumor involvement of the trigone and urethra at the time of robot-assisted
radical cystectomy is associated with adverse oncological outcomes.
Urol Oncol. 2025;43:268.
Abstract
Quantification of micropapillary component on transurethral resection is
associated with likelihood of occult lymph node metastasis at radical cystectomy.
Urol Oncol. 2025;43:266.
Abstract
Antibiotic use attenuates response to immune checkpoint blockade in urothelial
carcinoma via inhibiting CD74-MIF/COPA: revealing cross-talk between
anti-bacterial immunity and ant-itumor immunity.
Int J Surg. 2025;111:972-987.
Abstract
TNF-alpha drives bladder cancer metastasis via METTL3-mediated m6A modification to
promote CLASP2/IQGAP1-dependent cytoskeleton remodeling.
Biochim Biophys Acta Mol Basis Dis. 2025 Mar 19:167811.
Abstract
Survival analysis comparing bladder preservation techniques in octogenarians with
muscle-invasive bladder cancer.
Transl Androl Urol. 2025;14:280-288.
Abstract
Emodin Decreases Tumor-Associated Macrophages Accumulation and Suppresses Bladder
Cancer Development by Inhibiting CXCL1 Secretion from Cancer-Associated
Fibroblasts.
Nutr Cancer. 2025 Mar 20:1-16. doi: 10.1080/01635581.2025.2480309.
Abstract
Robot-assisted radical cystectomy with the clinical application of "Y-shaped"
end-to-side ureteral anastomosis in elderly and obese patients.
BMC Urol. 2025;25:56.
Abstract
Effective Delivery of CRISPR/dCas9-SAM for Multiplex Gene Activation Based on
Mesoporous Silica Nanoparticles for Bladder Cancer Therapy.
Acta Biomater. 2025 Mar 18:S1742-7061(25)00205.
Abstract
Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR-Altered Bladder Cancer.
Adv Sci (Weinh). 2025 Mar 20:e2413209. doi: 10.1002/advs.202413209.
Abstract
Comparison of extended and standard lymph node dissection in radical cystectomy
for urothelial bladder cancer: a systematic review and meta-analysis.
World J Urol. 2025;43:181.
Abstract
BCG therapy in bladder cancer and its tumor microenvironment interactions.
Clin Microbiol Rev. 2025 Mar 20:e0021224. doi: 10.1128/cmr.00212.
Abstract
Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval
of Anktiva in combination with BCG.
Ann Med Surg (Lond). 2025;87:457-459.
Abstract
Integrated single-cell analysis reveals the regulatory network of
disulfidptosis-related lncRNAs in bladder cancer: constructing a prognostic model
and predicting treatment response.
Front Oncol. 2025;15:1527036.
Abstract
Exploring the utility of a NGS multigene panel to predict BCG response in
patients with non-muscle invasive bladder cancer.
Oncol Res. 2025;33:723-731.
Abstract
Biomarkers for predicting bladder cancer therapy response.
Oncol Res. 2025;33:533-547.
Abstract
Serum metabolomic analysis identified serum biomarkers predicting tumour
recurrence after Bacillus Calmette-Guerin therapy in patients with non-muscle
invasive bladder cancer.
Bladder Cancer. 2025;11:23523735251325100.
Abstract
ADME gene-driven prognostic model for bladder cancer: a breakthrough in
predicting survival and personalized treatment.
Hereditas. 2025;162:42.
Abstract
Radiofrequency induced hyperthermia in non-muscle invasive bladder cancer:
Oncologic outcomes in a real-world scenario.
Actas Urol Esp (Engl Ed). 2025 Mar 17:501746. doi: 10.1016/j.acuroe.2025.501746.
Abstract
DDR1 Targeting HOXA6 Facilitates Bladder Cancer Progression via Inhibiting
Ferroptosis.
J Cell Mol Med. 2025;29:e70410.
Abstract
The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through
enhancing HSP90AB1 expression.
FEBS J. 2025 Mar 19. doi: 10.1111/febs.70068.
Abstract
Clinical characterization and prognostic modeling of bladder cancer patients with
a history of prior tumors: a SEER database analysis.
Transl Cancer Res. 2025;14:1111-1123.
Abstract
Recent Advances and Emerging Innovations in Transurethral Resection of Bladder
Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of
Current Literature.
Res Rep Urol. 2025;17:69-85.
Abstract
Enhanced efficacy of immune checkpoint inhibitors by folate-targeted
multifunctional drug through synergistic therapy inducing ferroptosis and
immunogenic cell death in bladder cancer.
Mater Today Bio. 2025;31:101584.
Abstract
A Machine Learning Model Based on Multi-Phase Contrast-enhanced CT for the
Preoperative Prediction of the Muscle-Invasive Status of Bladder Cancer.
Curr Med Imaging. 2025 Mar 17. doi: 10.2174/0115734056377754250304040058.
Abstract
Assessing the clinical efficacy of neoadjuvant intravesical Mitomycin C in naive
non-muscle invasive urinary bladder cancer: A systematic review and
meta-analysis.
Curr Probl Cancer. 2025 Mar 17:101198.
Abstract
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial
cancer: primary analysis of a multicenter, single-arm, phase II,
investigator-initiated trial (NEXT).
J Immunother Cancer. 2025;13:e010572.
Abstract
Predicting variant histology in bladder cancer: the role of multiparametric MRI
and vesical imaging-reporting and data system (VI-RADS).
Abdom Radiol (NY). 2025 Mar 18. doi: 10.1007/s00261-025-04852.
Abstract
Enhanced Artificial Intelligence in Bladder Cancer Management: A Comparative
Analysis and Optimization Study of Multiple Large Language Models.
J Endourol. 2025 Mar 18. doi: 10.1089/end.2024.0860.
Abstract
Comprehensive analysis of RNA methylation-related genes to identify molecular
cluster for predicting prognosis and immune profiles in bladder cancer.
Sci Rep. 2025;15:9147.
Abstract
TPI1 promotes p53 ubiquitination in bladder cancer by recruiting AKT to enhance
MDM2 phosphorylation.
Pharmacol Res. 2025;215:107695.
Abstract
Impact of opium on bladder cancer incidence: A systematic review and
meta-analysis.
Actas Urol Esp (Engl Ed). 2025 Mar 15:501749. doi: 10.1016/j.acuroe.2025.501749.
Abstract
A nomogram based on preoperative NLR predicts distant metastasis of urothelial
carcinoma of the bladder.
Cancer Biomark. 2024;41.
Abstract
Deep learning-based model for prediction of early recurrence and therapy response
on whole slide images in non-muscle-invasive bladder cancer: a retrospective,
multicentre study.
EClinicalMedicine. 2025;81:103125.
Abstract
Efficacy and safety of Solifenacin combined with Mirabegron in treating
overactive bladder in female patients following bladder instillation for bladder
cancer.
Am J Transl Res. 2025;17:1144-1152.
Abstract
Recent Advances in Immunotherapy for Bladder Cancer Treatment.
Cureus. 2025;17:e79002.
Abstract
SUMOylation of SETD8 Promotes Tumor Growth by Methylating and Stabilizing MYC in
Bladder Cancer.
Adv Sci (Weinh). 2025 Mar 16:e2501734. doi: 10.1002/advs.202501734.
Abstract
High-fidelity telomerase activity assay based on light-triggered nucleic acid
separation system for the diagnosis of bladder cancer.
Biosens Bioelectron. 2025;278:117355.
Abstract
Correction: FENDRR Represses Bladder Cancer Cell Proliferation, Stemness,
Migration, Invasion, and EMT Process by Targeting miR-18a-5p/AFF4 Axis.
Biochem Genet. 2025 Mar 15. doi: 10.1007/s10528-025-11065.
Abstract
Sex as modifier of survival in patients with advanced urothelial cancer treated
with pembrolizumab.
Sci Rep. 2025;15:8815.
Abstract
Factor VIII a coagulation co-factor is a relevant survival factor in bladder
cancer cell lines.
J Thromb Haemost. 2025 Mar 12:S1538-7836(25)00142.
Abstract
Spatial expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer
and metastases: Implications for pathological and clinical management.
Mod Pathol. 2025 Mar 12:100753. doi: 10.1016/j.modpat.2025.100753.
Abstract
Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer:
Exploratory subject-based analysis in a prospective, single-arm, multicenter
phase III trial.
Photodiagnosis Photodyn Ther. 2025;53:104554.
Abstract
Analyzing Online Search Trends for Kidney, Prostate, and Bladder Cancers in
China: Infodemiology Study Using Baidu Search Data (2011-2023).
JMIR Cancer. 2025;11:e57414.
Abstract
4,4'-methylenebis(2-chloroaniline) induces chromosome aneuploidy associated with
premature chromatid separation in mammalian cells: A possible carcinogenic
mechanism.
Ecotoxicol Environ Saf. 2025;293:117981.
Abstract
Individualizing first-line treatment for advanced urothelial carcinoma: A
favorable dilemma for patients and physicians.
Cancer Treat Rev. 2025;134:102900.
Abstract
"Mannose glycans as key players in trained immunity: A novel anti-tumoral
catalyst".
Biochim Biophys Acta Gen Subj. 2025;1869:130779.
Abstract
Precise identification of bladder tumors utilizing mucoadhesive thiolated hollow
mesoporous silica nanoparticles.
J Control Release. 2025;380:1127-1140.
Abstract
Enhanced Recovery After Surgery for patients undergoing radical cystectomy:
Surgeons' perspectives and recommendations ten years after its implementation.
Eur J Surg Oncol. 2025;51:109543.
Abstract
Late-onset disseminated BCG infection with hepatosplenomegaly after intravesical
BCG immunotherapy in a non-immunocompromised patient.
Clin J Gastroenterol. 2025;18:337-342.
Abstract
Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo:
Insights from a comprehensive cohort population-based study.
J Am Acad Dermatol. 2025;92:741-752.
Abstract
Cryptotanshinone Suppresses the STAT3/BCL-2 Pathway to Provoke Human Bladder
Urothelial Carcinoma Cell Death.
Environ Toxicol. 2025;40:624-635.
Abstract
Primary Melanoma of the Urinary Bladder: Clinical, Histopathologic, and
Comprehensive Molecular Analysis of a Rare Tumor.
Int J Surg Pathol. 2025;33:477-483.
Abstract
Urothelial Carcinoma with Trophoblastic Differentiation-A Report with Review.
Int J Surg Pathol. 2025;33:490-494.
Abstract
Single-center analysis of a real-world cohort of patients with metastatic
urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of
targeted therapies.
Clin Transl Oncol. 2025;27:1211-1220.
Abstract
Construction and validation of a reliable disulfidptosis-related lncRNAs
signature of the subtype, prognostic, and immune landscape in bladder cancer.
Discov Oncol. 2025;16:418.
Abstract
Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in
Muscle-Invasive Bladder Cancer.
Biomedicines. 2025;13:740.
Abstract
UBC4: A Repurposed Drug Regimen for Adjunctive Use During Bladder Cancer
Treatment.
Biomedicines. 2025;13:706.
Abstract
Low GCNT2/I-Branching Glycan Expression Is Associated with Bladder Cancer
Aggressiveness.
Biomedicines. 2025;13:682.
Abstract
Loss of OBSCN expression promotes bladder cancer progression but enhances the
efficacy of PD-L1 inhibitors.
Cell Biosci. 2025;15:40.
Abstract
Correlation between thyroid hormone levels and the incidence and staging of
bladder cancer.
Eur J Med Res. 2025;30:211.
Abstract
Epidemiology of gall bladder cancer and its prevalence worldwide: a
meta-analysis.
Orphanet J Rare Dis. 2025;20:143.
Abstract
Spatial relationships and interactions of immune cell niches are linked to the
pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy.
J Transl Med. 2025;23:375.
Abstract
Robotic versus open surgery for ureteroenteric stricture after radical
cystectomy: a systematic review and meta-analysis.
J Robot Surg. 2025;19:130.
Abstract
Analysis of long-term trends and 15-year predictions of smoking-related bladder
cancer burden in china across different age and sex groups from 1990 to 2021.
Discov Oncol. 2025;16:408.
Abstract
Development and psychometric evaluation of a patient-reported symptom index for
patients with non-muscle invasive bladder cancer: the NMIBC-SI.
J Patient Rep Outcomes. 2025;9:36.
Abstract
Association of energy source with outcomes in en bloc TURB: secondary analysis of
a randomized trial.
World J Urol. 2025;43:191.
Abstract
Visceral Adipose Predicts Prognosis and Toxicities in Locally Advanced Bladder
Cancer Patients Treated With Adjuvant Gemcitabine Plus Cisplatin Chemotherapy.
Cancer Med. 2025;14:e70742.
Abstract
Effect of Perioperative Immunonutrition on Early-Postoperative Complications in
Patients Undergoing Radical Cystectomy for Bladder Cancer: A Case Series.
J Clin Med. 2025;14:1992.
Abstract
Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based
Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score.
J Clin Med. 2025;14:1954.
Abstract
Diagnostic Performance and Interobserver Agreement of the Vesical
Imaging-Reporting and Data System (VI-RADS) in Bladder Cancer Staging: A
Systematic Review.
Medicina (Kaunas). 2025;61:469.
Abstract
Intravesical BCG: A Double-Edged Sword? The Untold Story of Infection Risks.
Medicina (Kaunas). 2025;61:379.
Abstract
Development and validation of a nomogram for predicting prostatic urethral
involvement in bladder cancer.
Sci Rep. 2025;15:10431.
Abstract
RETRACTION: Impacts of Enhanced Recovery After Surgery Nursing Interventions on
Wound Infection and Complications Following Bladder Cancer Surgery: A
Meta-Analysis.
Int Wound J. 2025;22:e70449.
Abstract
FGFR3 gene mutations screening in non-muscle invasive bladder cancer (NMIBC) in
the Tunisian population.
Mol Biol Rep. 2025;52:338.
Abstract
Repurposing ProTAME for Bladder Cancer: A Combined Therapeutic Approach Targeting
Cell Migration and MMP Regulation.
Biology (Basel). 2025;14:263.
Abstract
USP5 Suppresses Ferroptosis in Bladder Cancer Through Stabilization of GPX4.
Curr Issues Mol Biol. 2025;47:211.
Abstract
Self-Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for
Enhanced Bladder Cancer Immunotherapy.
Adv Sci (Weinh). 2025 Mar 26:e2502750. doi: 10.1002/advs.202502750.
Abstract
Bladder cancer biomarkers.
Explor Target Antitumor Ther. 2025;6:1002301.
Abstract
Ailanthone inhibits bladder cancer tumor and cell proliferation,
epithelial-mesenchymal transition, and activation of the Janus kinase/signal
transducer and activator of transcription 3 signaling pathway.
Cytojournal. 2025;22:16.
Abstract
XIAP promotes metastasis of bladder cancer cells by ubiquitylating YTHDC1.
Cell Death Dis. 2025;16:205.
Abstract
Urogenital infection with M. bovis BCG most probably as a result of BCG
instillation 21 years ago.
BMJ Case Rep. 2025;18:e260496.
Abstract
Circular RNAs: driving forces behind chemoresistance and immune evasion in
bladder cancer.
Naunyn Schmiedebergs Arch Pharmacol. 2025.
Abstract
Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and
metastatic disease.
Scand J Urol. 2025;60:76-82.
Abstract
Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG
responders and non-responders.
Front Cell Infect Microbiol. 2025;15:1479795.
Abstract
Global research trends and hotspots on imaging of bladder cancer: A bibliometric
and visual analysis from 1981 to 2023.
Medicine (Baltimore). 2025;104:e41907.
Abstract
DTX3 suppresses bladder cancer cell invasion and metastasis by inhibiting the
Notch signaling pathway.
Int Immunopharmacol. 2025;153:114529.
Abstract
Preoperative prediction of muscle invasion in bladder cancer in the Indian
population using the Vesical Imaging-Reporting and Data System (VI-RADS) score
and individual multiparametric magnetic resonance imaging (MRI) characteristics.
Clin Radiol. 2025;84:106862.
Abstract
Is There Always a Need to Perform Urine Culture before Bacillus Calmette-Guerin
Instillation for Bladder Cancer?
Surg Infect (Larchmt). 2025 Mar 24:0. doi: 10.1089/sur.2024.
Abstract
Ureterocele with embedded stone suggesting a diagnosis of bladder tumor: beware
of the diagnostic trap! (case report and literature review).
Pan Afr Med J. 2024;49:119.
Abstract
Standard vs extended lymphadenectomy for muscle invasive bladder cancer.
Bladder Cancer. 2025;11:23523735251314984.
Abstract
2'-Hydroxyflavanone inhibits bladder cancer cell proliferation and angiogenesis
via regulating miR-99a-5p/mTOR signaling.
Am J Clin Exp Urol. 2025;13:20-32.
Abstract
Metabolomic Biomarkers for Prognosis in Non-Muscle Invasive Bladder Cancer: A
Comprehensive Systematic Review and Meta-Analysis.
Indian J Clin Biochem. 2025;40:176-190.
Abstract
Retraction Note: Epithelial-to-mesenchymal transition based diagnostic and
prognostic signature markers in non-muscle invasive and muscle invasive bladder
cancer patients.
Mol Biol Rep. 2025;52:334.
Abstract
Machine Learning and Mendelian Randomization Reveal a Tumor Immune Cell Profile
for Predicting Bladder Cancer Risk and Immunotherapy Outcomes.
Am J Pathol. 2025 Mar 21:S0002-9440(25)00077.
Abstract
Prognostic biomarker PSMD14 facilitates bladder cancer tumorigenesis and
progression by regulating Nucleolin-YAP1 axis.
Transl Oncol. 2025;55:102370.
Abstract
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
via interpretable multimodal deep learning.
NPJ Digit Med. 2025;8:174.
Abstract
Deep learning on T2WI to predict the muscle-invasive bladder cancer: a
multi-center clinical study.
Sci Rep. 2025;15:9942.
Abstract
MiR-125b suppresses bladder Cancer cell growth and triggers apoptosis by
regulating IL-6/IL-6R/STAT3 axis in vitro and in vivo.
Cytokine. 2025;190:156926.
Abstract
Protocol for single-cell RNA sequencing and spatial transcriptomics of bladder
Ewing sarcoma.
STAR Protoc. 2025;6:103687.
Abstract
Association of body mass index and tumor response in metastatic urothelial
carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.
Int J Clin Oncol. 2025;30:761-769.
Abstract
Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for
Treating Advanced Urothelial Carcinoma.
Eur Urol Oncol. 2025;8:242-244.
Abstract
Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk
Populations in England: A Microsimulation Study of Long-Term Impact and
Cost-Effectiveness.
Pharmacoeconomics. 2025;43:441-452.
Abstract
Molecular mechanisms of antiproliferative and pro-apoptotic effects of essential
oil active constituents in MCF7 and T24 cancer cell lines: in vitro insights and
in silico modelling of proapoptotic gene product-compound interactions.
Apoptosis. 2025;30.
Abstract
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with
Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Eur Urol Oncol. 2025;8:258-262.
Abstract
Genetics of urinary bladder paragangliomas: a multi-center study of a Chinese
cohort.
J Endocrinol Invest. 2025;48:931-939.
Abstract
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with
Advanced Urothelial Carcinoma in France: Overall Results from the
Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line
Treatment.
Eur Urol Oncol. 2025;8:407-416.
Abstract
En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A
Systematic Review and Meta-analysis of Oncological, Histopathological, and
Surgical Outcomes.
Eur Urol Oncol. 2025;8:520-533.
Abstract
Pairing the Right Individual with the Right Regimen: Patient Selection Criteria
in the Treatment of Advanced Urothelial Carcinoma.
Eur Urol Oncol. 2025;8:237-238.
Abstract
Lights and Shadows of Bacillus Calmette-Guerin (BCG)-exposed and BCG-unresponsive
Definitions: A Practical Overview.
Eur Urol Oncol. 2025;8:231-233.
Abstract
Effects of the Paris System on the Unsatisfactory Category in a Cytohistologic
Correlation Study of Patients With Urothelial Carcinoma.
Arch Pathol Lab Med. 2025;149:368-371.
Abstract
Constructing a prognostic model based on MPT-related genes and investigate the
characteristics of immune infiltration in bladder cancer.
Discov Oncol. 2025;16:460.
Abstract
Prospective clinical study of sentinel node detection in bladder cancer using a
hybrid tracer - Towards replacement of pelvic lymph node dissection in cases with
sentinel node visualization on SPECT/CT?
Eur J Nucl Med Mol Imaging. 2025 Apr 4. doi: 10.1007/s00259-025-07240.
Abstract
Clinical outcomes of BCG infections in patients undergoing intravesical
immunotherapy for non-muscle-invasive bladder cancer: a systematic review and
meta-analysis.
Minerva Urol Nephrol. 2025;77:13-24.
Abstract
Chaetoglobosin A induces apoptosis in T-24 human bladder cancer cells through
oxidative stress and MAPK/PI3K-AKT-mTOR pathway.
PeerJ. 2025;13:e19085.
Abstract
Implementing VIRADS score for image-guided assessment of muscle invasiveness in
bladder cancer pre-TURBT: An updated meta-analysis.
Arab J Urol. 2024;23:97-108.
Abstract
Intravesical gemcitabine and docetaxel vs. re-induction Bacillus Calmette Guerin
as first-line salvage therapy for non-muscle invasive bladder cancer.
BJUI Compass. 2025;6:e70012.
Abstract
Nerve infiltration of bladder cancer predicts response to immunotherapy.
Biochem Biophys Res Commun. 2025;761:151687.
Abstract
RNF112 Facilitates Ubiquitin-Mediated Degradation of c-Myc, Suppressing
Proliferation, Migration and Lipid Synthesis in Bladder Cancer.
Adv Sci (Weinh). 2025 Apr 3:e2408311. doi: 10.1002/advs.202408311.
Abstract
The safety and efficacy of BCG combined with mitomycin C compared with BCG
monotherapy in patients with non-muscle-invasive bladder cancer: A systematic
review and meta-analysis.
Open Med (Wars). 2025;20:20241134.
Abstract
Key immune cells and their crosstalk in the tumor microenvironment of bladder
cancer: insights for innovative therapies.
Explor Target Antitumor Ther. 2025;6:1002304.
Abstract
Effectiveness of the Continuous Care Model on Quality of Life, Sexual
Satisfaction and Function in Bladder Cancer Patients Undergoing Tumor Resection
Surgery: A Randomized Control Trial.
Clin Genitourin Cancer. 2025 Mar 4:102321. doi: 10.1016/j.clgc.2025.102321.
Abstract
A mendelian randomization study on the association between type 2 diabetes and
the risk of bladder cancer.
Discov Oncol. 2025;16:446.
Abstract
Usefulness of multiparametric MRI for local staging of bladder cancer.
Urologia. 2025;92:231-236.
Abstract
A novel feedback regulation loop of METTL11A-MAFG-NPL4 promotes bladder cancer
cell proliferation and tumor progression.
FASEB J. 2025;39:e70466.
Abstract
Correction to "Loss of Polarity Protein Par3, via Transcription Factor Snail,
Promotes Bladder Cancer Metastasis".
Cancer Sci. 2025 Apr 1. doi: 10.1111/cas.70073.
Abstract
Bladder Cancer in Lebanon: An Updated Epidemiological Comparison with Global
Regions and a Comprehensive Review of Risk Factors.
Cancer Control. 2025;32:10732748251330696.
Abstract
An efficient graph attention framework enhances bladder cancer prediction.
Sci Rep. 2025;15:11127.
Abstract
PLA2G7 promotes immune evasion of bladder cancer through the JAK-STAT-PDL1 axis.
Cell Death Dis. 2025;16:234.
Abstract
Differential response of low- and high-grade intermediate-risk
non-muscle-invasive bladder cancer to bacillus Calmette-Guerin and
gemcitabine-docetaxel therapy.
Urol Oncol. 2025 Mar 31:S1078-1439(25)00105.
Abstract
Advocating female genital-sparing cystectomy as the standard of care for women
with bladder cancer Re: "2025 Canadian Urological Association Guideline:
Muscle-invasive bladder cancer" (Can Urol Assoc J 2025;19:E1-16).
Can Urol Assoc J. 2025;19:E138-E139.
Abstract
Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment
of muscle-invasive urothelial carcinoma at high risk of recurrence in France.
World J Urol. 2025;43:202.
Abstract
Will artificial intelligence (AI) replace cytopathologists: a scoping review of
current applications and evidence of A.I. in urine cytology.
World J Urol. 2025;43:200.
Abstract
Prognostic and predictive value of pre-treatment blood-based inflammatory
biomarkers in patients with urothelial carcinoma treated with immune checkpoint
inhibitors: a systematic review and meta-analysis.
Front Immunol. 2025;16:1554048.
Abstract
Case Report: Pembrolizumab in a patient with preexisting paraneoplastic
dermatomyositis and sarcomatoid urothelial carcinoma. Searching for balance.
Front Immunol. 2025;16:1558964.
Abstract
Investigation of new autoantibodies in urothelial bladder cancer for biomarker
discovery using immunoproteomics.
Discov Oncol. 2025;16:436.
Abstract
Drug-Loaded Mitochondrial Targeted Nanoparticles for Tumor Imaging and PDT/PTT
Combined Chemotherapy in Muscle-Invasive Bladder Cancer.
Macromol Biosci. 2025 Mar 31:e2400575. doi: 10.1002/mabi.202400575.
Abstract
Contribution of smoking to the global burden of bladder cancer from 1990 to 2021
and projections to 2046.
Tob Induc Dis. 2025;23:10.
Abstract
Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a
decision analysis.
World J Urol. 2025;43:197.
Abstract
Single-cell sequencing uncovers a high ESM1-expression endothelial cell
subpopulation associated with bladder cancer progression and the
immunosuppressive microenvironment.
Sci Rep. 2025;15:10946.
Abstract
N6-methyladenosine-modified RNF220 induces cisplatin resistance and immune escape
via regulating PDE10A K48-linked ubiquitination in bladder cancer.
Biochem Pharmacol. 2025;236:116903.
Abstract
Exploring The Prevalence of Telomerase Reverse Transcriptase Promoter Mutations
in Bladder Cancer Patients and Their Correlation with Tumor Characteristics.
Asian Pac J Cancer Prev. 2025;26:1053-1058.
Abstract
CD 14 Expression in Urothelial Carcinoma of The Urinary Bladder
(Histopathological and Immunohistochemical Study).
Asian Pac J Cancer Prev. 2025;26:889-897.
Abstract
Optimizing treatment selection: outcomes of radical cystectomy in patients
eligible for trimodal therapy.
World J Urol. 2025;43:196.
Abstract
CELF2 inhibits bladder cancer progression by decreasing the stability of CXCL5.
Life Sci. 2025;370:123585.
Abstract
There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint
Blockade in Urothelial Carcinoma.
Cancer Immunol Res. 2025;13:454-455.
Abstract
Precision screening with sequential multi-algorithm reclassification technique
(SMART): Saving bladders from unnecessary cystectomy.
Comput Biol Med. 2025;189:109980.
Abstract
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of
advanced urothelial carcinoma.
Expert Rev Anticancer Ther. 2025;25:319-326.
Abstract
Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and
Therapeutic Decision in Urothelial Carcinoma of the Bladder.
Curr Oncol Rep. 2025;27:225-235.
Abstract
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in
Urothelial Cancer.
Cancer Immunol Res. 2025;13:476-486.
Abstract
Patient-specific adaptive planning margin for whole bladder radiation therapy.
J Appl Clin Med Phys. 2025;26:e14617.
Abstract
Risk factors for benign uretero-enteric anastomotic strictures after open radical
cystectomy and ileal conduit.
Urologia. 2025;92:224-230.
Abstract
[An extremely rare case of multiple recurrences of urothelial carcinoma in an
ileal neobladder: a case report and review of the literature].
Aktuelle Urol. 2025;56:164-169.
Abstract
Primary signet ring cell adenocarcinoma arising in exstrophy of the urinary
bladder (epispadias-exstrophy complex).
Indian J Pathol Microbiol. 2025;68:165-167.
Abstract
High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder
cancer to enfortumab vedotin therapy.
Cell Rep. 2025;44:115545.
Abstract
SIGMAR1 screened by a GPCR-related classifier regulates endoplasmic reticulum
stress in bladder cancer.
J Transl Med. 2025;23:417.
Abstract
Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder
Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma.
JCO Precis Oncol. 2025;9:e2400947.
Abstract
Effect of Prehabilitation Interventions in People Affected by Bladder Cancer on
Long-Term Physical, Clinical, and Patient-Reported Outcome Measures: A Systematic
Review.
JCO Oncol Pract. 2025 Apr 10:OP2400984. doi: 10.1200/OP-24-00984.
Abstract
Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical
Complete Response after Neoadjuvant Therapy: Evidence and Consideration for
Active Surveillance.
Curr Urol Rep. 2025;26:36.
Abstract
Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a
systematic review and meta-analysis.
World J Surg Oncol. 2025;23:133.
Abstract
Comparison of hyperthermic intravesical chemotherapy using pirarubicin and
Bacillus Calmette-Guerin in the treatment of patients with high-risk
non-muscle-invasive bladder carcinoma: a retrospective study.
BMC Urol. 2025;25:81.
Abstract
A single-cell atlas of bladder cancer unveils dynamic cellular composition and
endothelial functional shifts during progression.
Discov Oncol. 2025;16:500.
Abstract
MIS18BP1 promotes bladder cancer cell proliferation and growth via inactivating
P53 signaling pathway.
Med Oncol. 2025;42:156.
Abstract
Investigating the role of HMGA2 plasma level as a diagnostic marker in bladder
urothelial carcinoma patients.
J Cancer Res Clin Oncol. 2025;151:134.
Abstract
Oncological Outcomes in Bacillus Calmette-Guerin-naive High-risk
Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current
Treatment Strategies and Future Perspectives.
Eur Urol Oncol. 2025 Apr 8:S2588-9311(25)00081-1. doi: 10.1016/j.euo.2025.
Abstract
Paradoxical Emergence of Cutaneous Squamous Cell Carcinoma During Pembrolizumab
Treatment for Non-muscle Invasive Bladder Cancer and Subsequent Successful
Therapeutic Adjustments.
Cureus. 2025;17:e80293.
Abstract
Bladder Cancer Medication Bacillus Calmette-Guerin-Cell Wall Skeleton Focusing on
Alternatives and Developments to Limitations.
J Cancer Prev. 2025;30:1-6.
Abstract
The Association between Tea Consumption and Bladder Cancer Risk Based on the
Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) International
Consortium.
Nutr Cancer. 2025 Apr 8:1-12. doi: 10.1080/01635581.2025.2488063.
Abstract
Radical cystectomy for bladder cancer in Sub-Saharan Africa: techniques,
challenges, and survival outcomes: a comprehensive review.
BMC Surg. 2025;25:143.
Abstract
mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive
Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL:
Vesical Tumor Early Monitoring: mRNA-Based Follow-up).
Clin Genitourin Cancer. 2025;23:102333.
Abstract
Integration and evaluation of implementation strategies to improve
guideline-concordant bladder cancer surveillance: a prospective observational
study.
Implement Sci Commun. 2025;6:37.
Abstract
Phenotypic characterization of tumor associated macrophages and circulating
monocytes in patients with Urothelial carcinoma of bladder.
Immunol Res. 2025;73:66.
Abstract
Perivascular epithelioid cell neoplasm of the bladder with peritoneal metastasis.
Can J Urol. 2025;32:47-53.
Abstract
Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3
studies.
Can J Urol. 2025;32:29-36.
Abstract
CB-5083 and luteolin synergistically induce the apoptosis of bladder cancer cells
via multiple mechanisms.
Toxicol Appl Pharmacol. 2025 Apr 5:117333. doi: 10.1016/j.taap.2025.117333.
Abstract
Evaluating the Efficacy and Safety of Durvalumab Plus Radiotherapy in Second-Line
Treatment for Advanced Bladder Cancer.
Arch Esp Urol. 2025;78:248-254.
Abstract
Retraction: Puerarin inhibits proliferation and induces apoptosis by upregulation
of miR-16 in bladder cancer cell line T24.
Oncol Res. 2025;33:993.
Abstract
The effect of concomitant drugs on oncological outcomes in patients treated with
immunotherapy for metastatic urothelial carcinoma: a narrative review.
Oncol Res. 2025;33:741-757.
Abstract
Circulating tumor DNA: a revolutionary approach for early detection and
personalized treatment of bladder cancer.
Front Pharmacol. 2025;16:1551219.
Abstract
A Rare Case of Bladder Cancer With Squamous Differentiation Causing Hypercalcemia
and Leukocytosis.
Cureus. 2025;17:e80111.
Abstract
Effect of a hydrogel-based scaffold material on the establishment of a
patient-derived bladder cancer xenograft model.
J Toxicol Pathol. 2025;38:139-145.
Abstract
Perspective on the use of optics in bladder cancer detection and diagnosis.
J Biomed Opt. 2025;30:040601.
Abstract
[Bladder Preservation Therapy for Bladder Cancer].
Gan To Kagaku Ryoho. 2025;52:217-223.
Abstract
Development and validation of interpretable machine learning models to predict
distant metastasis and prognosis of muscle-invasive bladder cancer patients.
Sci Rep. 2025;15:11795.
Abstract
Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal
transition and promote bladder cancer progression.
BMC Urol. 2025;25:77.
Abstract
Short-term outcomes comparison of KangDuo 2.0 and Da Vinci Xi in radical
cystectomy.
Sci Rep. 2025;15:11739.
Abstract
Genomics guiding personalized first-line immunotherapy response in lung and
bladder tumors.
J Transl Med. 2025;23:404.
Abstract
Apigenin inhibits recurrent bladder cancer progression by targeting VEGF-beta.
Cancer Lett. 2025;620:217676.
Abstract
Copper(II) Complexes of Pyrazolopyrimidine Derivatives as Anticancer Agents with
Enhanced Chemodynamic Therapy through Bimodal Apoptosis and Ferroptosis.
J Med Chem. 2025;68:7137-7152.
Abstract
A phase II study of lurbinectedin with or without avelumab in small cell
carcinoma of the bladder (laser)-design and rationale.
Future Oncol. 2025;21:1171-1177.
Abstract
Urological complications following pelvic exenteration are comparable to those
following radical cystectomy.
ANZ J Surg. 2025;95:761-765.
Abstract
Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma
Using Amide Proton Transfer-Weighted MRI.
Acad Radiol. 2025;32:2090-2098.
Abstract
Statin use after cancer diagnosis and survival among patients with cancer.
Cancer Causes Control. 2025;36:443-455.
Abstract
Neutrophil senescence drives sexual dimorphism in bladder cancer.
Nat Immunol. 2025 Apr 18. doi: 10.1038/s41590-025-02133.
Abstract
Oncolytic virotherapy provides a potent therapy option for squamous bladder
cancer.
Sci Rep. 2025;15:13443.
Abstract
Utility of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in
Detecting Lymph Node Involvement in Comparison to Conventional Imaging in
Patients with Bladder Cancer with Variant Histology.
Eur Urol Oncol. 2025 Apr 17:S2588-9311(25)00097.
Abstract
Machine learning developed immune-related exosome signature for prognosis and
immunotherapy benefit in bladder cancer.
Discov Oncol. 2025;16:557.
Abstract
Multifunctional and Scalable Nanoparticles for Bimodal Image-Guided Phototherapy
in Bladder Cancer Treatment.
Nanomicro Lett. 2025;17:222.
Abstract
International multicenter study of stereotactic radiosurgery for bladder cancer
brain metastases.
J Neurooncol. 2025 Apr 18. doi: 10.1007/s11060-025-05039.
Abstract
Increased expression of transglutaminase-2 is associated with invasive disease in
bladder cancer.
Arch Ital Urol Androl. 2025 Apr 16:13615. doi: 10.4081/aiua.2025.13615.
Abstract
Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy
decision-making for patients exposed to aristolochic acid.
Mol Med. 2025;31:140.
Abstract
TACC3 enhances glycolysis in bladder cancer cells through inducing acetylation of
c-Myc.
Cell Death Dis. 2025;16:311.
Abstract
Intravesical chemotherapy enhances anti-tumor immunity in bladder cancer by
modulating CD8(+) T cell activation and Treg populations.
Biochem Biophys Res Commun. 2025;764:151782.
Abstract
The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder
Cancer: A Systematic Review and Meta-Analysis.
Urol Res Pract. 2025;50:343-350.
Abstract
Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant
chemotherapy in patients with muscle-invasive bladder cancer in a Swedish
setting.
Front Oncol. 2025;15:1556881.
Abstract
Unlocking the secrets: Exploring the connection between HPV and bladder cancer in
Pakistan.
Urol Oncol. 2025 Apr 15:S1078-1439(25)00118.
Abstract
Challenges in Defining Clinical Complete Response to Systemic Therapy in
Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project.
Eur Urol Oncol. 2025 Apr 15:S2588-9311(25)00080.
Abstract
Dietary Fatty Acids and Bladder Cancer Risk: Insights from the PLCO Cancer
Screening Trial.
Nutr Cancer. 2025 Apr 16:1-11. doi: 10.1080/01635581.2025.2492138.
Abstract
Perioperative outcomes using template mapping after radical cystectomy and
extended lymph node dissection.
BMC Urol. 2025;25:91.
Abstract
Circulating tumour DNA and circulating tumour cells in bladder cancer - from
discovery to clinical implementation.
Nat Rev Urol. 2025 Apr 15. doi: 10.1038/s41585-025-01023.
Abstract
Accurate bladder cancer diagnosis using ensemble deep leaning.
Sci Rep. 2025;15:12880.
Abstract
Phases of tight junction barrier disruption during transurothelial migration of
invasive urothelial cancer cells.
Sci Rep. 2025;15:12975.
Abstract
METTL3 promotes an immunosuppressive microenvironment in bladder cancer via
m6A-dependent CXCL5/CCL5 regulation.
J Immunother Cancer. 2025;13:e011108.
Abstract
Rare complications of bladder perforation following the transurethral resection
of a bladder tumour with the immediate intravesical instillation of mitomycin C.
BMJ Case Rep. 2025;18:e265360.
Abstract
Integrated network pharmacology and RNA sequencing analysis to reveal the
mechanisms of Qici Sanling decoction in the treatment of gemcitabine resistant
bladder cancer.
J Pharm Biomed Anal. 2025;262:116885.
Abstract
Reduction of the planning target volume with daily online adaptive radiotherapy
in bladder cancer.
Strahlenther Onkol. 2025 Apr 15. doi: 10.1007/s00066-025-02397.
Abstract
Intravesical BCG therapy-induced granulomatous prostatitis in a patient with
non-muscle invasive bladder cancer and prostate adenocarcinoma.
Urol Case Rep. 2025;60:103020.
Abstract
Spectral CT findings of bladder urothelial carcinoma with gastric metastasis: a
case report.
BMC Urol. 2025;25:90.
Abstract
Microbiome landscapes of the bladder, intestine, and vagina in bladder cancer: a
systematic review.
Discov Oncol. 2025;16:525.
Abstract
Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming
Intravesical Instillation of [(211)At]At-anti-CA-IX Antibody (ATO-101) Study in
Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of
Care.
Cancers (Basel). 2025;17:1190.
Abstract
Relationship Among Body Mass Index, Survival, Cancer Treatment and Health-Related
Quality of Life Among Older Patients with Bladder Cancer.
Cancers (Basel). 2025;17:1200.
Abstract
From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment
of Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2025;17:1135.
Abstract
Patients with Metastatic or Locally Advanced Bladder Cancer Not Undergoing
Systemic Oncological Treatment-Characteristics and Long-Term Outcome in a
Single-Center Danish Cohort.
Cancers (Basel). 2025;17:1105.
Abstract
Erratum: Induction of apoptotic cell death in human bladder cancer cells by
ethanol extract of Zanthoxylum schinifolium leaf, through ROS-dependent
inactivation of the PI3K/Akt signaling pathway.
Nutr Res Pract. 2025;19:328-330.
Abstract
DLEU2 facilitates bladder cancer progression through miR-103a-2-5p/SOS1 axis.
PeerJ. 2025;13:e18995.
Abstract
Potential therapeutic targets for bladder cancer: a proteome-wide Mendelian
randomization study.
Am J Cancer Res. 2025;15:1096-1108.
Abstract
Significance of split-dose cisplatin-based neoadjuvant chemotherapy followed by
robotic-assisted radical cystectomy for muscle invasive bladder cancer.
Transl Androl Urol. 2025;14:589-601.
Abstract
Bladder Cancer Mortality Trend in Montenegro: 1990-2021.
Iran J Public Health. 2025;54:414-423.
Abstract
Enhanced prognostic prediction of cancer-specific mortality in elderly bladder
cancer patients post-radical cystectomy: an XGBoost model study.
Transl Cancer Res. 2025;14:1902-1914.
Abstract
MiR-146b overexpression promotes bladder cancer cell growth via the
SMAD4/C-MYC/Cyclin D1 axis.
Front Oncol. 2025;15:1565638.
Abstract
Molecular Dynamic Stability Study of VEGF Inhibitor in Patients with Bladder
Cancer.
Acta Inform Med. 2025;33:50-53.
Abstract
Survival outcomes and prognostic factors in bladder cancer treated with
radiotherapy.
J Radiat Res. 2025 Apr 14:rraf018. doi: 10.1093.
Abstract
The therapeutic potential of brazilin in bladder cancer: inhibition of DNA
topoisomerase I and tumor growth suppression.
Naunyn Schmiedebergs Arch Pharmacol. 2025.
Abstract
Causal Associations Between the Presence of Prostate Cancer or Testosterone
Levels and Bladder Cancer Risk: A Mendelian Randomization Study.
Clin Genitourin Cancer. 2025;23:102334.
Abstract
Recent Advances in Artificial Intelligence for Precision Diagnosis and Treatment
of Bladder Cancer: A Review.
Ann Surg Oncol. 2025 Apr 12. doi: 10.1245/s10434-025-17228.
Abstract
Predictive Potential of Contrast-Enhanced MRI-Based Delta-Radiomics for
Chemoradiation Responsiveness in Muscle-Invasive Bladder Cancer.
Diagnostics (Basel). 2025;15:801.
Abstract
Validation of a microRNA profile in urine liquid biopsy with diagnostic and
stratification value for bladder cancer classification, available through the
open app BladdermiRaCan.
Exp Hematol Oncol. 2025;14:58.
Abstract
Stapled vs. manually sutured bowel anastomosis in robot-assisted radical
cystectomy: a single-center retrospective analysis.
BMC Urol. 2025;25:85.
Abstract
Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder
cancer.
Nat Immunol. 2025 Apr 11. doi: 10.1038/s41590-025-02126.
Abstract
Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder
cancer.
Pathol Res Pract. 2025;270:155960.
Abstract
Suppression of cisplatin induced ATF3 expression and apoptosis by BK polyomavirus
and its encoded microRNA in bladder cancer cells.
Biomed Pharmacother. 2025;186:118032.
Abstract
Identification and characterization of tubulin as Ga(III)-binding protein in T24
cells.
J Pharm Biomed Anal. 2025;261:116842.
Abstract
Detection and agreement of blood- and lymph vessel invasion assessed by
immunohistochemistry in matched TURBT and radical cystectomy specimens.
Pathol Res Pract. 2025;269:155917.
Abstract
A biotin guided Pt(IV) amphiphilic prodrug synergized with CDK4/6 inhibition for
enhanced tumor targeted therapy.
Nanoscale. 2025;17:9907-9913.
Abstract
Practical use of nadofaragene firadenovec-vncg for pharmacists.
J Oncol Pharm Pract. 2025;31:488-494.
Abstract
An updated systematic review, meta-analysis, and trial sequential analysis of the
efficacy and safety of en bloc transurethral resection vs. conventional
transurethral resection for nonmuscle-invasive bladder tumor.
Int J Surg. 2025;111:3061-3077.
Abstract
Evaluating robustly standardized explainable anomaly detection of implausible
variables in cancer data.
J Am Med Inform Assoc. 2025;32:724-735.
Abstract
The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder
cancer.
Front Oncol. 2025;15:1543837.
Abstract
Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder
cancer.
BJC Rep. 2025;3:26.
Abstract
National complication and cost burden of transurethral resection of bladder tumor
for bladder cancer.
Urol Oncol. 2025 Apr 23:S1078-1439(25)00085.
Abstract
Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical
barriers.
Biochim Biophys Acta Rev Cancer. 2025 Apr 22:189327.
Abstract
Eosinophils but not mast cells exert anti-tumorigenic activity, without being
predictive markers of the long-term response to Bacillus Calmette-Guerin (BCG)
therapy in patients with bladder carcinoma.
Inflamm Res. 2025;74:68.
Abstract
Synergistic effects of curcumin and piperine in cocrystal form: a breakthrough in
bladder cancer therapy.
J Biomater Sci Polym Ed. 2025 Apr 24:1-28. doi: 10.1080/09205063.2025.2491606.
Abstract
LIMA1 inhibits cisplatin resistance and malignant biological behavior of bladder
cancer cells by suppressing the Wnt/beta-catenin pathway.
BMC Med Genomics. 2025;18:78.
Abstract
TTK promotes mitophagy by regulating ULK1 phosphorylation and pre-mRNA splicing
to inhibit mitochondrial apoptosis in bladder cancer.
Cell Death Differ. 2025 Apr 23. doi: 10.1038/s41418-025-01492.
Abstract
BCG response and oncological outcomes in high risk nonmuscle invasive bladder
cancer following previously treated upper tract urothelial carcinoma: A
propensity-matched analysis.
Urol Oncol. 2025 Apr 22:S1078-1439(25)00126.
Abstract
ADCYAP1 as a pan-solid cancer biomarker: predictor of immunotherapy efficacy in
bladder cancer and prognostic potential across solid tumors.
Discov Oncol. 2025;16:593.
Abstract
Intense FDG Activity of Renal Granuloma Following Intravesical Bacillus
Calmette-Guerin Therapy for Bladder Cancer Mimicking Malignancy.
Clin Nucl Med. 2025 Apr 23. doi: 10.1097/RLU.0000000000005810.
Abstract
Detection of hyaluronidase in urine using hyaluronic acid-coated silver
nanoparticles-based surface-enhanced Raman spectroscopy for the diagnosis of
bladder cancer.
Talanta. 2025;294:128139.
Abstract
The genetic associations of lipidome on bladder cancer: a Mendelian randomization
study.
Discov Oncol. 2025;16:586.
Abstract
Retraction: Tetracycline-controllable artificial microRNA-HOTAIR + EZH2
suppressed the progression of bladder cancer cells.
Mol Omics. 2025 Apr 22. doi: 10.1039/d5mo90007.
Abstract
Integrating machine learning models with multi-omics analysis to decipher the
prognostic significance of mitotic catastrophe heterogeneity in bladder cancer.
Biol Direct. 2025;20:56.
Abstract
Transurethral resection of a giant bladder leiomyoma.
BMC Urol. 2025;25:97.
Abstract
A review and meta-analysis: comparing the efficacy of robot-assisted and open
radical cystectomy in elderly bladder cancer patients.
J Robot Surg. 2025;19:168.
Abstract
The duality of GSK-3beta in urinary bladder cancer: Tumor suppressor and promoter
roles through multiple signaling pathways.
Biochim Biophys Acta Rev Cancer. 2025;1880:189324.
Abstract
New insights and emerging approaches in bladder-sparing treatment for
muscle-invasive bladder cancer.
Actas Urol Esp (Engl Ed). 2025 Apr 19:501758. doi: 10.1016/j.acuroe.2025.501758.
Abstract
A pilot study of [(18)F]F-fluciclovine positron emission tomography/computed
tomography for staging muscle invasive bladder cancer preceding radical
cystectomy.
Eur J Nucl Med Mol Imaging. 2025 Apr 21. doi: 10.1007/s00259-025-07287.
Abstract
Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic
Bladder Cancer Patients.
Cancer Med. 2025;14:e70896.
Abstract
Standard Versus Extended Pelvic Lymphadenectomy in Patients With Bladder Cancer:
A Systematic Review and Meta-analysis.
Am J Clin Oncol. 2025 Apr 21. doi: 10.1097/COC.0000000000001206.
Abstract
A case of severe immune-related adverse events, myocarditis with myositis, and
myasthenia gravis overlap syndrome following adjuvant nivolumab administration
for muscle-invasive bladder cancer.
Nagoya J Med Sci. 2025;87:156-162.
Abstract
Comprehensive analysis of angiogenesis and stemness-related genes in chemotherapy
and immunotherapy of bladder cancer.
Biomol Biomed. 2025 Apr 18. doi: 10.17305/bb.2025.12046.
Abstract
Simultaneous Laparoscopic and Thoracoscopic Biopsy via a Single Skin Incision
Using a Port-Sharing Procedure in Infantile Neuroblastoma: A Case Report.
Asian J Endosc Surg. 2025;18:e70064.
Abstract
Is the presence of lymphovascular invasion associated with recurrence and
progression in bladder cancer patients that have received adequate BCG therapy?
Actas Urol Esp (Engl Ed). 2025 Apr 18:501785. doi: 10.1016/j.acuroe.2025.501785.
Abstract
KIF26B promotes bladder cancer progression via activating Wnt/beta-catenin signaling
in a TRAF2-dependent pathway.
Cell Rep. 2025;44:115595.
Abstract
Glycosphingolipids as emerging attack points in bladder cancer.
Discov Oncol. 2025;16:569.
Abstract
RETRACTION: Comparative Analysis of Wound Healing Techniques in Postoperative
Bladder Cancer Patients.
Int Wound J. 2025;22:e70541.
Abstract
Leveraging Deep Learning in Real-Time Intelligent Bladder Tumor Detection During
Cystoscopy: A Diagnostic Study.
Ann Surg Oncol. 2025;32:3220-3226.
Abstract
Urothelial carcinoma in situ with "early papillary formation" vs "lateral
spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial
carcinoma: A survey of pathologist and urologist interpretations.
Am J Clin Pathol. 2025;163:629-640.
Abstract
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent
differentiation and aggressive urothelial carcinoma subtypes.
Am J Clin Pathol. 2025;163:618-628.
Abstract
BCG MEDAC(R) for the treatment of non-muscle invasive bladder tumors: Adverse
events and predictive factors for tolerance.
Fr J Urol. 2025;35:102843.
Abstract
Comparative analysis of non-coding and coding DNA mutations in flat urothelial
lesions: biological implications and insights.
Virchows Arch. 2025;486:729-737.
Abstract
The effect of incidental dose to pelvic nodes in bladder-only irradiation in the
era of IMRT: a dosimetric study.
Strahlenther Onkol. 2025;201:501-506.
Abstract
Erratum: Preliminary study of the mechanism of isolinderalactone inhibiting the
malignant behavior of bladder cancer: Erratum.
Curr Urol. 2025;19:144.
Abstract
Preliminary study of the mechanism of isolinderalactone inhibiting the malignant
behavior of bladder cancer.
Curr Urol. 2025;19:49-58.
Abstract
Current role of radiomics and radiogenomics in predicting oncological outcomes in
bladder cancer.
Curr Urol. 2025;19:43-48.
Abstract
Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome
research in bladder cancer.
Investig Clin Urol. 2025;66:272-280.
Abstract
Correlation of shear wave elastography with histopathological grade, tumor stage,
and microvessel density in bladder cancer.
Investig Clin Urol. 2025;66:207-214.
Abstract
a1,3-mannosyltransferase promotes the malignant progression of bladder cancer
through activating TNF signaling pathway.
Eur J Med Res. 2025;30:353.
Abstract
Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and
activate antitumor immune responses.
Commun Biol. 2025;8:689.
Abstract
The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities
in bladder cancer prognosis.
Front Immunol. 2025;16:1554829.
Abstract
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder
Cancer and Localized Muscle Invasive Bladder Cancer.
Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657.
Abstract
Epigenetic changes induced by carcinogenic agents or occupational exposure with
sufficient evidence for bladder cancer.
Cancer Prev Res (Phila). 2025 Apr 30. doi: 10.1158/1940-6207.CAPR-24-0450.
Abstract
Multiscale screening and identifying specific targets for artesunate in
suppressing bladder cancer.
Front Pharmacol. 2025;16:1584502.
Abstract
Antitumor Effects of Sesamin via the LincRNA-p21/STAT3 Axis in Human Bladder
Cancer: Inhibition of Metastatic Progression and Enhanced Chemosensitivity.
Int J Biol Sci. 2025;21:2692-2706.
Abstract
Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for
Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder
Sparing Surgery: A Phase 2 Trial.
Cancer Res Treat. 2025 Apr 28. doi: 10.4143/crt.2025.
Abstract
Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with
Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer.
Acta Med Okayama. 2025;79:81-92.
Abstract
Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy
on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical
Cystectomy.
Cancer Med. 2025;14:e70782.
Abstract
Association of rs2294008 (PSCA) Gene polymorphism in Urothelial Bladder Cancer of
South Indian Population.
Asian Pac J Cancer Prev. 2025;26:1441-1446.
Abstract
Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on
bladder cancer.
J Transl Med. 2025;23:489.
Abstract
TAZ/NRF2 positive feedback loop contributes to proliferation in bladder cancer
through antagonistic ferroptosis.
Cell Death Discov. 2025;11:208.
Abstract
Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in
vitro and in vivo.
Biomed Pharmacother. 2025;187:118108.
Abstract
Nanobody-based double antibody sandwich colloidal gold test strips for rapid
detection of urinary biomarkers NMP22 and survivin in bladder cancer.
J Pharm Biomed Anal. 2025;263:116905.
Abstract
Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+
lymphocytes by KLRG1 in bladder cancer.
JCI Insight. 2025 Apr 29:e177373. doi: 10.1172/jci.insight.177373.
Abstract
Engineered Expression of Hepatocyte Growth Factor Activator Inhibitor-1 (HAI-1)
Reduces the Growth of Bladder Cancer Cells.
Biomedicines. 2025;13:871.
Abstract
[Secondary bladder cancer following radiation therapy for prostate cancer:
a systematic review and meta-analysis of incidence and outcomes].
Urologie. 2025 Apr 29. doi: 10.1007/s00120-025-02592.
Abstract
Radical cystectomy for bladder cancer in solid organ transplant recipients.
Minerva Urol Nephrol. 2025;77:202-208.
Abstract
The current status of biomarkers for bladder cancer: progress and challenges.
Minerva Urol Nephrol. 2025;77:149-151.
Abstract
Change in the Neutrophil-Lymphocyte Ratio and Recurrence in Operated Bladder
Cancer.
Asia Pac J Clin Oncol. 2025 Apr 29. doi: 10.1111/ajco.14183.
Abstract
Urinary exosomal lnc-TAF12-2:1 promotes bladder cancer progression through the
miR-7847-3p/ASB12 regulatory axis.
Genes Dis. 2024;12:101384.
Abstract
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic
review from the beginning to the latest updates.
Bladder Cancer. 2025;11:23523735251335122.
Abstract
Organoid models in bladder cancer: From bench to bedside?
Bladder Cancer. 2025;11:23523735251330404.
Abstract
Cyclic Enrichment of Urinary Exosomes Using a MOF-on-MOF-Based Asymmetric
Impinging Streams Chip for Bladder Cancer Diagnosis and Prognosis Prediction.
Adv Healthc Mater. 2025 Apr 28:e2500848. doi: 10.1002/adhm.202500848.
Abstract
Study on extended-spectrum beta-lactamases genes and drug resistance in patients
with urinary tract infection of enterohemorrhagic Escherichia coli after bladder
cancer surgery.
Medicine (Baltimore). 2025;104:e42098.
Abstract
[A pan-cancer analysis of PYCR1 and its predictive value for chemotherapy and
immunotherapy responses in bladder cancer].
Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:880-892.
Abstract
Efficacy of Bacillus Calmette-Guerin compared to sequential gemcitabine and
docetaxel in Ta high-grade non-muscle invasive bladder cancer.
World J Urol. 2025;43:255.
Abstract
The current status of miRNA in urinary bladder cancer: A minireview and strength,
weakness, opportunity, and threat analysis.
Indian J Urol. 2025;41:98-103.
Abstract
Expanding horizons to cure muscle-invasive bladder cancer: A novel treatment
algorithm.
Indian J Urol. 2025;41:153-154.
Abstract
Viral infections and immune modulation in bladder cancer: implications for
immunotherapy.
Explor Target Antitumor Ther. 2025;6:1002311.
Abstract
Testicular Tuberculosis after Intravesical BCG for Urinary Bladder Cancer: A Role
of FDG PET-CT.
Indian J Nucl Med. 2024;39:460-462.
Abstract
Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive
Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Eur Urol Oncol. 2025 Apr 26:S2588-9311(25)00043.
Abstract
Evaluation of the diagnostic potential of Fourier transform-infrared spectroscopy
on urine for urothelial bladder cancer: an in-hospital field study.
Spectrochim Acta A Mol Biomol Spectrosc. 2025;339:126274.
Abstract
Current laser application in En bloc resection of bladder tumor- a narrative
literature review.
World J Surg Oncol. 2025;23:165.
Abstract
Heightened IDO1 levels predict Bacillus Calmette-Guerin failure in high-risk
non-muscle-invasive bladder cancer patients.
Cell Death Discov. 2025;11:203.
Abstract
Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated
with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to
Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade
Non-muscle-invasive Bl
Eur Urol Oncol. 2025 Apr 25:S2588-9311(25)00100.
Abstract
Significance of Body Surface Area Correction for Cisplatin Eligibility Based on
Renal Function of Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2025 Mar 28:102339. doi: 10.1016/j.clgc.2025.102339.
Abstract
Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A
Real-World Observational Study From the French National Healthcare System
Database.
Clin Genitourin Cancer. 2025;23:102344.
Abstract
Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment
of Bladder Cancer.
Pharmaceuticals (Basel). 2025;18:511.
Abstract
Paeonol Suppresses Bladder Cancer Progression via Apoptotic Pathways: Insights
from In Vitro and In Vivo Studies.
Pharmaceuticals (Basel). 2025;18:472.
Abstract
Perspectives on an Intensive Hospital-Based Smoking Cessation Intervention in
Relation to Transurethral Resection of the Bladder Tumour (TURBT): Interviews
with Patients, Relatives, and Clinicians.
Int J Environ Res Public Health. 2025;22:555.
Abstract
Which Surrogate Marker of Insulin Resistance Among Those Proposed in the
Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?
J Clin Med. 2025;14:2636.
Abstract
Proteomic and In Silico Analyses Highlight Complement System's Role in Bladder
Cancer Immune Regulation.
Medicina (Kaunas). 2025;61:735.
Abstract
Novel Urinary Biomarkers for the Detection of Bladder Cancer.
Cancers (Basel). 2025;17:1283.
Abstract
Association Between CKAP4 Expression and Poor Prognosis in Patients with Bladder
Cancer Treated with Radical Cystectomy.
Cancers (Basel). 2025;17:1278.
Abstract
Correction: The roles and mechanism of IFIT5 in bladder cancer
epithelial-mesenchymal transition and progression.
Cell Death Dis. 2025;16:339.
Abstract
WWP1 mediates the ubiquitination and degradation of HIPK3 in bladder cancer
cells.
J Biol Chem. 2025 Apr 23:108528. doi: 10.1016/j.jbc.2025.108528.
Abstract
Acidic urine as a prognostic factor after intravesical Bacillus Calmette-Guerin
induction therapy for nonmuscle-invasive bladder cancer.
World J Urol. 2025;43:247.
Abstract
Bioinformatics analysis reveals CTSF suppresses tumor cell malignant phenotype
and CD8 + T cell exhaustion by downregulating Bcl- 2 protein in the
microenvironment of bladder cancer.
Naunyn Schmiedebergs Arch Pharmacol. 2025.
Abstract
Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer
Cell Line HT-1197.
J Pers Med. 2025;15:143.
Abstract
Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer
Cells by Altering Integrins.
Cells. 2025;14:570.
Abstract
Phytochemicals as Chemo-Preventive and Therapeutic Agents Against Bladder Cancer:
A Comprehensive Review.
Diseases. 2025;13:103.
Abstract
Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the
c-Met/PI3K/Akt Pathway in the Three-Dimensional Bladder Cancer Spheroid Model.
Curr Oncol. 2025;32:236.
Abstract
Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab
Maintenance in US Patients with Locally Advanced or Metastatic Urothelial
Carcinoma: The SPEAR Bladder-II Study.
Curr Oncol. 2025;32:187.
Abstract
Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor
immune microenvironment and prognostic biomarker.
Front Immunol. 2025;16:1572108.
Abstract
SLAYER: a computational framework for identifying synthetic lethal interactions
through integrated analysis of cancer dependencies.
NAR Genom Bioinform. 2025;7:lqaf052.
Abstract
Clinicopathological features analysis of Paraganglioma of urinary bladder: A
retrospective study.
Ann Diagn Pathol. 2025;77:152477.
Abstract
Enfortumab vedotin and pembrolizumab: redefining the standard of care for
previously untreated advanced urothelial cancer.
Future Oncol. 2025;21:1333-1348.
Abstract
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term
outcomes from the JAVELIN Bladder 100 trial in older patients.
ESMO Open. 2025;10:104506.
Abstract
FGFR2/3 Gene Alterations and Clinical Outcomes in Advanced/Metastatic Urothelial
Cancer in Japan: MONSTAR-SCREEN Database Study.
Cancer Sci. 2025;116:1424-1432.
Abstract
Clinical outcomes and treatment patterns of maintenance avelumab in locally
advanced or metastatic urothelial carcinoma: a multicenter collaborative study.
Jpn J Clin Oncol. 2025;55:522-530.
Abstract
Real-world treatment patterns, survival outcomes, and health care resource
utilization for locally advanced or metastatic urothelial carcinoma in Spain.
Clin Transl Oncol. 2025;27:2232-2240.
Abstract
Comparative study on the efficacy of low-dose and full-dose BCG bladder perfusion
therapy.
Clin Transl Oncol. 2025;27:2174-2190.
Abstract
Early Palliative Care in Advanced or Metastatic Bladder Cancer: A Retrospective
Study.
Arch Esp Urol. 2025;78:371-379.
Abstract
Light-Responsive Ru-Se Coordinated Nanoreactor Spatiotemporally Relieves Hypoxia
for Photodynamic Therapy of Bladder Cancer.
ACS Appl Mater Interfaces. 2025 May 9. doi: 10.1021/acsami.5c05133.
Abstract
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided
Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk
Bladder Cancer.
Eur Urol Oncol. 2025 May 7:S2588-9311(25)00115-4. doi: 10.1016/j.euo.2025.
Abstract
Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment
of bladder cancer.
Eur J Med Chem. 2025;293:117710.
Abstract
ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using
[(64)Cu]Cu-NOTA-Padcev.
Mol Pharm. 2025 May 8. doi: 10.1021/acs.molpharmaceut.5c00469.
Abstract
The role of perioperative immunotherapy with chemotherapy in muscle-invasive
bladder cancer (MIBC).
Chin Clin Oncol. 2025;14:26.
Abstract
Treatment patterns in patients with locally advanced and metastatic bladder
cancer in Denmark 2015-2023 - an updated analysis.
Acta Oncol. 2025;64:630-632.
Abstract
Efficacy and safety of robotic-assisted laparoscopic "one-step" radical
nephroureterectomy and bladder cuff excision.
World J Urol. 2025;43:280.
Abstract
Oxymatrine Inhibits PKM2-Mediated Glycolysis and Enhances Cisplatin Sensitivity
in Bladder Cancer.
Tohoku J Exp Med. 2025 May 8. doi: 10.1620/tjem.2025.
Abstract
BAP1-mediated ubiquitination inhibition and CAS6/AXL signaling activation in
bladder cancer progression.
Cytotechnology. 2025;77:95.
Abstract
Advancing personalized, predictive, and preventive medicine in bladder cancer: a
multi-omics and machine learning approach for novel prognostic modeling, immune
profiling, and therapeutic target discovery.
Front Immunol. 2025;16:1572034.
Abstract
Progress on liposome delivery systems in the treatment of bladder cancer.
RSC Adv. 2025;15:14315-14336.
Abstract
Risk of upper urinary tract urothelial carcinoma after primary
non-muscle-invasive urinary bladder cancer: A nationwide population-based cohort
study.
BJUI Compass. 2025;6:e70021.
Abstract
Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.
Immunotherapy. 2025 May 6:1-9. doi: 10.1080/1750743X.2025.2501929.
Abstract
Intravesical gemcitabine and docetaxel in patients with recurrent high-grade
nonmuscle invasive bladder cancer-A prospective cohort study.
Urol Oncol. 2025 May 5:S1078-1439(25)00124-3. doi: 10.1016/j.urolonc.2025.
Abstract
Comment on: "A review and meta-analysis: comparing the efficacy of robot-assisted
and open radical cystectomy in elderly bladder cancer patients".
J Robot Surg. 2025;19:199.
Abstract
Comparison of perioperative outcomes between extracorporeal and intracorporeal
urethral diversion in robot-assisted radical cystectomy: a meta-analysis and
systematic review.
J Robot Surg. 2025;19:200.
Abstract
Lower MeDiC score is associated with non-referral to multidisciplinary team
meeting discussion in bladder cancer patients: a nationwide and population-based
study.
Acta Oncol. 2025;64:616-622.
Abstract
The role of multiparametric MRI-based VI-RADS in predicting the need for a second
TURB.
World J Urol. 2025;43:271.
Abstract
[Bladder sparing options for muscle invasive high risk bladder cancer].
Aktuelle Urol. 2025 May 5. doi: 10.1055/a-2586-5554.
Abstract
HDL cholesterol esters mediate the genetic link between sedentary behavior and
urological cancers: Insights from mediation and validation analyses.
Medicine (Baltimore). 2025;104:e42369.
Abstract
Identification of drug combinations to reduce the risk of pioglitazone-related
bladder cancer using the FDA adverse event reporting system database.
Expert Opin Drug Saf. 2025 May 6:1-10. doi: 10.1080/14740338.2025.2492744.
Abstract
4-Methylpyrazole-mediated inhibition of Cytochrome P450 2E1 protects renal
epithelial cells, but not bladder cancer cells, from cisplatin toxicity.
Toxicol Sci. 2025 May 5:kfaf053. doi: 10.1093.
Abstract
Current status of management and outcomes of muscle-invasive bladder cancer in
Yemen: a retrospective observational study.
Arch Ital Urol Androl. 2025 May 5. doi: 10.4081/aiua.2025.13760.
Abstract
Analysis and adherence to guidelines of mobile health application for bladder
cancer, where are we?
Arch Ital Urol Androl. 2025 May 5. doi: 10.4081/aiua.2025.13455.
Abstract
Prognostic impact of serum interleukin-6 and 17 level in patients with bladder
cancer: a systematic review and meta-analysis.
PeerJ. 2025;13:e19385.
Abstract
Correction to: Epidemiological and toxicological risk assessments of
ortho-toluidine for bladder cancer.
J Occup Health. 2025;67:uiaf024.
Abstract
Robust consensus molecular subtyping of muscle-invasive bladder cancer via 3' RNA
sequencing of FFPE tissues: potential impact for clinical and trial settings.
Lab Invest. 2025 May 2:104191. doi: 10.1016/j.labinv.2025.104191.
Abstract
Single-cell RNA sequencing reveals a fibroblast gene signature that promotes
T-cell infiltration in muscle-invasive bladder cancer.
Commun Biol. 2025;8:696.
Abstract
Astragalus polysaccharides inhibits tumor proliferation and enhances cisplatin
sensitivity in bladder cancer by regulating the PI3K/AKT/FoxO1 axis.
Int J Biol Macromol. 2025;311.
Abstract
Integrating analysis of multi-omics summary data identifies novel plasma protein
biomarkers and drug targets for bladder cancer.
Discov Oncol. 2025;16:660.
Abstract
Development of a CT radiomics model for detection of bladder invasion by
colorectal carcinoma.
Sci Rep. 2025;15:15389.
Abstract
Impact of marriage on diagnosis and survival in patients with urological cancers.
Sci Rep. 2025;15:15443.
Abstract
Prospective evaluation of comprehensive geriatric assessments in
multidisciplinary bladder cancer care and implications for personalized
vulnerability phenotyping.
Urol Oncol. 2025 May 1:S1078-1439(25)00123-1. doi: 10.1016/j.urolonc.2025.
Abstract
Low T cell diversity associates with poor outcome in bladder cancer: A
comprehensive longitudinal analysis of the T cell receptor repertoire.
Cell Rep Med. 2025 Apr 29:102101. doi: 10.1016/j.xcrm.2025.102101.
Abstract
Contribution of lesion shape features to the VI-RADS for predicting muscle
invasion in bladder tumors.
Eur J Radiol. 2025;187:112104.
Abstract
Novel risk factors for venous thromboembolism following outpatient or inpatient
transurethral resection of bladder tumors: Multivariable stepwise and LASSO
regression modeling from us insurance claim database.
Actas Urol Esp (Engl Ed). 2025;49:501738.
Abstract
Real-life perception of pathology reports in urology.
Actas Urol Esp (Engl Ed). 2025;49:501751.
Abstract
Evaluating the cost-effectiveness and evidence base for perioperative
chemotherapy in muscle-invasive bladder cancer.
World J Urol. 2025;43:310.
Abstract
[En bloc resection of the large bladder tumors].
Urologiia. 2025;:136-140.
Abstract
Evidence versus practice involving universal acceptance of neoadjuvant
chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care
center in India.
Indian J Cancer. 2025;62:111-119.
Abstract
[A clinical case of bladder metastasis of skin melanoma].
Urologiia. 2024;:118-121.
Abstract
Robot-Assisted Radical Cystectomy With Intracorporeal Ileal Conduit Using the
Hinotori Surgical Robot System: A Single Surgeon's Initial Experience of 20
Cases.
Int J Med Robot. 2025;21:e70074.
Abstract
Advances in bladder preservation therapy for muscle-invasive bladder cancer.
Front Oncol. 2025;15:1562260.
Abstract
Identification and validation of a 9-RBPs-related gene signature associated with
prognosis and immune infiltration in bladder cancer based on bioinformatics
analysis and machine learning.
Transl Androl Urol. 2025;14:1066-1081.
Abstract
The effect of intravesical Bacillus Calmette-Guerin (BCG) treatment on sperm
parameters in non-muscle-invasive bladder cancer patients.
Basic Clin Androl. 2025;35:17.
Abstract
Corrigendum to "Unlocking the secrets: Exploring the connection between HPV and
bladder cancer in Pakistan" [Urologic Oncology: Seminars and Original
Investigations, In Press, Corrected Proof].
Urol Oncol. 2025 May 14:S1078-1439(25)00171.
Abstract
LRP8 Regulates Lipid Metabolism to Stimulate Malignant Progression and Cisplatin
Resistance in Bladder Cancer.
Kaohsiung J Med Sci. 2025 May 15:e70042. doi: 10.1002/kjm2.70042.
Abstract
Corrigendum: Insights into vitamin A in bladder cancer, lack of attention to gut
microbiota?
Front Immunol. 2025;16:1609154.
Abstract
Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review.
Front Immunol. 2025;16:1591379.
Abstract
Identification of Selected Genes Associated With the Prediction of Prognosis in
Bladder Cancer.
Comb Chem High Throughput Screen. 2025.
Abstract
Real-world Efficacy of Intravesical Gemcitabine for BCG-Unresponsive
Non-Muscle-Invasive Bladder Cancer.
Cancer Res Treat. 2025 May 12. doi: 10.4143/crt.2025.
Abstract
Patient-derived organoid co-culture systems as next-generation models for bladder
cancer stem cell research.
Cancer Lett. 2025 May 12:217793. doi: 10.1016/j.canlet.2025.217793.
Abstract
Metal-organic framework nanomaterials alter cellular metabolism in bladder
cancer.
Ecotoxicol Environ Saf. 2025;298:118292.
Abstract
Quality of Life Analysis in Patients with Simple Cutaneous Ureterostomy versus
Ileal Conduit Bricker Following Radical Cystectomy.
Chirurgia (Bucur). 2025;120:205-217.
Abstract
Single-cell analysis reveals potential therapeutic markers of peripheral blood
mononuclear cells from bladder cancer patients.
Braz J Med Biol Res. 2025;58:e14002.
Abstract
EIF2S1 in Urinary Extracellular Vesicles as a Novel Diagnostic Marker for Bladder
Cancer.
Cancer Med. 2025;14:e70964.
Abstract
Drive Time to Physicians and Outcomes for Bladder Cancer.
JU Open Plus. 2025;3:e00033.
Abstract
Simulation Models for Bladder Cancer: A Scoping Review.
medRxiv [Preprint]. 2025 Mar 18:2025.03.17.25324125.
Abstract
Prognostic significance of circulating tumor DNA in urothelial carcinoma patients
undergoing immune checkpoint inhibitor therapy: a systematic review and
meta-analysis.
Front Immunol. 2025;16:1574449.
Abstract
Diagnostic and Prognostic Potential of SH3YL1 and NOX4 in Muscle-Invasive Bladder
Cancer.
Int J Mol Sci. 2025;26:3959.
Abstract
Contemporary Trends and Predictors Associated with Adverse Pathological Upstaging
Among Non-Metastatic Localized Clinical T2 Muscle-Invasive Bladder Cancers
Undergoing Radical Cystectomy: Outcomes from a Single Tertiary Centre in the
United Kingdom.
Cancers (Basel). 2025;17:1477.
Abstract
Sex differences in bladder cancer: understanding biological and clinical
implications.
Biol Sex Differ. 2025;16:31.
Abstract
Integrating genetic and gene expression data in network-based stratification
analysis of cancers.
BMC Bioinformatics. 2025;26:126.
Abstract
Acquired semi-squamatization during chemotherapy suggests differentiation as a
therapeutic strategy for bladder cancer.
Cancer Cell. 2025;43:985-987.
Abstract
A rare case report: Bladder endometriosis at the urachus.
J Int Med Res. 2025;53:3000605251340535.
Abstract
Prognostic impact of nutritional indicators based on Lasso-Cox regression for
non-muscle-invasive bladder cancer.
Front Nutr. 2025;12:1560655.
Abstract
Characteristics, management and survival outcomes in patients with
muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup
analysis from the coblance cohort.
BMC Urol. 2025;25:120.
Abstract
Repurposing amiodarone for bladder cancer treatment.
Cancer Res Commun. 2025 May 12. doi: 10.1158/2767-9764.CRC-24-0433.
Abstract
[A Case of Open Poucholithotomy for Recurrence of Indiana Pouch Stones].
Hinyokika Kiyo. 2025;71:115-119.
Abstract
[Nephrogenic Adenoma : A Case Report].
Hinyokika Kiyo. 2025;71:111-113.
Abstract
Tumour-infiltrating immune cells as a novel prognostic model for bladder cancer.
Discov Oncol. 2025;16:725.
Abstract
Infiltrating Natural Killer cells influence the efficacy of BCG immunotherapy in
non-muscle-invasive bladder cancer.
Pathol Res Pract. 2025;270:155997.
Abstract
Reducing the effective dosage of Mitomycin C on a high-grade bladder cancer cell
line through combination with selenium nanoparticles: An in vitro study.
Med Oncol. 2025;42:207.
Abstract
Integrated prognostic assessment of apoptosis and chemotherapy related gene in
bladder cancer: a prognostic signature.
Discov Oncol. 2025;16:718.
Abstract
Mechanistic study of Liquiritigenin inhibiting bladder cancer cell proliferation
and migration by regulating STING1.
Cancer Genet. 2025;294-295:156-170.
Abstract
Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive
bladder cancer: Japanese multicenter retrospective study.
Int J Clin Oncol. 2025 May 10. doi: 10.1007/s10147-025-02778.
Abstract
Letter: Comment on "Enhanced Artificial Intelligence in Bladder Cancer
Management: A Comparative Analysis and Optimization Study of Multiple Large
Language Models".
J Endourol. 2025 May 9. doi: 10.1089/end.2025.0277.
Abstract
Circ_RPPH1 promotes bladder urothelium carcinoma proliferation and EMT by
recruiting and binding to EIF4 A3.
Hereditas. 2025;162:72.
Abstract
Bousigonine D from Bousigonia mekongensis inhibits bladder cancer growth and
overcomes cisplatin resistance.
Sci Rep. 2025;15:16254.
Abstract
Icing on the Cake: Integrating Optical Fiber with Second Near-Infrared
Aggregation-Induced Emission Luminogen for Exceptional Phototheranostics of
Bladder Cancer.
Adv Mater. 2025 May 9:e2502452. doi: 10.1002/adma.202502452.
Abstract
New Paradigms for Bladder Cancer Management in Geriatrics.
Clin Geriatr Med. 2025;41:175-185.
Abstract
Mental distress and inflammation in bladder cancer: The nerve makes things less
vague.
Brain Behav Immun Health. 2025;46:100995.
Abstract
Evaluation of the EMT Markers SNAIL-SLUG and TWIST in Urothelial Carcinoma of the
Bladder: A Retrospective Study.
Arch Esp Urol. 2025;78:289-295.
Abstract
Impact of Extended Versus Limited Lymph Node Dissection on Surgical Outcome,
Recurrence Patterns and Survival After Radical Cystectomy.
Clin Genitourin Cancer. 2025;23:102337.
Abstract
The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in
Urothelial Carcinoma.
Gene. 2025;959:149503.
Abstract
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term
Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial
Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase
3 CheckMate 274 Trial
Clin Genitourin Cancer. 2025;23:102335.
Abstract
Pattern and risk factors of local recurrence and intravesical recurrence after
segmental ureterectomy for upper tract urothelial carcinoma.
Urol Oncol. 2025;43:330.
Abstract
Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes
in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial
Carcinoma: A Real-world Analysis From a Multicenter Study.
Clin Genitourin Cancer. 2025;23:102326.
Abstract
Survival in Responders and Nonresponders of Neoadjuvant and Induction
Chemotherapy in Invasive Urothelial Carcinoma of the Urinary Bladder: A Clinical
and Pathological Stage-Matched Analysis.
Clin Genitourin Cancer. 2025;23:102319.
Abstract
Characterisation of Gene Expression in Canine Invasive Urothelial Carcinoma Using
a NanoString-Based Urine Assay.
Vet Comp Oncol. 2025;23:205-215.
Abstract
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab
vedotin in patients with urothelial carcinoma.
Expert Opin Investig Drugs. 2025;34:259-265.
Abstract
Temozolomide as neoadjuvant therapy for bladder paraganglioma.
Endocrine. 2025;88:431-433.
Abstract
Immediate second resection versus restage transurethral resection of bladder
tumor: A prospective randomized clinical trial (IMMERSE trial).
Urol Oncol. 2025;43:331.
Abstract
Geographical variation in the incidence of colorectal cancer and urinary tract
cancer is associated with population exposure to colibactin-producing Escherichia
coli.
Lancet Microbe. 2025;6:101015.
Abstract
"I was in a very deep, dark place... I wasn't prepared for that": A qualitative
assessment of the emotional well-being needs of patients undergoing cystectomy.
Urol Oncol. 2025;43:328.
Abstract
The clinical relevance of cut-off percentage for high-grade urothelial carcinoma
within low-grade urothelial carcinoma: A determining factor?
Urol Oncol. 2025;43:329.
Abstract
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial
carcinoma: Results from a phase II single-arm study (PIVOT-10).
Urol Oncol. 2025;43:330.
Abstract
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial
cancer.
Nat Rev Urol. 2025;22:256-267.
Abstract
Real-world treatment patterns and outcomes of patients with unresectable or
metastatic urothelial carcinoma receiving systemic therapy in Japan.
Urol Oncol. 2025;43:329.
Abstract
Oncologic outcomes of pelvic organ-preserving radical cystectomy vs. Standard
radical cystectomy: A systematic review and meta-analysis.
Urol Oncol. 2025;43:275-285.
Abstract
Factors influencing health-related quality of life in patients with bladder or
kidney cancer: a prospective cohort study of the impact of nutritional status and
frailty phenotype.
J Cancer Surviv. 2025;19:743-753.
Abstract
The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.
J Racial Ethn Health Disparities. 2025;12:1416-1422.
Abstract
Circulating metabolic biomarkers mediated causal relationship between gut
microbiota and bladder cancer: a two-step mendelian randomization study.
Discov Oncol. 2025;16:877.
Abstract
Identification of SCAMP2 as a regulator of NOTCH signaling in cisplatin
resistance through a novel prognostic model for bladder cancer.
Front Immunol. 2025;16:1573412.
Abstract
Efficacy of brachytherapy for locally advanced bladder cancer: a single-center
retrospective clinical study.
Cancer Biol Ther. 2025;26:2509200.
Abstract
SRSF1-mediated alternative splicing regulates bladder cancer progression and
cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.
J Transl Med. 2025;23:571.
Abstract
RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in
bladder cancer.
Discov Oncol. 2025;16:863.
Abstract
Youth matters: a systematic review of the molecular and clinical landscape of
bladder cancer in young adults.
World J Urol. 2025;43:321.
Abstract
Nanoparticle-mediated targeting of PGC-1alpha reveals critical metabolic pathways in
bladder cancer metastasis.
Commun Biol. 2025;8:788.
Abstract
Perioperative Complications and In-hospital Mortality After Cystectomy for
Nonbladder Cancer Conditions Versus Radical Cystectomy for Bladder Cancer.
Ann Surg Oncol. 2025 May 22. doi: 10.1245/s10434-025-17456.
Abstract
Establishment of a m6 A-associated lncRNAs-derived risk model for enhanced
patient prognosis stratification and personalized therapy approaches in bladder
cancer.
Discov Oncol. 2025;16:856.
Abstract
Discovery and Validation of a New Biomarker Integrating Ferroptosis and
Glycolysis-Related Genes in Bladder Cancer.
IUBMB Life. 2025;77:e70028.
Abstract
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting
nectin-4 for the treatment of bladder cancer.
Expert Opin Investig Drugs. 2025 May 22. doi: 10.1080/13543784.2025.2510669.
Abstract
Insights Into Rural Chemotherapy Usage for Muscle-Invasive Bladder Cancer: An
Australian Multi-Site Institution Perspective.
ANZ J Surg. 2025 May 22. doi: 10.1111/ans.70175.
Abstract
SPP1A and VEGFC splice isoforms as predictive diagnostic biomarkers for high and
low-grade bladder cancer.
Am J Clin Exp Urol. 2025;13:156-168.
Abstract
Open radical cystectomy and ileal loop diversion under combined spinal-epidural
anaesthesia for the elderly and frail.
BMC Surg. 2025;25:222.
Abstract
Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in
muscle-invasive bladder cancer.
Sci Rep. 2025;15:17588.
Abstract
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk
Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 May 20:S2588-9311(25)00104.
Abstract
Prognostic Significance of Regulatory CD25+ T Cells in Bladder Cancer: An
Immunohistochemical Analysis.
Turk Patoloji Derg. 2025;1.
Abstract
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive
non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain
language summary.
Future Oncol. 2025 May 21:1-11. doi: 10.1080/14796694.2025.2493041.
Abstract
Tertiary Lymphoid Structures as Independent Predictors of Favorable Prognosis in
Muscle-Invasive Bladder Cancer.
Cancer Med. 2025;14:e70978.
Abstract
Unraveling the multifaceted roles of extracellular vesicles in bladder cancer:
diagnostic insights and therapeutic opportunities.
Front Oncol. 2025;15:1554819.
Abstract
Small bowel obstruction from urachal cyst abscess: a diagnostic challenge easily
confused with invasive urachal cancer-A case report.
J Med Case Rep. 2025;19:240.
Abstract
Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis
combining bibliometric and meta-analysis approaches.
BMC Urol. 2025;25:132.
Abstract
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder
Cancer Treated with Bacillus Calmette-Guerin (BCG): A Comparative Analysis of
Adequate Versus Inadequate BCG Treatment.
Eur Urol Focus. 2025 May 19:S2405-4569(25)00111.
Abstract
Bladder Cancer with Undetectable Circulating Tumor DNA After Radical Cystectomy
May Be Amenable to a Less Intense Imaging Surveillance Protocol: A Diagnostic
Accuracy Study.
Eur Urol Oncol. 2025 May 19:S2588-9311(25)00124.
Abstract
Identification of a panel of lncRNAs derived from urinary extracellular vesicles
as non-invasive diagnostic biomarkers for bladder cancer.
Clin Chim Acta. 2025 May 18:120376. doi: 10.1016/j.cca.2025.120376.
Abstract
Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder
Cancer: A Step Forward.
Am Soc Clin Oncol Educ Book. 2025;45:e472822.
Abstract
Comparative effectiveness of en-bloc resection techniques vs. conventional
transurethral resection for non-muscle-invasive bladder cancer: A systematic
review and meta-analysis.
Can Urol Assoc J. 2025 May 16. doi: 10.5489/cuaj.9070.
Abstract
Non-Invasive Tumor Budding Evaluation and Correlation with Treatment Response in
Bladder Cancer: A Multi-Center Cohort Study.
Adv Sci (Weinh). 2025 May 20:e2416161. doi: 10.1002/advs.202416161.
Abstract
Determination of Nitrogen Metabolism-Related Prognostic Signatures for
Forecasting Bladder Cancer Prognosis.
Endocr Metab Immune Disord Drug Targets. 2025.
Abstract
Relationship between urinary pH and efficacy of Bacillus Calmette-Guerin
treatment in patients with carcinoma in situ of the bladder.
World J Urol. 2025;43:317.
Abstract
Identification of a panel of volatile organic compounds in urine for early
detection of for bladder cancer.
Sci Rep. 2025;15:17383.
Abstract
Advances in the diagnosis and treatment of urethral metastasis after urothelial
carcinoma surgery: A case series and literature review of 3 total ureterectomy
cases.
Medicine (Baltimore). 2025;104:e42329.
Abstract
Organizational impact of systematic urine culture before Bacillus Calmette Guerin
(BCG) induction instillations.
World J Urol. 2025;43:316.
Abstract
Can ureteral stents be omitted from radical cystectomy with continent diversion?
An ACS-NSQIP analysis of the early postoperative outcomes.
World J Urol. 2025;43:314.
Abstract
Advancements in bladder cancer treatment: The synergy of radiation and
immunotherapy.
Oncotarget. 2025;16:337-346.
Abstract
AP1M2 Drives Gemcitabine-Cisplatin Chemoresistance by Enhancing RAD54B-Associated
DNA Repair in Bladder Cancer.
FASEB J. 2025;39:e70595.
Abstract
Changing Clinical Spectrum and Disease Progression in Young Patients With Bladder
Cancer: A Retrospective Observational Study.
Cureus. 2025;17:e82516.
Abstract
Behind the Smoke: A Bladder Cancer Case Report Through the Eyes of Primary Care.
Cureus. 2025;17:e82435.
Abstract
KHSRP promotes the malignant behavior and cisplatin resistance of bladder cancer
cells through the CLASP2/MAPRE1 axis.
Pharmacogenomics J. 2025;25:14.
Abstract
National Belgian survey on managing non-muscle invasive bladder cancer during
Mitomycin and bacillus Calmette-Guerin shortage.
Fr J Urol. 2025 May 15:102905. doi: 10.1016/j.fjurol.2025.102905.
Abstract
Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of
Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy.
ACS Nano. 2025 May 17. doi: 10.1021/acsnano.4c17444.
Abstract
Photo-Activated PROTACs for Targeted BRD4 Degradation and Synergistic
Photodynamic Therapy in Bladder Cancer.
Mol Pharm. 2025 May 17. doi: 10.1021/acs.molpharmaceut.5c00271.
Abstract
Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4.
Hum Vaccin Immunother. 2025;21:2504776.
Abstract
Dual-source powered sea urchin-like nanomotors for intravesical photothermal
therapy of bladder cancer.
J Nanobiotechnology. 2025;23:355.
Abstract
Tobacco smoking exposure-mediated ELAVL1 regulates bladder cancer cell senescence
via autophagy activation.
Toxicology. 2025;516:154193.
Abstract
Anti-biopassivated Reticular Micromotors for Bladder Cancer Therapy.
J Am Chem Soc. 2025 May 16. doi: 10.1021/jacs.5c02949.
Abstract
ROICellTrack: a deep learning framework for integrating cellular imaging
modalities in subcellular spatial transcriptomic profiling of tumor tissues.
Bioinformatics. 2025;41:btaf152.
Abstract
Two-year resource utilization of open vs. robot-assisted radical cystectomy:
Results from optum's de-identified clinformatics(R) data mart database.
Urol Oncol. 2025;43:391.
Abstract
Risks of colorectal and extracolonic cancers following colorectal cancer: a
systematic review and meta-analysis.
JNCI Cancer Spectr. 2025;9:pkaf031.
Abstract
Contemporary outcomes for robotic radical cystectomy and intracorporeal
neobladder urinary diversion.
Urol Oncol. 2025;43:392.
Abstract
Roles for Androgen Receptor, ADAR2, and PD-L1 in Primary Urothelial Carcinoma In
Situ of the Bladder Treated with Bacillus Calmette-Guerin Therapy.
Lab Invest. 2025;105:104120.
Abstract
SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to
evaluate clinical net benefit.
Urol Oncol. 2025;43:393.
Abstract
Comparison of direct oral anticoagulant (DOAC) versus low-molecular-weight
heparin (LMWH) for venous thromboprophylaxis after radical cystectomy: A
systematic review and meta-analysis.
Urol Oncol. 2025;43:341-347.
Abstract
Analysis of IGFL2 Gene Expression and Prognostic Value in Bladder Cancer Based On
TCGA Database.
Asia Pac J Clin Oncol. 2025 May 29. doi: 10.1111/ajco.14191.
Abstract
NEURL1 acts as a candidate suppressor in bladder cancer by down-regulating PDE9A.
In Vitro Cell Dev Biol Anim. 2025 May 29. doi: 10.1007/s11626-025-01047.
Abstract
miR-944 inhibits malignant progression of bladder cancer through ATIC/AKT/FOXO3 A
axis mediated by SHMT1.
In Vitro Cell Dev Biol Anim. 2025 May 29. doi: 10.1007/s11626-025-01050.
Abstract
Disulfide bond-related gene signature development for bladder cancer prognosis
prediction and immune microenvironment characterization.
Sci Rep. 2025;15:18826.
Abstract
Impact of pelvic lymph node dissection on survival outcomes in non-muscle
invasive bladder cancer: a multicenter retrospective study.
Sci Rep. 2025;15:18905.
Abstract
Association of different treatment modalities for rectal cancer and second
primary urinary system neoplasms, findings from SEER.
Sci Rep. 2025;15:18782.
Abstract
What motivates bladder cancer patients to be active? A qualitative study
assessing attitudes towards physical activity and digital health technologies.
Urol Oncol. 2025 May 28:S1078-1439(25)00176.
Abstract
CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects
in bladder cancer.
Neoplasia. 2025;66:101187.
Abstract
Does having an asymptomatic renal stone increase morbidity after radical
cystectomy?
World J Urol. 2025;43:336.
Abstract
The Effect of Surgeon Experience on the Recurrence of Non-Muscle Invasive Bladder
Cancer (NMIBC), Following Transurethral Resection of the Bladder Tumor (TURBT): A
double Blinded Prospective Randomized Study.
Asian Pac J Cancer Prev. 2025;26:1767-1771.
Abstract
Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle
invasive bladder cancer: A meta-analysis with exploratory chemotherapy
comparisons.
Oncol Lett. 2025;30:348.
Abstract
A lactate-related tSNE signature defines prognostic subtypes of bladder cancer
and reveals LINC01094-mediated VIM stabilization in metastasis and drug
resistance.
Front Immunol. 2025;16:1593523.
Abstract
Septicemia following sudden pituitary apoplexy after bladder tumor surgery: a
case report.
BMC Neurol. 2025;25:228.
Abstract
ASO Author Reflections: Artificial Intelligence in Bladder Cancer-Transforming
Diagnosis and Treatment Paradigms.
Ann Surg Oncol. 2025 May 28. doi: 10.1245/s10434-025-17538.
Abstract
The key regulator circPDE3B promotes arsenic-induced bladder carcinogenesis by
affecting STAT3 and NF-kappaB stability.
Cell Biol Toxicol. 2025;41:91.
Abstract
Associations of a claims-based frailty index with perioperative outcomes and
survival among older adults undergoing radical cystectomy for bladder cancer.
Urol Oncol. 2025 May 27:S1078-1439(25)00168.
Abstract
RETRACTION: Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances
Cell Proliferation, Migration, and Invasion in Bladder Cancer.
Dis Markers. 2025;2025:9803765.
Abstract
Antibody-drug conjugates as game changers in bladder cancer: current progress and
future directions.
Front Immunol. 2025;16:1591191.
Abstract
Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in
non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Front Immunol. 2025;16:1578069.
Abstract
A Prospective Assessment of the Vesical Imaging Reporting and Data System in the
Diagnosis of Muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e83068.
Abstract
Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of
Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients.
Pharmaceuticals (Basel). 2025;18:701.
Abstract
Correction: Sturm et al. Exposure of Bladder Cancer Cells to Blue Light (lambda = 453
nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic
Efficiency of Gemcitabine. Int. J. Mol. Sci. 2024, 25, 4868.
Int J Mol Sci. 2025;26:4790.
Abstract
Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across
Bladder Cancer Stages.
Int J Mol Sci. 2025;26:4891.
Abstract
Integration of Single-Cell and Bulk Transcriptome to Reveal an Endothelial
Transition Signature Predicting Bladder Cancer Prognosis.
Biology (Basel). 2025;14:486.
Abstract
Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review.
Cancers (Basel). 2025;17:1714.
Abstract
Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer:
A Multidisciplinary Bioinformatics Approach.
Biomedicines. 2025;13:1203.
Abstract
Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision
Medicine Approach.
Biomedicines. 2025;13:1145.
Abstract
Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in
T2N0M0 Urothelial Bladder Cancer.
Ann Surg Oncol. 2025 May 27. doi: 10.1245/s10434-025-17488.
Abstract
Association Between Rheumatoid Arthritis, Frailty Status, and Mortality in Older
Adults with Bladder Cancer.
Clin Genitourin Cancer. 2025 Apr 30:102369. doi: 10.1016/j.clgc.2025.102369.
Abstract
Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of
anti-PD-L1 immunotherapy in bladder cancer.
Biomed Pharmacother. 2025;188:118188.
Abstract
Desmocollin-3 and Bladder Cancer.
Diseases. 2025;13:131.
Abstract
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial
Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for
Bladder Cancer Care and Research Symposium.
Curr Oncol. 2025;32:278.
Abstract
AMIGO2 expression at the invasive front of bladder cancer predicts
recurrence-free and overall survival after radical cystectomy.
Oncol Lett. 2025;30:339.
Abstract
Novel neoadjuvant therapies for muscle-invasive bladder cancer: Systematic review
and meta-analysis.
BJUI Compass. 2025;6:e70031.
Abstract
Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based
on the VIM and CDH2 protein macromolecules influence: From molecular-protein
subtyping to therapeutic target prioritization.
Int J Biol Macromol. 2025;315.
Abstract
Engineered Salmonella Carrying siRNA-PD-1 Shrinks orthotopically implanted
Bladder Cancer in Rats.
J Drug Target. 2025 May 26:1-12. doi: 10.1080/1061186X.2025.2512619.
Abstract
The use of ctDNA for muscle-invasive bladder cancer before and after radical
cystectomy.
Expert Rev Anticancer Ther. 2025 May 26. doi: 10.1080/14737140.2025.2512036.
Abstract
Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial
carcinoma of the bladder? The end of the "jump" of the lamina propria layer myth.
World J Urol. 2025;43:324.
Abstract
Identification and Evaluation of the Urinary Microbiota Associated With Bladder
Cancer.
Cancer Innov. 2025;4:e70012.
Abstract
Bladder cancer biomarker analysis and drugtarget prediction based on
pyroptosis-related genes.
Discov Oncol. 2025;16:924.
Abstract
Microsatellite instability and mismatch repair deficiency in bladder urothelial
carcinoma: a Tunisian single-center study.
J Egypt Natl Canc Inst. 2025;37:22.
Abstract
Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guerin
(BCG)-unresponsive non-muscle-invasive bladder cancer.
Urol Oncol. 2025 May 24:S1078-1439(25)00134.
Abstract
Molecular mechanistic approach to reveal decitabine's effect on DNMT gene
modulation and its inhibitory role in heavy metal-induced proliferation in
urinary bladder cancer cell line.
Toxicol In Vitro. 2025 May 23:106082. doi: 10.1016/j.tiv.2025.106082.
Abstract
The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder
cancer: a retrospective analysis.
BMC Urol. 2025;25:135.
Abstract
Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in
Bladder Cancer: A Justified Standard.
Eur Urol Focus. 2025 May 23:S2405-4569(25)00121.
Abstract
Prognostic role of pathological substaging in high-grade pT1 bladder cancer
undergoing BCG therapy: Insights on recurrence and progression.
Urol Oncol. 2025 May 23:S1078-1439(25)00174.
Abstract
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder
cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
J Immunother Cancer. 2025;13:e012045.
Abstract
Combining Radiotherapy with Immune Checkpoint Inhibitors for the Management of
Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review from the Y-ECI
ROSC EORTC group.
Pract Radiat Oncol. 2025 May 22:S1879-8500(25)00147.
Abstract
A meta-analytic appraisal of robotic-assisted cystectomy outcomes in the elderly
octogenarian population.
J Robot Surg. 2025;19:232.
Abstract
HER2 prognostic values in non-muscle-invasive bladder cancer: a step towards
personalized treatment for BCG instillation.
Discov Oncol. 2025;16:891.
Abstract
From exposure to innovation: decoding aromatic amines' role in bladder cancer
mechanisms.
Discov Oncol. 2025;16:888.
Abstract
Sex-specific gut microbiota and neutrophil senescence in bladder cancer.
Nat Cancer. 2025;6:738.
Abstract
Bladder lesion detection using EfficientNet and hybrid attention transformer
through attention transformation.
Sci Rep. 2025;15:18042.
Abstract
Metanephrine normal, DOTATATE negative paraganglioma of the urinary bladder.
BMJ Case Rep. 2025;18:e266048.
Abstract
Infrapubic Foley catheter balloon tamponade for retropubic venous haemorrhage
during radical cystoprostatectomy and urethrectomy.
BMJ Case Rep. 2025;18:e265030.
Abstract
Uncovering citron kinase as a key biomarker for predicting outcomes and therapy
efficacy in non-muscle-invasive bladder cancer.
Gene. 2025 May 21:149590. doi: 10.1016/j.gene.2025.149590.
Abstract
Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution
experience with focus on next-generation sequencing (NGS) and PD-L1
immunohistochemistry.
Hum Pathol. 2025;158:105788.
Abstract
[mpMRI of the Urinary Bladder: Significance and Clinical Use].
Aktuelle Urol. 2025;56:248-257.
Abstract
Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer:
comparison between patients from a Dutch nationwide cohort and KEYNOTE-045.
Cancer Treat Res Commun. 2025;43:100931.
Abstract
Diagnostic workout of glandular malignant lesions of the bladder according to the
5th WHO classification.
Crit Rev Clin Lab Sci. 2025;62:301-312.
Abstract
Urological cancer risk in patients with rheumatoid arthritis compared to matched
controls: a nationwide cohort study.
Rheumatology (Oxford). 2025;64:3458-3467.
Abstract
[Bimodal and multimodal endoscopy of the urinary bladder in diagnosis and
treatment].
Aktuelle Urol. 2025;56:242-247.
Abstract
Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic
Urothelial Carcinoma.
Chemotherapy. 2025;70:85-91.
Abstract
Cytologic Assessment of the Supernatants of Formalin Solution Following
Histologic Examination of Transurethral Biopsy/Resection Specimens: Potential
Detection of Denuded Urothelial Cancer Cells.
Arch Pathol Lab Med. 2025;149:573-577.
Abstract
Prognostic significance of copper metabolism-related genes as risk markers in
bladder urothelial carcinoma.
Nucleosides Nucleotides Nucleic Acids. 2025;44:598-616.
Abstract
Chromosomal instability by low-coverage whole-genome sequencing assay predicts
prognosis in bladder cancer patients underwent radical cystectomy.
BMC Med Genomics. 2025;18:103.
Abstract
Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in
Patients with Bladder Cancer: A Systematic Review and Meta-analysis.
Ann Surg Oncol. 2025 Jun 5. doi: 10.1245/s10434-025-17600.
Abstract
Design and synthesis of 3,4-seco-lupane triterpene-tryptamine derivatives and
revealing their anti-bladder cancer mechanisms by combining TCGA and
transcriptomic approaches.
Sci Rep. 2025;15:19723.
Abstract
[A Case of Cut-to-the-light Incision for Ureteroileal Anastomotic Obstruction
after Robot-Assisted Radical Cystectomy and Ileal Conduit].
Hinyokika Kiyo. 2025;71:155-158.
Abstract
Intervention of machine learning in bladder cancer research using multi-omics
datasets: systematic review on biomarker identification.
Discov Oncol. 2025;16:1010.
Abstract
Outpatient transurethral resection of bladder tumors: A systematic review of
oncologic and safety outcomes.
World J Urol. 2025;43:359.
Abstract
Gene network changes after exposure to nanoliposomes containing antisense miR-21
and miR-373 in bladder cancer Cells: An in vitro model study.
Biochem Biophys Rep. 2025;42:102041.
Abstract
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC)
combined immunotherapy in patients with muscle-invasive bladder cancer: A
multi-center real-world study.
Imeta. 2025;4:e70033.
Abstract
Pediatric papillary urothelial neoplasm: 18-year single-center experience in
diagnosis and treatment.
BMC Urol. 2025;25:148.
Abstract
Development of a machine learning-based model to predict urethral recurrence
following radical cystectomy: a multicentre retrospective study and updated
meta-analysis.
Sci Rep. 2025;15:19573.
Abstract
ASO Visual Abstract: Cancer-Specific Mortality of Partial Cystectomy Versus
Radical Cystectomy in T2N0M0 Urothelial Bladder Cancer.
Ann Surg Oncol. 2025 Jun 4. doi: 10.1245/s10434-025-17637.
Abstract
LEADR, a p63 target, dampens interferon signalling in bladder cancer.
Cell Death Discov. 2025;11:264.
Abstract
Methodological evaluation of ultrasound-guided modified traumatic catheterization
in dogs with suspected urothelial carcinoma.
J Vet Sci. 2025;26:e32.
Abstract
Elucidating the pathogenesis of bladder cancer through single-cell chromatin
accessibility and DNA methylation analysis.
Genes Dis. 2025;12:101578.
Abstract
Deciphering riddles in molecular subtyping of bladder cancer.
Asian J Urol. 2025;12:217-231.
Abstract
Integrative multi-omics study identifies sex-specific molecular signatures and
immune modulation in bladder cancer.
Front Bioinform. 2025;5:1575790.
Abstract
Low-carbohydrate diet score and risk of bladder cancer: Findings from a
prospective cohort study.
BJUI Compass. 2025;6:e70033.
Abstract
Unsupervised learning-based quantitative analysis of CT intratumoral subregions
predicts risk stratification of bladder cancer patients.
BMC Med. 2025;23:328.
Abstract
Double-J stenting during TURBT increases risk of metachronous upper tract
urothelial carcinoma.
BMC Urol. 2025;25:146.
Abstract
Socioeconomic disparities and MIBC survival outcome-An analysis of a statewide
cohort.
World J Urol. 2025;43:349.
Abstract
Hyperspectral Imaging for Predicting Bladder Cancer Grading: A Novel Diagnostic
Approach.
J Biophotonics. 2025 Jun 2:e202500161. doi: 10.1002/jbio.202500161.
Abstract
When A Health Economist Becomes A Cancer Patient.
Health Aff (Millwood). 2025;44:761-765.
Abstract
Tuberculosis epididymitis presenting as an acute scrotum in a 65 year-old man
undergoing BCG treatment for bladder cancer.
Urol Case Rep. 2025;61:103009.
Abstract
Unveiling Oncogenic Power of WAVE1 in Bladder Cancer Progression.
Biochemistry (Mosc). 2025;90:534-543.
Abstract
Primary urothelial carcinoma of an ileal conduit; six decades after childhood
bladder exstrophy surgery: a rare and late complication.
World J Surg Oncol. 2025;23:211.
Abstract
Global insight of early-onset genitourinary cancers in adolescents and adults
from 1990 to 2021: temporal trends and health inequalities analyses.
World J Surg Oncol. 2025;23:208.
Abstract
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer:
the randomized phase 3 CREST trial.
Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03738.
Abstract
Self-enhanced ROS-responsive camptothecin prodrug nanoparticles elicit safe and
efficient intravesical instillation therapy of bladder cancer.
J Control Release. 2025;384:113905.
Abstract
Aminopeptidase N-Triggered Electron Rearrangement of Fluorescein for Covalent
Fluorescent Labeling and Image-Guided Orthotopic Bladder Cancer Resection.
Anal Chem. 2025 May 31. doi: 10.1021/acs.analchem.5c02393.
Abstract
CXCL12 links bladder cancer and diabetes as a potential biomarker.
Sci Rep. 2025;15:19017.
Abstract
Reassessing the role of the gut microbiome in bladder cancer: A review of
methodological approaches and future research directions.
Urol Oncol. 2025;43:436-437.
Abstract
Socioeconomic disparities and bladder cancer stage at diagnosis: a statewide
cohort analysis.
JNCI Cancer Spectr. 2025 May 30:pkaf054. doi: 10.1093.
Abstract
First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody
AZD8853 in Patients with Advanced/Metastatic Solid Tumors.
Cancer Res Commun. 2025;5:896-905.
Abstract
Sex-related differences in response to neoadjuvant and adjuvant chemotherapy in
urothelial carcinoma of urinary bladder treated with radical cystectomy.
Urol Oncol. 2025;43:442.
Abstract
The impact of age on BCG treatment response.
Urol Oncol. 2025;43:440.
Abstract
Impact of IRAES on the outcomes of pembrolizumab therapy in patients with MUC: A
comprehensive analysis of severity and the type and number of affected organs.
Urol Oncol. 2025;43:441.
Abstract
Biological and therapeutic implications of FGFR alterations in urothelial cancer:
A systematic review from non-muscle-invasive to metastatic disease.
Actas Urol Esp (Engl Ed). 2025;49:501719.
Abstract
The impact of a multidisciplinary approach on treatment decisions and outcomes in
urothelial carcinoma: A systematic review.
Actas Urol Esp (Engl Ed). 2025;49:501718.
Abstract
Metformin intake and risk of metabolic acidosis after radical cystectomy with
urinary diversion: A comparative study using data from the TriNetX research
network.
Urol Oncol. 2025;43:441.
Abstract
Benign Glomus Tumor of the Urinary Bladder: A Case Report and Literature Review.
Int J Surg Pathol. 2025;33:1082-1088.
Abstract
Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic
Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39.
Eur Urol Oncol. 2025;8:681-688.
Abstract
Copper Nanoparticles Green-Formulated by Curcuma longa Extract Induce Apoptosis
via P53 and STAT3 Signaling Pathways in Bladder Carcinoma Cell.
Biol Trace Elem Res. 2025;203:2606-2618.
Abstract
Incidence and Pitfalls of Adipose Tissue Encountered in Urinary Bladder
Biopsy/Transurethral Resection Specimens.
Int J Surg Pathol. 2025;33:596-604.
Abstract
Cancer-Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0
Non-Urothelial Bladder Cancer.
J Surg Oncol. 2025 Jun 13. doi: 10.1002/jso.70014.
Abstract
A comprehensive risk model of disulfidoptosis-related lncRNAs predicts prognosis
and therapeutic implications in bladder cancer.
Biochem Biophys Rep. 2025;42:102060.
Abstract
Smoking-related bladder cancer burden from 1990 to 2021: An age-period-cohort
analysis of the global burden of disease study.
Tob Induc Dis. 2025;23.
Abstract
Prospective Analysis of Residual Urine Volume and Its Association With
Intravesical Recurrence in Patients With Non-Muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e84023.
Abstract
Evolutionary Transcriptomics of Cancer Development.
Int J Mol Sci. 2025;26:5041.
Abstract
Usability Evaluation of Urinary HAI-1, STMN-1 and TN-C in the Diagnosis of
Bladder Cancer.
J Clin Med. 2025;14:3664.
Abstract
Global clinical trial landscape and therapeutic trends in bladder cancer: a
systematic analysis.
Int J Surg. 2025 Jun 12. doi: 10.1097/JS9.0000000000002662.
Abstract
Homeobox C6 plays an oncogenic role in bladder cancer.
World J Clin Oncol. 2025;16:103830.
Abstract
TRPV4 Channels Mediate Bladder Cancer Cell Proliferation, Migration and
Chemoresistance.
bioRxiv [Preprint]. 2025 Jun 7:2025.06.05.657842. doi: 10.1101/2025.06.05.657842
Abstract
Characterization of treatment patterns and outcomes in muscle-invasive bladder
cancer patients in Sweden.
Scand J Urol. 2025;60:108-114.
Abstract
Caspase-1-dependent pyroptosis converts alphaSMA(+) CAFs into collagen-III(high)
iCAFs to fuel chemoresistant cancer stem cells.
Sci Adv. 2025;11:eadt8697.
Abstract
Real-world oncological and toxicity outcomes with the Moscow strain of
intravesical BCG for non-muscle invasive bladder cancer-Implications for global
shortage.
BJUI Compass. 2025;6:e70034.
Abstract
RETRACTION: KIF5A Promotes Bladder Cancer Proliferation In Vitro and In Vivo.
Dis Markers. 2025;2025:9767430.
Abstract
Enhancing bladder cancer awareness and knowledge through multifaceted community
engagement in Egypt: a cross-sectional study.
Ecancermedicalscience. 2025;19:1886.
Abstract
Cytotoxic effect of bladder cancer oncolytic virus on bladder cancer stem-like
cells via pyroptosis pathway.
Technol Health Care. 2025 Jun 11:9287329251349081.
Abstract
Impact of transurethral resection of bladder tumors on sexual function and
quality of life using ePROMs in patients with bladder cancer- a prospective
cohort study.
World J Urol. 2025;43:370.
Abstract
Loss of RNF41 promotes bladder cancer metastasis through increasing NUDC
stability to enhance tubulin polymerization.
Cell Death Dis. 2025;16:443.
Abstract
Genes driving three-dimensional growth of immortalized cells and cancer.
Cell Death Dis. 2025;16:442.
Abstract
A Systematic Review and Meta-analysis on Perioperative Stenting/Dwell Time and
Postoperative Outcomes in Patients Undergoing Radical Cystectomy and Urinary
Diversion for Bladder Cancer.
Eur Urol Focus. 2025 Jun 9:S2405-4569(25)00154-3. doi: 10.1016/j.euf.2025.
Abstract
Long Noncoding RNAs Identify a Subgroup of Patients with Low-grade
Non-muscle-invasive Bladder Cancer with Less Favorable Outcomes.
Eur Urol Oncol. 2025 Jun 9:S2588-9311(25)00151-8. doi: 10.1016/j.euo.2025.
Abstract
Anti-Cancer Role of Ellagic Acid by Modulating the Altered PI3K/PTEN/Akt Pathway
in Bladder Cancer.
J Environ Pathol Toxicol Oncol. 2025;44:57-69.
Abstract
Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via
deglycosylation of CD47.
Cancer Commun (Lond). 2025 Jun 10. doi: 10.1002/cac2.70040.
Abstract
Bladder Cancer Growth is Inhibited by Upregulating CircFUT8 through the
METTL14/FMR1 Signaling Pathway.
Cell Biochem Biophys. 2025 Jun 10. doi: 10.1007/s12013-025-01794.
Abstract
Role of tumor mutational burden in patients with urothelial carcinoma treated
with immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2025;16:1592761.
Abstract
Intravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In
Murine Model.
Int J Nanomedicine. 2025;20:7169-7183.
Abstract
Causal relationship between the plasma lipidome and urological cancers: A
two-sample Mendelian randomization study.
Medicine (Baltimore). 2025;104:e42577.
Abstract
Causal association between blood and urine biomarkers, immune cells, and bladder
cancer: A Mendelian randomization and mediation analysis.
Medicine (Baltimore). 2025;104:e42814.
Abstract
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated
With Nivolumab.
JAMA Netw Open. 2025;8:e2514427.
Abstract
Is miR-10a a tumor suppressor that modulates proliferation and invasion in
high-grade bladder cancer?
Oncol Res. 2025;33:1377-1382.
Abstract
Recent advances in understanding the role of sex hormone receptors in urothelial
cancer.
Oncol Res. 2025;33:1255-1270.
Abstract
Intradermal priming to intravesical Bacillus Calmette-Guerin in non-muscle
invasive bladder cancer: A translational research and phase I clinical trial.
Oncol Res. 2025;33:1495-1503.
Abstract
Inflammation as a key mediator: linking triglyceride-glucose index to prognosis
in non-muscle-invasive bladder cancer.
Front Oncol. 2025;15:1545985.
Abstract
Correction: Qi et al. Development of Mitomycin C-Loaded Nanoparticles Prepared
Using the Micellar Assembly Driven by the Combined Effect of Hydrogen Bonding and
pi-pi Stacking and Its Therapeutic Application in Bladder Cancer. Pharmaceutics
2021, 13,
Pharmaceutics. 2025;17:733.
Abstract
Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in
patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic
correlations.
Urol Oncol. 2025 Jun 7:S1078-1439(25)00207-8. doi: 10.1016/j.urolonc.2025.
Abstract
Sex-based differences in genetic alterations and immune checkpoint inhibitor
response in urothelial bladder cancer.
Urol Oncol. 2025 Jun 6:S1078-1439(25)00204-2. doi: 10.1016/j.urolonc.2025.
Abstract
Bladder cancer risk in aluminum production workers: A systematic review.
Actas Urol Esp (Engl Ed). 2025 Jun 5:501789. doi: 10.1016/j.acuroe.2025.501789.
Abstract
Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer.
Cancer Immunol Immunother. 2025;74:240.
Abstract
Genetically engineered T cell membrane-camouflaged nanoparticles triggered
cuproptosis for synergistic bladder cancer photothermal-immunotherapy.
J Nanobiotechnology. 2025;23:425.
Abstract
A novel efferocytosis-related gene signature for predicting prognosis and
therapeutic response in bladder cancer.
Sci Rep. 2025;15:19912.
Abstract
A polygenic risk score is associated with risk of bladder cancer and earlier age
of diagnosis, independent of lifestyle factors.
Urol Oncol. 2025 Jun 5:S1078-1439(25)00180-2. doi: 10.1016/j.urolonc.2025.
Abstract
AgAu@Ag core-shell triangular nanonet jointed with composite SERS enhanced
substrate for capturing and sensing urine biomarkers FGFR3 and NMP22.
Biosens Bioelectron. 2025;286:117635.
Abstract
Expression of TIM-3 in transitional cell carcinoma: A comparative study of tissue
and serum levels.
Pathol Res Pract. 2025;271:156031.
Abstract
FGFR3 immunohistochemistry as a surrogate biomarker for FGFR3 alterations in
urothelial carcinoma.
Pathol Res Pract. 2025;271:156028.
Abstract
Molecular profile of micropapillary urothelial carcinoma of the urinary bladder:
An analysis of 99 cases by next-generation sequencing.
Hum Pathol. 2025;159:105812.
Abstract
Structural and Mechanical Characterization of Collagen-Hyaluronan Hydrogels Used
to Study Cancer Cell Invasion through the Bladder Wall.
ACS Biomater Sci Eng. 2025;11:3443-3454.
Abstract
Economic evaluation of Erdafitinib as a second-line treatment for advanced
metastatic urothelial carcinoma: real-world data from the USA and prospective
analysis from China.
Future Oncol. 2025;21:1919-1927.
Abstract
Expression of inflammatory proteins STAT & NFkB for phenotypic diagnosis of gall
bladder cancer: A pilot study.
Indian J Med Res. 2025;161:414-419.
Abstract
Second-hand smoke and bladder cancer risk among nonsmokers: a systematic review
and a meta-analysis.
Eur J Cancer Prev. 2025 Jun 18. doi: 10.1097/CEJ.0000000000000979.
Abstract
Resveratrol Induces Oxidative Stress and Downregulates GPX4 and xCT to Activate
the Ferroptosis Pathway for Anti-Bladder Cancer Organoids.
J Cancer. 2025;16:2613-2625.
Abstract
Retinoic acid metabolism related gene CYP26B1 promotes tumor stemness and tumor
microenvironment remodeling in bladder cancer.
J Cancer. 2025;16:2476-2491.
Abstract
Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via
interactions with HRAS to facilitate cholesterol synthesis.
Oncol Lett. 2025;30:385.
Abstract
Performance of the Oncuria-Detect bladder cancer test for evaluating patients
presenting with haematuria: results from a real-world clinical setting.
J Transl Med. 2025;23:680.
Abstract
The association between diet and bladder cancer risk: a two-sample mendelian
randomization.
Eur J Nutr. 2025;64:223.
Abstract
Machine Learning Characterization of Immunometabolism in the Tumor
Microenvironment and Immunotherapy Responses in Bladder Cancer.
J Immunother. 2025 Jun 18. doi: 10.1097/CJI.0000000000000568.
Abstract
A Multifunctional Fe-EGCG@RSL3 Nanomedicine Synergizes Ferroptosis Induction and
Tumor Microenvironment Remodeling for Enhanced Bladder Cancer Immunotherapy.
Research (Wash D C). 2025;8:0735.
Abstract
Variant histology muscle invasive bladder cancer should not preclude neoadjuvant
chemotherapy before cystectomy.
Transl Androl Urol. 2025;14:1187-1189.
Abstract
Clinical outcomes of modified partial cystectomy in muscle-invasive bladder
cancer: balancing tumor control and quality of life.
Transl Androl Urol. 2025;14:1444-1455.
Abstract
Neoadjuvant chemotherapy for muscle-invasive bladder cancer with variant
histology and/or divergent differentiation.
Transl Androl Urol. 2025;14:1155-1157.
Abstract
Pathway-based cancer transcriptome deciphers a high-resolution intrinsic
heterogeneity within bladder cancer classification.
J Transl Med. 2025;23:666.
Abstract
LINC00525 drives aggressive phenotypes in bladder cancer via YAP
stabilization-mediated transcriptional activation.
Cancer Cell Int. 2025;25:214.
Abstract
Bladder cancer variants share aggressive features including a CA125+ cell state
and targetable TM4SF1 expression.
Nat Commun. 2025;16:5312.
Abstract
Enfortumab vedotin-induced widespread vesiculobullous eruption mimicking
disseminated herpetic infection in a patient with metastatic urothelial
carcinoma.
Dermatol Online J. 2024;30.
Abstract
Assessment of atypical cells in detecting bladder cancer in female patients.
Clin Chem Lab Med. 2025 Jun 18. doi: 10.1515/cclm-2025-0268.
Abstract
Optimizing enfortumab vedotin plus pembrolizumab therapy.
Oncotarget. 2025;16:481-494.
Abstract
Prognostic analysis of bladder cancer with neddylation-related genes.
Hereditas. 2025;162:105.
Abstract
Neoadjuvant Radiotherapy Combined with Transurethral Photoselective Vaporization
of Bladder Tumors and Postoperative Adjuvant Radiotherapy and Chemotherapy for T3
Muscle-Invasive Bladder Cancer: A Retrospective Case Series Study.
Photobiomodul Photomed Laser Surg. 2025 Jun 16. doi: 10.1089/photob.2024.0150.
Abstract
Effect of sex on adverse in-hospital outcomes after radical cystectomy according
to urinary diversion type.
World J Urol. 2025;43:375.
Abstract
The importance of maximal TURBT in trimodality therapy for muscle-invasive
bladder cancer (MIBC).
Bladder Cancer. 2025;11:23523735251346569.
Abstract
Impact of immediate intravesical therapy on non-muscle invasive bladder cancer
with risk factors analysis for recurrence.
Am J Cancer Res. 2025;15:2275-2284.
Abstract
Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder
cancer treatment.
RSC Adv. 2025;15:20183-20191.
Abstract
Magnetic-Driven Hydrogel Robots Loaded with Mitomycin for Active Therapy of
Bladder Cancer.
ACS Appl Mater Interfaces. 2025 Jun 16. doi: 10.1021/acsami.5c03787.
Abstract
Re: Alexandra Masson-Lecomte, Guillaume Grisay, Julien Van Damme, et al.
Challenges in Defining Clinical Complete Response to Systemic Therapy in
Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project. Eur
Urol Oncol. In press. http
Eur Urol Focus. 2025 Jun 14:S2405-4569(25)00161.
Abstract
Smoking and bladder cancer: insights into pathogenesis and public health
implications from a bibliometric analysis (1999-2023).
Subst Abuse Treat Prev Policy. 2025;20:25.
Abstract
ASO Visual Abstract: Perioperative Complications and In-Hospital Mortality after
Cystectomy for Non-Bladder Cancer Conditions versus Radical Cystectomy for
Bladder Cancer.
Ann Surg Oncol. 2025 Jun 14. doi: 10.1245/s10434-025-17629.
Abstract
Real-World Experience with a Commercial Circulating Tumor DNA Assay in
Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 Jun 13:S2588-9311(25)00165.
Abstract
Comment on "Oncological outcomes of patients with node positive disease following
neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder
cancer: A multicenter observational study of the EAU Young Academic Urologists
(YAU) urotheli
Actas Urol Esp (Engl Ed). 2025 Jun 12:501792. doi: 10.1016/j.acuroe.2025.501792.
Abstract
Exploring the chemotherapeutic potential of diosmetin ruthenium-p-cymene complex
in bladder cancer treatment through the regulation of the PI3K/beta-catenin/TJP1/AR
signaling pathway.
J Trace Elem Med Biol. 2025;90:127680.
Abstract
Nano-orchestrated magnetotactic-like navigation for electromagnetic theranostics
and immune enhancement via photoautotrophic oxygenation, mild hyperthermia, and
ferroptosis.
J Nanobiotechnology. 2025;23:442.
Abstract
Galphai3: a crucial biomarker and therapeutic target in bladder cancer.
NPJ Precis Oncol. 2025;9:181.
Abstract
Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its
Origin.
Clin Genitourin Cancer. 2025 May 20:102378. doi: 10.1016/j.clgc.2025.102378.
Abstract
Prognostic Implications of Patients With Clinically Node Positive Bladder Cancer
Undergoing Radical Cystectomy.
Clin Genitourin Cancer. 2025 May 17:102377. doi: 10.1016/j.clgc.2025.102377.
Abstract
Stapled W-shaped (Hautmann) Orthotopic Ileal Neobladder. Functional Results and
Complications over a 13-year Period.
Eur Urol Focus. 2025;11:165-171.
Abstract
Recurrence of urothelial carcinoma. An unusual cause of upper gastrointestinal
bleeding.
Rev Esp Enferm Dig. 2025;117:346-347.
Abstract
Prognostic role of circRNAs and RNA methylation enzymes in bladder cancer: A
systematic review and meta-analysis of Chinese studies.
Urol Oncol. 2025 Jun 26:S1078-1439(25)00218.
Abstract
Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage
Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2025 Jun 26:S2405-4569(25)00152.
Abstract
[Apelin promotes proliferation, migration, and angiogenesis in bladder cancer by
activating the FGF2/FGFR1 pathway].
Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:1289-1296.
Abstract
Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced
Bladder Cancer Recurrence Following Radical Cystectomy.
In Vivo. 2025;39:2196-2208.
Abstract
Deep Learning Model for Natural Language to Assess Effectiveness of Patients With
Non-Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus
Calmette-Guerin Therapy.
JCO Clin Cancer Inform. 2025;9:e2400249.
Abstract
Corrigendum: Prognostic impact of nutritional indicators based on Lasso-Cox
regression for non-muscle-invasive bladder cancer.
Front Nutr. 2025;12:1630197.
Abstract
Exploring the molecular mechanism of Xiao Ji (Cirsium setosum) in treating
bladder cancer using network pharmacology and molecular docking.
Asian Biomed (Res Rev News). 2025;19:94-105.
Abstract
Comparison of long-term survival for muscle-invasive bladder cancer patients who
underwent bladder preservation therapy and radical cystectomy: A systematic
review and meta-analysis.
Urologia. 2025 Jun 26:3915603251347444. doi: 10.1177/03915603251347444.
Abstract
Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with
Carcinoma in Situ: Still a No Go?
Eur Urol Oncol. 2025 Jun 25:S2588-9311(25)00173.
Abstract
Contribution of MRE11, RAD50, and NBS1 Genotypes to Bladder Cancer
Susceptibility.
Cancer Genomics Proteomics. 2025;22:575-591.
Abstract
Morphological changes in the muscle layer associated with invasion of bladder
cancer.
Clin Radiol. 2025;87:106973.
Abstract
Survival According to Source of Treatment Funding in Bladder Cancer: Analysis of
a Large Public Database From Sao Paulo, Brazil.
JCO Glob Oncol. 2025;11:e2400648.
Abstract
Lifetime Water Arsenic, Genetic Susceptibility, And Bladder Cancer In The New
England Bladder Cancer Study.
JNCI Cancer Spectr. 2025 Jun 16:pkaf064. doi: 10.1093.
Abstract
TET3 facilitates bladder cancer progression through targeted modulation of
stemness pathways.
Med Oncol. 2025;42:284.
Abstract
Prevalence and predictive factors of complicated urinary tract infections post
bladder and prostate transurethral resections.
World J Urol. 2025;43:398.
Abstract
KIAA1429 and AlkB Homolog 5 Regulate Bladder Cancer Progression via
N(6)-Methyladenosine-Dependent Modulation of Sonic Hedgehog Signaling.
Mol Carcinog. 2025 Jun 26. doi: 10.1002/mc.70004.
Abstract
Survival outcomes with pelvic node dissection after partial cystectomy among
octogenarians with muscle-invasive bladder cancer.
Can J Urol. 2025;32:137-143.
Abstract
Knockdown of PLK1 suppresses malignant phenotypes and tumor growth in bladder
cancer via activating Hippo pathway.
Gen Physiol Biophys. 2025;44:259-274.
Abstract
Metabolic Reprogramming of Urothelial Carcinoma-A Theragnostic Target for
Betulinic Acid.
Int J Mol Sci. 2025;26:5598.
Abstract
Investigation of Anti-Cancer Properties of Nano-Encapsulated Ciprofloxacin Using
3D Cancer Cell Spheroids as Tumour Models.
Int J Mol Sci. 2025;26:5530.
Abstract
Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with
Early-Stage Bladder Cancer Treated with BCG Immunotherapy.
Cancers (Basel). 2025;17:2027.
Abstract
Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: Implications for
Prognosis and Treatment Personalization.
Cancers (Basel). 2025;17:1908.
Abstract
Laparoscopic Colectomy for Sigmoid Colon Cancer in a Patient With a History of
Radical Cystectomy and Ileal Conduit Urinary Diversion.
Asian J Endosc Surg. 2025;18:e70108.
Abstract
The role of preoperative and postoperative exercise in enhancing quality of life
following cystectomy for bladder cancer: a systematic review and meta-analysis.
Support Care Cancer. 2025;33:629.
Abstract
The role and mechanism of human papillomavirus in urinary system tumors.
J Int Med Res. 2025;53:3000605251348233.
Abstract
High-resolution transcriptome atlas of bladder cancer highlights the functional
myeloid subsets in modulating immune microenvironment.
EBioMedicine. 2025;117:105801.
Abstract
Apigenin and treating bladder cancer: a mini-review of the current literature.
Nat Prod Res. 2025 Jun 25:1-6. doi: 10.1080/14786419.2025.2524610.
Abstract
Clinical relevance of Nectin-4 downregulation and biological changes caused by
cytotoxic chemotherapy in bladder cancer.
Cancer Chemother Pharmacol. 2025;95:62.
Abstract
Gut Parabacteroides distasonis-derived Indole-3-Acetic Acid Promotes Phospholipid
Remodeling and Enhances Ferroptosis Sensitivity via the AhR-FASN Axis in Bladder
Cancer.
Adv Sci (Weinh). 2025 Jun 25:e04688. doi: 10.1002/advs.202504688.
Abstract
Analyzing Smoking Challenges in Bladder Cancer Patients From an Online Forum: A
Contemporary Qualitative Study of Peer Support and Cessation Motivators.
Tob Use Insights. 2025;18:1179173X251355758.
Abstract
Assessing the Impact of VEGF -2578C>A (rs699947) and -7C>T (rs2010963)
Polymorphisms on Bladder Cancer Susceptibility: A Pilot Study.
World J Oncol. 2025;16:295-298.
Abstract
Iatrogenic Bladder Rupture After Insertion of a Urinary Catheter in a Patient
With Bladder Cancer: A Case Report.
J Emerg Nurs. 2025 Jun 23:S0099-1767(25)00172-2. doi: 10.1016/j.jen.2025.
Abstract
A prospective randomised pilot study evaluating the safety of the novel
LubriShield Foley catheter: a permanently coated indwelling urinary catheter.
Scand J Urol. 2025;60:124-129.
Abstract
Use of Photodynamic diagnosis (PDD) at primary TURB: Potential influence on
recurrence and progression rates in NMIBC: a registry-based study using a country
cohort.
Scand J Urol. 2025;60:115-123.
Abstract
Single-Cell RNA Sequencing Identifies MMP11(+) Cancer-Associated Fibroblasts as
Drivers of Angiogenesis and Bladder Cancer Progression.
Adv Sci (Weinh). 2025 Jun 24:e02774. doi: 10.1002/advs.202502774.
Abstract
Response to Letter: Reply Letter to Dr. Kumar et al. on: Enhanced Artificial
Intelligence in Bladder Cancer Management: A Comparative Analysis and
Optimization Study of Multiple Large Language Models.
J Endourol. 2025 Jun 24. doi: 10.1089/end.2025.0426.
Abstract
Long-Term Complications and Quality of Life After Urinary Diversion for Bladder
Cancer: A Systematic Review and Meta-Analysis.
Cureus. 2025;17:e84744.
Abstract
Utility of restaging transurethral resection in patients with primary high-grade
Ta bladder cancer.
World J Urol. 2025;43:387.
Abstract
GSK343, an inhibitor of EZH2, prevents acquired cisplatin resistance in bladder
cancer.
Mol Genet Genomics. 2025;300:63.
Abstract
Microbiome And Immunotherapy In Bladder Cancer: The Missing Link.
Fr J Urol. 2025 Jun 21:102922. doi: 10.1016/j.fjurol.2025.102922.
Abstract
Preoperative prediction of severe short-term complications in patients with
bladder cancer undergoing radical cystectomy.
Surg Oncol. 2025;61:102253.
Abstract
Ureteral calculus complicated by bladder malakoplakia: A case report.
Medicine (Baltimore). 2025;104:e42926.
Abstract
Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive
Bladder Cancer.
JAMA Netw Open. 2025;8:e2517056.
Abstract
LncRNA TRPM2-AS promotes cell proliferation, migration, and invasion by
regulating the miR-195-5p/COP1 axis in bladder cancer.
Naunyn Schmiedebergs Arch Pharmacol. 2025.
Abstract
Integrated Multiomics Analysis and Machine Learning Approaches in Bladder Cancer:
Unveiling the Impact of Immunogenic Cell Death and Its Key Gene SLC2A3 on
Prognosis and Personalized Treatment Strategies.
ACS Omega. 2025;10:24655-24674.
Abstract
Potential of Urinary Mutation and Methylation Biomarkers in Selecting Candidates
for Repeat Transurethral Resection of Bladder Tumor in Non-muscle-invasive
Bladder Cancer: A Prospective Multicenter Study.
Eur Urol Open Sci. 2025;77:49-57.
Abstract
Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The
neglected impact of informative censoring. A systematic review and meta-analysis.
Crit Rev Oncol Hematol. 2025;214:104815.
Abstract
Investigating the expression of HERV-K env, np9, gag, and rec in bladder cancers.
Infect Agent Cancer. 2025;20:41.
Abstract
Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and
development of new hydronephrosis.
Radiat Oncol. 2025;20:104.
Abstract
Type 2 Diabetes Mellitus and bladder cancer: A narrative review on associated
signaling pathways.
Mol Aspects Med. 2025;104:101381.
Abstract
Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and
potentiates antitumor immunity in bladder cancer.
Int Immunopharmacol. 2025;162:115057.
Abstract
Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment
Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers.
Curr Urol Rep. 2025;26:51.
Abstract
Autophagy-related biological targets and network mechanisms of juglone against
bladder cancer.
J Cancer Res Clin Oncol. 2025;151:194.
Abstract
Comprehensive multi-omics analysis of nucleotide metabolism: elucidating the role
and prognostic significance of UCK2 in bladder cancer.
Funct Integr Genomics. 2025;25:133.
Abstract
TFAP2C Drives Cisplatin Resistance in Bladder Cancer by Upregulating YAP and
Activating beta-Catenin Signaling.
J Biol Chem. 2025 Jun 18:110387. doi: 10.1016/j.jbc.2025.110387.
Abstract
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a
phase 1 trial.
Nat Cancer. 2025;6:988-999.
Abstract
LINE-1 DNA methylation mediates smoking-related risk in site-specific urothelial
carcinoma: a Taiwan case-control study.
Arch Toxicol. 2025;99:3035-3046.
Abstract
Market-Level Features May Influence a Hospital's Decision to Perform Robotic
Radical Cystectomy in Florida.
Urol Pract. 2025;12:391-400.
Abstract
Poorly Differentiated Carcinoma with only Clear Glandular Differentiation Arising
from the Bladder Trigone: A Case of Adenocarcinoma or Urothelial Carcinoma?
Keio J Med. 2025;74:113-118.
Abstract
Online Adaptive Radiation Therapy for Bladder Preservation: Transitioning to
Hypofractionation.
Int J Radiat Oncol Biol Phys. 2025;122:995-1001.
Abstract
Management and desensitization to Avelumab in anaphylaxis and metastatic
urothelial carcinoma: A case report.
J Oncol Pharm Pract. 2025;31:839-841.
Abstract
Primary Visceral Ewing Sarcoma (Gastric and Bladder) with KIT Expression: A
Report of Two Patients and a Differential Diagnostic Approach.
Int J Surg Pathol. 2025;33:1299-1316.
Abstract
Noninvasive identification of HER2 status by integrating multiparametric
MRI-based radiomics model with the vesical imaging-reporting and data system
(VI-RADS) score in bladder urothelial carcinoma.
Abdom Radiol (NY). 2025;50:3126-3136.
Abstract
A novel artificial intelligence segmentation model for early diagnosis of bladder
tumors.
Abdom Radiol (NY). 2025;50:3092-3099.
Abstract
Intravesical BCG therapy: implications for radiologists in abdominal imaging
follow-up.
Abdom Radiol (NY). 2025;50:3249-3261.
Abstract
Primary melanoma of the urinary tract: a clinicopathological study of cases and
literature review.
J Clin Pathol. 2025;78:443-448.
Abstract
mTORC1 Selective Nano-Inhibitor by Disrupting the Lysosomal Arginine-SLC38A9-
mTORC1-CDKs Axis for Precision Bladder Cancer Therapy.
Adv Mater. 2025 Jul 4:e2504798. doi: 10.1002/adma.202504798.
Abstract
A nomogram for predicting overall survival in patients with muscle-invasive
bladder cancer undergoing radical cystectomy: a retrospective cohort study.
Front Oncol. 2025;15:1597107.
Abstract
Comprehensive analysis of phagocytosis regulatory genes in bladder cancer:
implications for prognosis and immunotherapy.
Front Mol Biosci. 2025;12:1608519.
Abstract
AEBP1-GLI1 pathway attenuates the FACT complex dependency of bladder cancer cell
survival.
Biochem Biophys Rep. 2025;43:102101.
Abstract
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local
Adhesion and Drug Release to Bladder Cancers.
Adv Mater. 2025 Jul 4:e2505231. doi: 10.1002/adma.202505231.
Abstract
Transcription factor TCF3 promotes bladder cancer development via
TMBIM6-Ca(2+)-dependent ferroptosis.
Cell Death Discov. 2025;11:303.
Abstract
The Role of m(6)A-RNA Methylation in the Development, Progression, and Treatment
Response of Bladder Cancer.
Biochemistry (Mosc). 2025;90:650-670.
Abstract
Long-term impact of synchronous and metachronous bladder cancer on prognosis
after radical nephroureterectomy for upper urinary tract urothelial carcinoma:
results from a large population-based cohort in China.
Int J Surg. 2025 Jul 3. doi: 10.1097/JS9.0000000000002892.
Abstract
Combination of Neoadjuvant Gemcitabine-Cisplatin and Anti-Tuberculosis Therapy
for a Patient With Muscle-Invasive Bladder Cancer and Renal Granulomatosis That
Progressed After Intravesical Bacillus Calmette-Guerin Therapy.
IJU Case Rep. 2025;8:419-422.
Abstract
Bladder cancer subtypes exhibit limited plasticity across different
microenvironments and in metastases.
Exp Hematol Oncol. 2025;14:91.
Abstract
Nordihydroguaiaretic acid inhibits bladder cancer metastasis through suppression
of alpha1,3-mannosyltransferase expression and LRFN4 N-glycosylation.
J Transl Med. 2025;23:733.
Abstract
The impact of surgery and survival prediction in patients with bladder
neuroendocrine carcinoma: a novel propensity score-matched population-based
cohort study.
Eur J Med Res. 2025;30:564.
Abstract
DSG3 promotes bladder cancer growth and metastasis via AKT/GSK3beta/beta-catenin
pathway.
J Transl Med. 2025;23:729.
Abstract
Promise without practice - charting the path forward for bladder cancer
biomarkers.
Nat Rev Urol. 2025 Jul 2. doi: 10.1038/s41585-025-01064.
Abstract
mTOR pathway targeted inhibition via Rapamycin-loaded PLGA nanoparticles for
enhanced bladder cancer therapy.
Sci Rep. 2025;15:23138.
Abstract
FGFR inhibitors promote the autophagic degradation of IFN-gamma-induced PD-L1 and
alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in
non-muscle-invasive bladder cancer.
Cell Death Dis. 2025;16:485.
Abstract
Clinical relevance of the somatic mutational landscaping in predicting outcome of
bladder cancer patients.
Sci Rep. 2025;15:23292.
Abstract
The bibliometric analysis of documents concerning the relationship between the
microbiota and urological malignancies.
J Med Microbiol. 2025;74:002041.
Abstract
Toripalimab treatment of bladder-preserving therapy for locally advanced bladder
cancer: a case report.
Front Oncol. 2025;15:1581452.
Abstract
Long-term resident adipose-derived stromal stem cells in the microenvironment
remodeling BLCA cell stemness and EMT promotes bladder cancer progression.
Sci Rep. 2025;15:23049.
Abstract
Exposure to ileal feces with frailty-associated dysbiosis elevates
gastrointestinal complication risk after intracorporeal urinary diversion.
Sci Rep. 2025;15:22333.
Abstract
Disease burden of bladder cancer in China and the different SDI regions over the
world from 1990 to 2021.
Sci Rep. 2025;15:20811.
Abstract
Diagnostic accuracy of urinary PENK methylation test for urothelial and other
cancers: A prospective study.
Sci Rep. 2025;15:22149.
Abstract
Expression of ALDH1 isotypes and its potential as a prognostic and diagnostic
marker in patients with muscle invasive bladder cancer.
Sci Rep. 2025;15:22599.
Abstract
Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with
chemotherapeutic agents in cisplatin resistant bladder cancer cells.
Sci Rep. 2025;15:20922.
Abstract
Hypoxia-induced HIF-1alpha/VASN promotes bladder cancer progression.
Sci Rep. 2025;15:21635.
Abstract
Comparison of genetic mutations in bladder cancers that arose following
radiotherapy for prostate cancer with those in primary bladder cancers.
Sci Rep. 2025;15:20495.
Abstract
PKIB facilitates bladder cancer proliferation and metastasis through mediation of
HSP27 phosphorylation by PKA.
Cell Death Dis. 2025;16:470.
Abstract
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and
Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB
90601.
JCO Precis Oncol. 2025;9:e2400938.
Abstract
Diagnostic efficacy of [(18)F]FDG PET/CT and [(18)F]FDG PET/MRI in preoperative
staging of locoregional urinary bladder cancer: a systematic review and
Meta-Analysis.
Discov Oncol. 2025;16:1241.
Abstract
Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder
cancer.
Discov Oncol. 2025;16:1197.
Abstract
Machine Learning and Experimental Validation Reveal MYH11 as a Novel Prognostic
Biomarker and Therapeutic Target in Bladder Cancer.
J Inflamm Res. 2025;18:8357-8387.
Abstract
Corrigendum to "Protein profile in urinary extracellular vesicles is a marker of
malignancy and correlates with muscle invasiveness in urinary bladder cancer"
[Cancer Lett 609 (2025) 217352].
Cancer Lett. 2025 Jun 29:217876. doi: 10.1016/j.canlet.2025.217876.
Abstract
The effect of race/ethnicity on systemic chemotherapy in urothelial carcinoma
patients exposed to radiotherapy.
World J Urol. 2025;43:403.
Abstract
Multiparametric MRI for assessing residual tumors in patients with
muscle-invasive bladder cancer after neoadjuvant treatment: a reliable tool for
guiding bladder preservation.
Eur Radiol. 2025 Jun 30. doi: 10.1007/s00330-025-11773.
Abstract
NR4A3 suppresses bladder cancer progression by modulating autophagy via the
PI3K/AKT/mTOR pathway.
Eur J Histochem. 2025;69.
Abstract
Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving
horizon.
J Basic Clin Physiol Pharmacol. 2025 Jul 1. doi: 10.1515/jbcpp-2025-0106.
Abstract
A Comparative Study of Gemcitabine-Cisplatin vs. Dose-Dense MVAC (Methotrexate,
Vinblastine, Doxorubicin, and Cisplatin) as Neoadjuvant Chemotherapy for
Muscle-Invasive Bladder Cancer: A Single-Institution Experience.
Cureus. 2025;17:e85071.
Abstract
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder
cancer.
Bladder Cancer. 2025;11:23523735251348842.
Abstract
The associations between sleep-related factors and bladder cancer: A
cross-sectional study in the UK Biobank.
Cancer Epidemiol. 2025;97:102871.
Abstract
The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide
metabolites, protecting urothelial bladder cancer patients from recurrence.
Mol Biol Rep. 2025;52:649.
Abstract
Broadband Collision-Induced Dissociation Mass Spectrometry Imaging.
J Am Soc Mass Spectrom. 2025;36:1443-1455.
Abstract
Comprehensive characterization of the real-world perioperative morbidity of
radical cystectomy in older adults.
J Geriatr Oncol. 2025;16:102265.
Abstract
Evaluating Cost-Effective Strategies for Asymptomatic Microhematuria Diagnosis: A
Risk-Based Alternative to the American Urological Association Guidelines.
J Surg Oncol. 2025;131:1661-1669.
Abstract
Hypoxia-inducible factor 1alpha expression does not differ between canine urothelial
carcinoma and normal urinary bladder tissue.
Am J Vet Res. 2025;86:ajvr.
Abstract
Identification of risk factors for evisceration in open radical cystectomy.
Actas Urol Esp (Engl Ed). 2025;49:501759.
Abstract
Robot-Assisted Versus Open Radical Cystectomy: Comparison of Adverse In-Hospital
Outcomes.
J Surg Oncol. 2025;131:1651-1660.
Abstract
New Bladder Preservation Strategies in Urothelial Carcinoma of the Bladder.
Dtsch Arztebl Int. 2025;122:211-218.
Abstract
Long-term trends in bladder cancer incidence using a harmonized staging variable
- A SEER-based study.
Cancer Epidemiol Biomarkers Prev. 2025.
Abstract
SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy
Response in Urothelial Carcinoma.
Cells. 2025;14:949.
Abstract
An evidence gap map of the personalized medicine in bladder cancer.
Per Med. 2025 Jul 11:1-10. doi: 10.1080/17410541.2025.2530918.
Abstract
Senescence-associated signature based on immunotherapy response sequencing
reveals PPIL3 as target for bladder cancer treatment and prognosis prediction.
Front Immunol. 2025;16:1613056.
Abstract
The role of DNA methylation and demethylation in bladder cancer: a focus on
therapeutic strategies.
Front Oncol. 2025;15:1567242.
Abstract
Urogenital Function and Oncologic Outcomes after Nerve-Sparing Radical
Cystectomy: A Systematic Review and Meta-Analysis.
Arch Esp Urol. 2025;78:604-612.
Abstract
Construction of a column-line graphical model of poor outcome of neoadjuvant
regimens for muscle-invasive bladder cancer based on NLR, dNLR and SII
indicators.
World J Surg Oncol. 2025;23:274.
Abstract
MSH6 as a prognostic biomarker in bladder cancer and its correlation with
immunity.
Sci Rep. 2025;15:24837.
Abstract
Malevolent alliance of MYBL2(hi) cancer stem cell and SPP1+ macrophage confers
resistance to neoadjuvant immunotherapy in bladder cancer.
J Immunother Cancer. 2025;13:e011319.
Abstract
Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among
Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study.
Ann Surg Oncol. 2025 Jul 10. doi: 10.1245/s10434-025-17654.
Abstract
Development and Utilization of a Novel EHR-Based Care Pathway for Non-muscle
Invasive Bladder Cancer.
Urol Pract. 2025 Jul 10:101097UPJ0000000000000872.
Abstract
A population-based analysis of patterns of care in patients with high-risk
non-muscle-invasive bladder cancer from Alberta, Canada.
Can Urol Assoc J. 2025 Jul 8. doi: 10.5489/cuaj.9110.
Abstract
A case of rapidly progressive fatal pulmonary hypertension in a patient with
metastatic bladder cancer: reflections on the early recognition of pulmonary
tumour thrombotic microangiopathy.
J Geriatr Cardiol. 2025;22:596-599.
Abstract
Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.
Adv Pharm Bull. 2025;15:4-6.
Abstract
Changing landscape of first-line treatment for locally advanced or metastatic
urothelial carcinoma: the progression from platinum-based chemotherapy to
platinum-free therapy.
Front Immunol. 2025;16:1604395.
Abstract
Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of
emerging therapeutic targets.
iScience. 2025;28:112720.
Abstract
Analysis of Single-Cell RNA-Seq Data to Investigate Tumor Cell Heterogeneity in
Uroepithelial Bladder Cancer and Predict Immunotherapy Response.
Curr Cancer Drug Targets. 2025 Jul 8. doi: 10.2174/0115680096377593250626133719.
Abstract
Preoperative CRP is a predictive factor for prolonged hospital stay after radical
cystectomy for bladder cancer.
BMC Urol. 2025;25:162.
Abstract
Correspondence on "METTL3 promotes an immunosuppressive microenvironment in
bladder cancer via m6A-dependent CXCL5/CCL5 regulation" by Tong et al.
J Immunother Cancer. 2025;13:e012565.
Abstract
Long non-coding RNA MINCR silencing contributes to suppressed gemcitabine
resistance in bladder cancer by blocking the ZEB1/PHGDH axis through
microRNA-876-5p up-regulation.
J Mol Histol. 2025;56:220.
Abstract
Response to Comment on "Artificial Intelligence Can Facilitate Application of
Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios".
Clin Med Insights Oncol. 2025;19:11795549251350233.
Abstract
Comment on: "Artificial Intelligence Can Facilitate Application of Risk
Stratification Algorithms to Bladder Cancer Patient Case Scenarios".
Clin Med Insights Oncol. 2025;19:11795549251350242.
Abstract
Intrinsic higher potency of basal urothelial cells to intermediate and umbrella
cells as the cell of origin for bladder cancer.
bioRxiv [Preprint]. 2025 Jul 3:2025.06.28.662140. doi: 10.1101/2025.06.28.662140
Abstract
Taurine-mediated metabolic immune crosstalk indicates and promotes
immunosuppression with anti-PD-1 resistance in bladder cancer.
Front Immunol. 2025;16:1618439.
Abstract
Nanotherapeutic System with Effective Microwave Sensitization and Pyroptosis
Programming Enable Synergistic Microwave-Immunotherapy in Bladder Cancer.
Biomater Res. 2024;28:0077.
Abstract
CHMP6 as a novel prognostic biomarker in bladder cancer: insights from a
comprehensive cell death-related gene risk model.
Front Oncol. 2025;15:1564826.
Abstract
Enhanced photodynamic therapy with riboflavin@ dual minerals doped hydroxyapatite
nanoparticles: A promising in vitro approach for bladder cancer.
J Photochem Photobiol B. 2025;270:113207.
Abstract
Geographical Differences in the Management and Outcomes of Patients With Advanced
Urothelial Carcinoma Treated With Pembrolizumab After Progression on
Platinum-Based Chemotherapy: Results From ARON-2 Study.
JCO Glob Oncol. 2025;11:e2400564.
Abstract
KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas
of the urinary bladder.
Pathologica. 2025;117:296-305.
Abstract
Invasiveness or growth pattern in urothelial tumours. A perspective to rethink
the current WHO classification.
Pathologica. 2025;117:243-248.
Abstract
Epigenetic dysregulation-induced metabolic reprogramming fuels tumor progression
in bladder cancer.
Front Mol Biosci. 2025;12:1602700.
Abstract
BCG plus beta-glucan trains neutrophils to beat bladder cancer.
Nat Rev Immunol. 2025 Jul 7. doi: 10.1038/s41577-025-01209.
Abstract
From immunotherapy to autoimmunity: reactive arthritis following intravesical
BCG.
BMJ Case Rep. 2025;18:e267448.
Abstract
Comparison of perioperative outcomes between Bricker and Wallace anastomosis
techniques in robotic-assisted radical cystectomy with intracorporeal diversion.
World J Urol. 2025;43:415.
Abstract
Preoperative systemic inflammatory biomarkers can improve recurrence prediction
of non-muscle invasive bladder cancer after endoscopic resection - a prospective
observational study.
Contemp Oncol (Pozn). 2025;29:188-194.
Abstract
Galactosylated silver nanoparticles as a biocompatible intrinsic SERS probe for
bladder cancer imaging and ex vivo tumor detection.
J Mater Chem B. 2025 Jul 7. doi: 10.1039/d5tb00546.
Abstract
The role of Uro-Vaxom in reducing infectious adverse effects and improving
outcomes in bacillus Calmette-Guerin therapy for non-muscle-invasive bladder
cancer.
Investig Clin Urol. 2025;66:344-351.
Abstract
Totally intracorporeal ileal neobladder following robot-assisted radical
cystectomy in male patients using the Juntendo technique: Initial experience.
Investig Clin Urol. 2025;66:320-328.
Abstract
Impact of regular cystoscopy on prognosis in non-muscle-invasive bladder cancer:
A nationwide study.
Investig Clin Urol. 2025;66:302-310.
Abstract
Predictive value of tumor invasion patterns on intravesical bacillus
Calmette-Guerin response for stage T1 high-grade non-muscle-invasive bladder
cancer.
Investig Clin Urol. 2025;66:295-301.
Abstract
National trends in diagnoses of subtype histologies in bladder cancer: A
population-based study based on the SEER database.
Urol Oncol. 2025 Jul 4:S1078-1439(25)00239-X. doi: 10.1016/j.urolonc.2025.
Abstract
Causal Role of Phenylalanine and Cholesterol Metabolism in Bladder Cancer
Chemoresistance: Insights from Mendelian Randomization and Targeted Molecular
Docking.
Arch Biochem Biophys. 2025 Jul 3:110530. doi: 10.1016/j.abb.2025.110530.
Abstract
Extracorporeal vs. intracorporeal urinary diversion at robot-assisted radical
cystectomy: adverse in-hospital outcomes.
J Robot Surg. 2025;19:351.
Abstract
Extended field chemoradiation in M1a bladder carcinoma: A case report.
J Cancer Res Ther. 2025;21:725-729.
Abstract
Identification and single-cell analysis of prognostic genes related to
mitochondrial and neutrophil extracellular traps in bladder cancer.
Sci Rep. 2025;15:23982.
Abstract
Age-related differences in unmet needs and their predictors among adults with
bladder cancer.
Urol Oncol. 2025 Jul 3:S1078-1439(25)00241-8. doi: 10.1016/j.urolonc.2025.
Abstract
Health-related quality of life in patients treated for non-metastatic
muscle-invasive bladder cancer: radical cystectomy versus bladder preserving
therapy.
Int J Radiat Oncol Biol Phys. 2025 Jul 2:S0360-3016(25)04509.
Abstract
Central trained immunity in the context of bladder cancer immunotherapy.
Cancer Cell. 2025 Jun 27:S1535-6108(25)00260-0. doi: 10.1016/j.ccell.2025.
Abstract
LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered
Cancers.
J Med Chem. 2025;68:13858-13871.
Abstract
Nanoparticle-Protein Corona Boosted Cancer Diagnosis with Proteomic Transfer
Learning.
ACS Nano. 2025;19:23592-23605.
Abstract
Prospective Evaluation of the Effect of Vesical Imaging Reporting and Data System
Scoring on the Identification of Candidates for Repeated Transurethral Resection.
J Laparoendosc Adv Surg Tech A. 2025;35:557-563.
Abstract
Postoperative continuous saline bladder irrigation reduces active urinary cancer
cells: a prospective study in NMIBC.
Cell Oncol (Dordr). 2025;48:991-1003.
Abstract
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line
Metastatic Urothelial Cancer in the United States.
Value Health. 2025;28:1009-1017.
Abstract
Clinical significance of the dose modification of enfortumab vedotin monotherapy
for advanced urothelial carcinoma.
Jpn J Clin Oncol. 2025;55:791-796.
Abstract
Long-term outcome of transurethral laser ablation for recurrent non-muscle
invasive bladder cancer: An EORTC risk-matched study.
BJUI Compass. 2025;6:e70052.
Abstract
Case Report: A patient with metastatic bladder cancer in the stomach.
Front Oncol. 2025;15:1591475.
Abstract
The impact of METTL3 on bladder cancer through m(6)A modification: a potential
therapeutic target and prognostic biomarker.
Front Oncol. 2025;15:1622117.
Abstract
Correction: Intravesical instillation-based mTOR-STAT3 dual targeting for bladder
cancer treatment.
J Exp Clin Cancer Res. 2025;44:210.
Abstract
ERRATUM FOR CYSTECTOMY IN METASTATIC BLADDER CANCER: FEASIBILITY, SAFETY AND
OUTCOMES PUBLISHED IN EXP ONCOL 2024;46(4).
Exp Oncol. 2025;47:124.
Abstract
[Pirfenidone inhibits bladder cancer xenograft growth in mice by regulating
regulatory T cells].
Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:1513-1518.
Abstract
Beta-Lapachone: Effects on Proliferation, Survival, Migration, Cell Cycle, and
lncRNA Modulation in Bladder Cancer Cells With Distinct TP53 Profiles.
Drug Dev Res. 2025;86:e70128.
Abstract
Assessing the Impact of Treatment Timing Protocols in Clinical Trials for
Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 Jul 15:S2588-9311(25)00164.
Abstract
Reinforcing expectations after robot-assisted intracorporeal orthotopic
neobladder: long-term functional, urodynamic and metabolic outcome.
World J Urol. 2025;43:437.
Abstract
Perioperative durvalumab for muscle invasive bladder cancer: the start of a new
chapter.
Future Oncol. 2025 Jul 16:1-3. doi: 10.1080/14796694.2025.2531574.
Abstract
Piezo1/ITGB1 Synergizes With Ca(2+)/YAP Signaling to Propel Bladder Carcinoma
Progression via a Stiffness-Dependent Positive Feedback Loop.
Cancer Med. 2025;14:e71059.
Abstract
Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and
facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer.
J Exp Clin Cancer Res. 2025;44:207.
Abstract
ERalpha-dependent crosstalk between macrophages and cancer cells potentiates
vasculogenic mimicry and M2 macrophage polarization in bladder cancer.
Cell Commun Signal. 2025;23:339.
Abstract
Posterior conduit fixation with retroperitonealization of uretero-ileal
anastomosis after open radical cystectomy reduces the postoperative complication
rate: a retrospective, matched-paired single-center analysis.
BMC Urol. 2025;25:173.
Abstract
Developing angiogenesis-related prognostic biomarkers and therapeutic strategies
in bladder cancer using deep learning and machine learning.
Sci Rep. 2025;15:25534.
Abstract
Bioinformatics analysis of COMMD family in pan-cancer reveals potential
biomarkers and therapeutic targets.
Sci Rep. 2025;15:25490.
Abstract
MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial
carcinoma of the urinary bladder.
Sci Rep. 2025;15:25581.
Abstract
Radical Surgery Compared to Bladder-Preserving Approaches for Limited Stage
Small-Cell Bladder Cancer: Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2025 Jun 22:102389. doi: 10.1016/j.clgc.2025.102389.
Abstract
Exploring novel genomic biomarkers for response and survival after neoadjuvant
chemotherapy and radical cystectomy of muscle-invasive bladder cancer.
ESMO Open. 2025;10:105512.
Abstract
Myeloid cell differentiation-related gene signature predicts the prognosis and
immunotherapy response in bladder cancer.
Comput Methods Biomech Biomed Engin. 2025.
Abstract
Identification of DNA Replication Stress-Related Genes as Prognostic Biomarkers
for Bladder Cancer.
Comb Chem High Throughput Screen. 2025.
Abstract
Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk
Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial
Study.
MedComm (2020). 2025;6:e70288.
Abstract
CENPF overexpression in bladder cancer cells enhances proliferation, migration,
invasion, and apoptosis.
Sci Rep. 2025;15:25398.
Abstract
The role of SHMT2 and NDUFA4L2 gene expression and UCA1 levels in Egyptian
patients with bladder cancer.
J Immunoassay Immunochem. 2025 Jul 14:1-15. doi: 10.1080/15321819.2025.2533800.
Abstract
High FSTL1 expression promotes bladder cancer progression by enhancing tumor cell
migration.
Clin Transl Oncol. 2025 Jul 14. doi: 10.1007/s12094-025-03964.
Abstract
Role of 256 and 128 Slice Multidetector Computed Tomography Scan (MDCT) in the
Staging of Urinary Bladder Cancer with its Histopathological Correlation.
J Pharm Bioallied Sci. 2025;17.
Abstract
Protein Tyrosine Kinase 2 Circular RNA Promotes Proliferation and Invasion of
Bladder Cancer.
Cell Physiol Biochem. 2025;59:453-464.
Abstract
Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive
urothelial carcinoma.
Sci Rep. 2025;15:25247.
Abstract
Glucose-induced STUB1-GOT2 axis promotes aspartate synthesis and mitochondrial
dysfunction in bladder cancer.
Cell Death Dis. 2025;16:516.
Abstract
In Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy,
Dynamics of Circulating Tumor DNA Following Cystectomy: Association with Patient
Outcomes.
Eur Urol Focus. 2025 Jul 11:S2405-4569(25)00184.
Abstract
Disease burden and trends of bladder cancer in the world and BRICS from 1990 to
2021 and its projection until 2036: analysis based on the global burden of
disease study 2021.
Discov Oncol. 2025;16:1319.
Abstract
Integrative Analysis of GATA3 Expression and Variants as Prognostic Biomarkers in
Urothelial Cancer.
Int J Mol Sci. 2025;26:6378.
Abstract
Genotoxicity Induced by Carcinogenic Agents or Occupational Exposure with
Sufficient Evidence for Bladder Cancer.
J Clin Med. 2025;14:4492.
Abstract
Sex-Specific Associations of Glycemic Status and Smoking with Bladder Cancer
Risk: A Nationwide Cohort Study.
Cancers (Basel). 2025;17:2262.
Abstract
Expression Profiles of Co-Inhibitory Receptors in Non-Urothelial Bladder Cancer:
Preclinical Evidence for the Next Generation of Immune Checkpoint Inhibitors.
Cancers (Basel). 2025;17:2210.
Abstract
Prognostic Value of PLR, SIRI, PIV, SII, and NLR in Non-Muscle Invasive Bladder
Cancer: Can Inflammatory Factors Influence Pathogenesis and Outcomes?
Cancers (Basel). 2025;17:2189.
Abstract
Novel Strategies and Therapeutic Advances for Bladder Cancer.
Cancers (Basel). 2025;17:2070.
Abstract
Smoking promotes the progression of bladder cancer through FOXM1/CKAP2L axis.
J Transl Med. 2025;23:785.
Abstract
Enhancing the therapeutic efficacy of gemcitabine in bladder cancer through
TGF-beta1 inhibition and pluronic F-127-based microsphere delivery.
J Biol Eng. 2025;19:62.
Abstract
Re: Guru P. Sonpavde. Role of Adjuvant Therapy in Current Perioperative
Immunotherapy-based Trials in Bladder Cancer: A Justified Standard. Eur Urol
Focus. In press. https://doi.org/10.1016/j.euf.2025.05.008.
Eur Urol Focus. 2025 Jul 10:S2405-4569(25)00188.
Abstract
Cistanoside F acts as a Monoacylglycerol Lipase inhibitor that synergizes the
anti-tumor effect of 2-Arachidonoyl Glycerol on Bladder cancer.
Phytomedicine. 2025;145:157046.
Abstract
A mono-substituted aluminum phthalocyanine photosensitizer with high
phototoxicity index for effective bladder cancer treatment.
Bioorg Chem. 2025;163:108730.
Abstract
Arsenic enhances endoplasmic reticulum stress via YTHDC1/AKR1C3 aix to promote
the malignant transformation of human urothelial cells.
Toxicol Lett. 2025;410:199-210.
Abstract
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered
Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed
Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in
the THOR Phase 3
Clin Genitourin Cancer. 2025;23:102376.
Abstract
Impact of Muscle Depletion on Prognosis in Patients Undergoing Radical
Cystectomy.
Clin Genitourin Cancer. 2025;23:102373.
Abstract
Risk assessment for the bladder carcinogenesis of 4-aminobiphenyl in smokers: A
source-to-outcome study.
Toxicol Lett. 2025;410:23-31.
Abstract
Phenotypic Diversity of Immunosuppressive B Cells Associated in Urothelial
Carcinoma of the Bladder.
Clin Genitourin Cancer. 2025;23:102351.
Abstract
A Novel Scoring System to Assess Continence Quality Outcomes of Orthotopic Ileal
Neobladders After Open and Robot-Assisted Radical Cystectomy: The Urodynamic
Trifecta.
Neurourol Urodyn. 2025;44:1255-1263.
Abstract
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced
Urothelial Carcinoma and Histology Subtypes.
Clin Genitourin Cancer. 2025;23:102356.
Abstract
An All-in-One Nanohole Array for Size-Exclusive Trapping and High-Throughput
Digital Counting of Single Extracellular Vesicles for Non-Invasive Cancer
Screening.
Angew Chem Int Ed Engl. 2025;64:e202506744.
Abstract
Assessment of the Impact of Grade Heterogeneity on Survival in Ta and T1 Tumors:
A Subgroup Analysis of NMIBC Cohort.
Clin Genitourin Cancer. 2025;23:102357.
Abstract
Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy
for Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2025;23:102354.
Abstract
Chromatin accessibility states affect transrenal clearance of plasma DNA:
Implications for urine-based diagnostics.
Med. 2025;6:100646.
Abstract
Prophylactic heparin does not increase clinically significant bleeding following
transurethral resection of a bladder tumor.
Urol Oncol. 2025;43:469.
Abstract
The association between perioperative activity levels and discharge outcomes
after radical cystectomy.
Urol Oncol. 2025;43:468.
Abstract
Clinical advances and practice updates in genitourinary cancers: a 2024 review
from the multidisciplinary Spanish 'Cambados annual meeting'.
Clin Transl Oncol. 2025;27:3307-3324.
Abstract
Concomitant Interstitial Pneumonia and Disseminated BCG Infection after
Intravesical BCG Therapy.
Intern Med. 2025;64:2218-2222.
Abstract
Post-radiation simple cystectomy for end-stage bladder in cancer survivors is not
associated with occult malignancy.
World J Urol. 2025;43:455.
Abstract
Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary
Bladder: A Propensity Score-Matched Analysis.
Curr Oncol. 2025;32:394.
Abstract
What Is the Optimal Perioperative Treatment for Variant Subtypes of Bladder
Cancer?
Eur Urol Focus. 2025 Jul 23:S2405-4569(25)00206.
Abstract
Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what's new in
2025?
Expert Rev Anticancer Ther. 2025 Jul 24. doi: 10.1080/14737140.2025.2535657.
Abstract
Neolactotetraosylceramide enables urinary detection of bladder cancer.
Cell Rep Med. 2025 Jul 18:102246. doi: 10.1016/j.xcrm.2025.102246.
Abstract
2025 ASCO Bladder Cancer Highlights.
Oncol Res Treat. 2025 Jul 24:1-6. doi: 10.1159/000547631.
Abstract
Bimetallic nanozyme-mediated dual ferroptosis/cuproptosis synergy potentiates
immunotherapy in bladder cancer.
Colloids Surf B Biointerfaces. 2025;255:114954.
Abstract
Immunohistochemistry scoring for human epidermal growth factor receptor 2 can be
used to predict pathological response to cisplatin-based neoadjuvant chemotherapy
in a subset of immunohistochemically subtyped muscle-invasive bladder cancer.
Virchows Arch. 2025 Jul 24. doi: 10.1007/s00428-025-04196.
Abstract
Identification of lactylation-associated immune and metabolic regulators in
bladder cancer via integrated bulk and single-cell transcriptomics.
Front Immunol. 2025;16:1604758.
Abstract
Testing Protein Stress Signals in Peripheral Immunocytes Under the Same Treatment
Capable of Decreasing the Incidence of Alzheimer's Disease in Bladder Cancer
Patients.
Curr Issues Mol Biol. 2025;47:392.
Abstract
TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in
Bladder Cancer Cells.
Curr Issues Mol Biol. 2025;47:369.
Abstract
Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects.
Curr Issues Mol Biol. 2025;47:278.
Abstract
Liquid Biopsy: Current advancements in clinical practice for bladder cancer.
J Liq Biopsy. 2025;9:100310.
Abstract
Comparison of Intravesical Bacillus Calmette-Guerin (BCG) and Mitomycin C for the
Treatment of Non-Muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e86524.
Abstract
Advancements in bladder cancer immunotherapy: a focus on intravesical approaches.
Front Pharmacol. 2025;16:1578146.
Abstract
Epigenetic Regulation and Targeted Therapy in Gall Bladder Cancer.
J Biochem Mol Toxicol. 2025;39:e70403.
Abstract
Immune Landscape and Prognostic Significance of Gene Expression Profiles in
Bladder Cancer: Insights from Immune Cell Infiltration and Risk Modeling.
Iran J Allergy Asthma Immunol. 2025;24:519-532.
Abstract
CuOTeDsP nanotherapeutics enhance cuproptosis-mediated immunotherapy by
modulating cholesterol metabolism in bladder cancer.
J Nanobiotechnology. 2025;23:534.
Abstract
Exploring bladder cancer through urinary microbiota: innovative "urinetypes"
classification and establishment of a diagnostic model.
J Transl Med. 2025;23:809.
Abstract
Development and preliminary verification of the scale of care needs of family
caregivers of patients with bladder cancer undergoing urostomy.
Sci Rep. 2025;15:26588.
Abstract
Computational Morphological Assessment of Bladder Cancer Tissue Is Prognostic of
Recurrence and Overall Survival Following Transurethral Resection.
JCO Clin Cancer Inform. 2025;9:e2400304.
Abstract
Integrative Analysis Reveals the Prognostic Effects of Epigenetic Regulators in
Bladder Cancer.
Cancer Med. 2025;14:e71057.
Abstract
A urine detection chip for the analysis of urinary cells and extracellular
vesicles for bladder cancer screening.
Lab Chip. 2025 Jul 22. doi: 10.1039/d5lc00511.
Abstract
The role of exosomes in bladder cancer immunotherapy.
J Natl Cancer Cent. 2025;5:252-266.
Abstract
Extracellular volume fraction quantification by equilibrium contrast-enhanced CT
via automated segmentation predicts survival outcomes in bladder cancer: a
propensity score-matched study.
Ann Med. 2025;57:2534856.
Abstract
Intracorporeal versus extracorporeal urinary diversion during robotic radical
cystectomy: outcomes from a large single-institutional study.
BMC Urol. 2025;25:179.
Abstract
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle
invasive bladder cancer: the randomized phase 3 CREST trial.
Nat Med. 2025 Jul 21. doi: 10.1038/s41591-025-03894.
Abstract
Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for
residual extravesical disease in muscle-invasive bladder cancer: insights from a
nationwide cohort.
Int J Clin Oncol. 2025 Jul 21. doi: 10.1007/s10147-025-02833.
Abstract
The 6-methyladenine erasers ALKBH5 and FTO influence chemotherapy efficiency in
bladder cancer cell lines.
Ann Transl Med. 2025;13:26.
Abstract
[(89)Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder
cancer.
Am J Nucl Med Mol Imaging. 2025;15:87-96.
Abstract
Comprehensive Pan-Cancer Analysis Identifies IGFL1 as an Oncogenic Biomarker and
Immunotherapeutic Target with Experimental Validation in Bladder Cancer.
Int J Gen Med. 2025;18:3881-3900.
Abstract
Utilization of Neoaduvant Chemotherapy and Oncological Outcomes in Patients
Undergoing Radical Cystectomy for Variant Histology Versus Pure Urothelial
Bladder Cancer - A Retrospective Comparative Cohort Study.
Indian J Surg Oncol. 2025;16:753-761.
Abstract
Immune-related genes can accurately predict survival in bladder cancer: a
retrospective study via two independent immunotherapy cohorts.
Transl Androl Urol. 2025;14:1661-1678.
Abstract
Leveraging hypoxia-related genes signature for predicting the prognosis of
bladder cancer.
Transl Androl Urol. 2025;14:1701-1722.
Abstract
Integrated single-cell genomics, transcriptomics, and pathomics to identify
potential biomarkers in muscle-invasive bladder cancer.
Transl Androl Urol. 2025;14:1610-1630.
Abstract
Does neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder
cancer obliterate survival differences between genders?
Transl Androl Urol. 2025;14:1589-1600.
Abstract
Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder
cancer in preclinical and translational models.
Mol Ther Oncol. 2025;33:201016.
Abstract
Erratum: MT-12 inhibits the growth and metastasis of bladder cancer cells via
suppressing tumor angiogenesis in vivo and in vitro.
Transl Cancer Res. 2025;14:3874-3876.
Abstract
Single-surgeon outcomes of open radical cystectomy for muscle-invasive bladder
cancer: Experience from a tertiary center in Azerbaijan.
Surg Pract Sci. 2025;22:100296.
Abstract
Non-muscle invasive bladder cancer in a pregnant patient.
Urol Case Rep. 2025;62:103119.
Abstract
Ro 31-8220 suppresses bladder cancer progression via enhancing autophagy in vitro
and in vivo.
FEBS Open Bio. 2025 Jul 21. doi: 10.1002/2211-5463.70089.
Abstract
Targeting BACH1/PSPH axis suppresses bladder cancer progression and gemcitabine
resistance by downregulating S100A2 expression.
Biochem Pharmacol. 2025;241:117182.
Abstract
The effect of HOTAIR gene variants on the development of bladder cancer and its
clinicopathological characteristics in a Caucasian population.
Cancer Genet. 2025;296-297:145-149.
Abstract
Identification of FADS2 as a Contributor of Ferroptosis Escape in Bladder Cancer.
J Cell Mol Med. 2025;29:e70710.
Abstract
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced
urothelial carcinoma.
Sci Rep. 2025;15:26127.
Abstract
Risk factors and therapeutic significance of HER2 overexpression in urothelial
carcinoma.
Pathol Res Pract. 2025;272:156079.
Abstract
Multimodal Diffusion MRI Synergized with VI-RADS for Precision Grading of Bladder
Urothelial Carcinoma: A Prospective Diagnostic Model Validation.
Acad Radiol. 2025;32:4631-4641.
Abstract
Calcified and Impacted Cervical Fibroid in a Young Female in a Low-resource
Setting Mistaken for Bladder Mass: Case Report and Literature Review.
Ann Afr Med. 2025;24:699-703.
Abstract
Improving the quality of transurethral resection of bladder tumour (TURBT)
operative notes following the European Association of Urology guidelines.
Ir J Med Sci. 2025;194:847-851.
Abstract
[Muscle-invasive and metastatic urothelial carcinoma from a pathological point of
view].
Aktuelle Urol. 2025;56:344-348.
Abstract
Diagnostic Values of Electrochemiluminescent Detection of Urinary CYFRA21-1 and
FDP and Their Combined Detection in Bladder Cancer.
Cancer Med. 2025;14:e71056.
Abstract
Tolerability and efficacy of induction Bacillus Calmette-Guerin for non-muscle
invasive bladder cancer.
Bladder (San Franc). 2025;12:e21200031.
Abstract
Advances in recombinant Bacillus Calmette-Guerin therapy for bladder cancer from
2015 to 2024: Innovations and challenges.
Bladder (San Franc). 2025;12:e21200047.
Abstract
SPEF1 and SPEF2 as potential biomarkers in bladder cancer: Insights from a
comprehensive bioinformatic analysis.
Bladder (San Franc). 2025;12:e21200039.
Abstract
Potential synergistic effect of radiotherapy and immune checkpoint inhibitors on
advanced bladder cancer: A case report.
Bladder (San Franc). 2025;12:e21200045.
Abstract
Kidney function improvement after urinary diversion for cisplatin eligibility in
bladder cancer patients.
Bladder (San Franc). 2025;12:e21200027.
Abstract
Assessment of lower urinary tract symptoms and their impact on quality of life
following radiation therapy for bladder cancer.
Bladder (San Franc). 2025;12:e21200033.
Abstract
The role and clinical potential of RNA modifications in bladder cancer.
Bladder (San Franc). 2025;12:e21200037.
Abstract
Trends in surgical procedures for bladder cancer within the Brazilian public
health system: An 11-year analysis.
Bladder (San Franc). 2025;12:e21200030.
Abstract
Advancements in genetic circuits as part of intelligent biotherapy for the
treatment of bladder cancer: A review.
Bladder (San Franc). 2025;12:e21200032.
Abstract
Association of Thrombomodulin Expression with Bladder Cancer Grade, Stage, and
Recurrence: A Single-Center Prospective Pilot Study.
Iran J Pathol. 2025;20:266-272.
Abstract
Graph theoretic and machine learning approaches in molecular property prediction
of bladder cancer therapeutics.
Sci Rep. 2025;15:28025.
Abstract
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With
UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm,
Phase 2b Optima II Study.
Clin Genitourin Cancer. 2025 Jun 25:102392. doi: 10.1016/j.clgc.2025.102392.
Abstract
Hypofractionated radiotherapy in the management of bladder cancer.
Cancer Radiother. 2025;29.
Abstract
MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the
TGF-beta-H3K4me3 Epigenetic Axis.
Mol Carcinog. 2025 Jul 31. doi: 10.1002/mc.70001.
Abstract
HOXC6-TIMELESS axis: Unveiling novel therapeutic strategies in bladder cancer.
World J Clin Oncol. 2025;16:108071.
Abstract
Comprehensive Mendelian randomization and colocalization analysis of plasma
proteomics to identify new therapeutic targets for bladder cancer.
J Cancer. 2025;16:3163-3179.
Abstract
Prediction of response to neoadjuvant chemotherapy in patients with
muscle-invasive urothelial bladder cancer: role of immune-related gene
expression.
Cancer Immunol Immunother. 2025;74:279.
Abstract
Circadian Rhythm Genes-based Prognostic Signature for Bladder Cancer: Association
of EZH2 Expression with Anesthetic-related Changes in Circulating Tumor Cells.
Curr Med Chem. 2025 Jul 28. doi: 10.2174/0109298673362736250702043230.
Abstract
Lactylation prognostic signature identifies DHCR7 as a modulator of
chemoresistance and immunotherapy efficacy in bladder cancer.
Front Immunol. 2025;16:1585727.
Abstract
Histological and immunohistochemical approaches to molecular subtyping in
muscle-invasive bladder cancer.
Front Oncol. 2025;15:1546160.
Abstract
Survival Outcomes in Bladder Cancer: An Ambispective Study of Patients Undergoing
Radical Cystectomy.
Cureus. 2025;17:e86938.
Abstract
Predictive model of double-J pipe scab size after radical total cystectomy based
on Boruta feature selection and LASSO technique: A retrospective cross-sectional
study.
Sci Prog. 2025;108:368504251363901.
Abstract
Sarcopenia in Urothelial Bladder Carcinoma: A Narrative Review.
Medicina (Kaunas). 2025;61:1307.
Abstract
Adductor Muscle Contraction Under Deep Neuromuscular Blockade During TURBT Under
General Anesthesia: Is Obturator Nerve Block Still Necessary?-A Prospective,
Single-Arm, Exploratory Study.
Medicina (Kaunas). 2025;61:1207.
Abstract
Intravesical mitomycin (Zusduri) for bladder cancer.
Med Lett Drugs Ther. 2025;67:e128-e129.
Abstract
Bladder cancer.
JAAPA. 2025;38:45-46.
Abstract
Decreased Expression Levels Of PIWIL2, PIWIL3 and PIWIL4 Are Associated with Poor
Prognosis and Worse Survival in Bladder Cancer Patients.
Asian Pac J Cancer Prev. 2025;26:2467-2477.
Abstract
Extracellular vesicles-derived extracellular RNA in bladder cancer: current
progress and future prospects.
Ther Adv Med Oncol. 2025;17:17588359251349288.
Abstract
As a New Tumor Suppressor Gene, PID1 Activates the AMPK-mTOR Signal to Inhibit
the Progression of Bladder Cancer.
Res Rep Urol. 2025;17:235-248.
Abstract
Prolonged Release of Bacillus Calmette-Guerin by Floating Microbubbles to Enhance
Intravesical Immunotherapy for Bladder Cancer.
ACS Nano. 2025 Jul 28. doi: 10.1021/acsnano.5c06540.
Abstract
Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer
Patients Treated with Radical Cystectomy.
J Clin Med. 2025;14:5120.
Abstract
Robot-Assisted Radical Cystectomy with Ureterocutaneostomy: A Potentially Optimal
Solution for Octogenarian and Frail Patients with Bladder Cancer.
J Clin Med. 2025;14:4898.
Abstract
Detection of High-Risk Human Papillomavirus in Bladder Cancer: An Exploratory
Study from a UK-Based Population.
Biomedicines. 2025;13:1548.
Abstract
Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay
Using Three Different Luminex xMAP Instruments.
Diagnostics (Basel). 2025;15:1749.
Abstract
Introduction of an Integrated Pathology Image Management, Artificial
Intelligence, and Reporting System.
J Vis Exp. 2025;.
Abstract
Knockdown of CSF1R molecules enhances the antitumor effects of CD8(+) T
lymphocytes in bladder cancer.
Discov Oncol. 2025;16:1426.
Abstract
Understanding oncological and sexual function outcomes with gynaecological organ
preserving cystectomy in women with bladder cancer; a systematic review.
BJUI Compass. 2025;6:e70053.
Abstract
Successful complex endovascular treatment of a contained rupture of a
thoracoabdominal aortic aneurysm caused by Mycobacterium bovis after intravesical
Bacillus Calmette-Guerin immunotherapy for bladder cancer.
J Vasc Surg Cases Innov Tech. 2025;11:101895.
Abstract
A Case of Malignant Priapism Secondary to Muscle Invasive Bladder Cancer and
Review of Palliative Management.
Case Rep Urol. 2025;2025:2340917.
Abstract
Long-term effect of treatment for non-muscle invasive bladder cancer on Quality
of life: a cross-sectional study.
Scand J Urol. 2025;60:141-147.
Abstract
Association between physical function before radical cystectomy for urinary
bladder cancer and recovery after discharge from hospital.
Scand J Urol. 2025;60:135-140.
Abstract
Bladder cancer prevalence and diagnostic test accuracy: French results from the
IDENTIFY study.
Fr J Urol. 2025 Jul 24:102935. doi: 10.1016/j.fjurol.2025.102935.
Abstract
Letter to editor: SRSF1-mediated alternative splicing regulates bladder cancer
progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.
J Transl Med. 2025;23:839.
Abstract
Emerging biomarkers in bladder cancer: Translating molecular advances into
precision oncology.
Crit Rev Oncol Hematol. 2025;215:104862.
Abstract
Primary Extranodal Natural Killer/T-cell Lymphoma of the Bladder on 18F-FDG
PET/CT.
Clin Nucl Med. 2025 May 13. doi: 10.1097/RLU.0000000000005956.
Abstract
Metastasis of Urothelial Carcinoma to the Wrist: A Case Report of an Overlooked
Finding on Whole-body 99m Tc-MDP Scan.
Clin Nucl Med. 2025;50:e561-e563.
Abstract
Ultrasound-guided obturator nerve block technique at the distal end of the
obturator canal: case series and cadaver evaluation.
J Anesth. 2025;39:652-656.
Abstract
Risk Score Model of Aging-Related Genes for Bladder Cancer and Its Application in
Clinical Prognosis.
JCO Clin Cancer Inform. 2025;9:e2500019.
Abstract
Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with
response to atezolizumab in a Real-World-Evidence biomarker study for advanced
urothelial carcinoma patients.
Oncoimmunology. 2025;14:2538687.
Abstract
Contemporary rates and predictors of prolonged hospital stay after radical
cystectomy: a population-based analysis.
World J Urol. 2025;43:478.
Abstract
Unraveling the dual role of METTL3-mediated m(6)A RNA modification in bladder
cancer: mechanisms, therapeutic vulnerabilities, and clinical implications.
Cancer Biol Ther. 2025;26:2545057.
Abstract
Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer
risk? A meta-analysis.
Afr Health Sci. 2024;24:118-127.
Abstract
Long live the kidney despite every threats: a case report.
Pan Afr Med J. 2025;51:35.
Abstract
Temozolomide Resistance in Smoking-Related Bladder Cancer through
TNFAIP6-Mediated Post-Translational Modifications.
Arch Esp Urol. 2025;78:732-742.
Abstract
Value of Preoperative Inflammatory Burden Index in Predicting Overall Survival
and Progression in Nonmetastatic Muscle-Invasive Bladder Cancer.
Arch Esp Urol. 2025;78:660-670.
Abstract
The TCF7L2/miR-206/Cofilin1 axis promotes the metastasis of bladder cancer cells
by regulating the formation of invadopodia.
Acta Biochim Biophys Sin (Shanghai). 2025 Aug 6. doi: 10.3724/abbs.2025114.
Abstract
Efficient Training Corpus Retrieval for Large Language Model Fine Tuning: A Case
Study in Cancer.
Stud Health Technol Inform. 2025;329:1251-1255.
Abstract
[(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in
Triple-Negative Breast and Urothelial Bladder Cancers.
J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132.
Abstract
Disitamab vedotin combined with toripalimab and radiotherapy for multimodal
organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept
study.
Neoplasia. 2025;68:101216.
Abstract
Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper
Tract and Bladder Urothelial Carcinoma.
JCO Precis Oncol. 2025;9:e2500289.
Abstract
Comment on "Long-term impact of synchronous and metachronous bladder cancer on
prognosis after radical nephroureterectomy for upper urinary tract urothelial
carcinoma: results from a large population-based cohort in China.
Int J Surg. 2025 Aug 7. doi: 10.1097/JS9.0000000000003146.
Abstract
Genetic influence of coffee intake on bladder cancer risk: a two-sample Mendelian
randomization analysis.
Food Funct. 2025 Aug 7. doi: 10.1039/d4fo05538.
Abstract
Retraction Note: LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer
via restoration of RARB as a sponge of microRNA-146.
Cancer Cell Int. 2025;25:298.
Abstract
Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes
for enhancing the PDT of bladder cancer.
J Nanobiotechnology. 2025;23:554.
Abstract
Letter to editor: SIGMAR1 screened by a GPCR-related classifier regulates
endoplasmic reticulum stress in bladder cancer.
J Transl Med. 2025;23:874.
Abstract
Collagen gene signature in the tumor microenvironment predicts survival and
guides prognosis in bladder cancer.
Discov Oncol. 2025;16:1479.
Abstract
Novel glycoprotein SBSPON suppressed bladder cancer through the AKT signal
pathway by inhibiting HSPA5 membrane translocation.
Int J Biol Sci. 2025;21:4586-4603.
Abstract
Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With
Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.
Cancer Rep (Hoboken). 2025;8:e70308.
Abstract
Risk of secondary bladder cancer after postoperative radiotherapy for rectal
cancer: A population-based cohort study.
Radiography (Lond). 2025 Aug 4:103112. doi: 10.1016/j.radi.2025.103112.
Abstract
LC3 and beclin-1 immunohistochemical and gene expressions in bladder cancer.
Clin Transl Oncol. 2025 Aug 5. doi: 10.1007/s12094-025-04002.
Abstract
NR4A3 regulates anoikis resistance and metastasis of bladder cancer through
EWSR1.
Cancer Biol Ther. 2025;26:2535774.
Abstract
Bladder cancer microbiome and its association with chemoresponse.
Front Oncol. 2025;15:1506319.
Abstract
[A Case of Paraneoplastic Neurological Syndrome Caused by Bladder Cancer
Manifesting as Limbic Encephalitis].
Hinyokika Kiyo. 2025;71:239-243.
Abstract
Chemotherapeutic dihydromyricetin with remarkable anti-tumor activity and
biosafety for muscle invasive bladder cancer.
Front Pharmacol. 2025;16:1609354.
Abstract
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for
muscle invasive bladder cancer in the United States.
Ther Adv Med Oncol. 2025;17:17588359251357519.
Abstract
Exploring of bladder cancer immune-related genes and potential therapeutic
targets based on transcriptomic data and Mendelian randomization analysis.
Front Immunol. 2025;16:1607098.
Abstract
Correction to "Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and
Increases Cisplatin Sensitivity in Bladder Cancer".
Adv Sci (Weinh). 2025 Aug 4:e13864. doi: 10.1002/advs.202513864.
Abstract
[Risk assessment of perioperative adverse events and management of antiplatelet
therapy in patients with bladder cancer and coronary atherosclerotic heart
disease undergoing transurethral resection of bladder cancer].
Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57:698-703.
Abstract
Repeat TURBT for Ta and T1 bladder cancer: An updated review.
Urol Oncol. 2025 Aug 2:S1078-1439(25)00257-1. doi: 10.1016/j.urolonc.2025.
Abstract
Exploring the Impact of 5-Alpha Reductase Inhibitors on Bladder Cancer: Insights
from a Large-Scale Prospective Cohort Study.
Ann Surg Oncol. 2025 Aug 3. doi: 10.1245/s10434-025-17981.
Abstract
Re: Mariana Silva-Ferreira, Joao A. Carvalho, Sofia Salta, et al. Diagnostic Test
Accuracy of Urinary DNA Methylation-based Biomarkers for Bladder Cancer:
Considerations for Further Research. Eur Urol Focus 2024;10:922-34.
Eur Urol Focus. 2025 Aug 2:S2405-4569(25)00241-X. doi: 10.1016/j.euf.2025.
Abstract
The molecular mechanism of ambrosin induced cytotoxicity of human breast cancer
and bladder cancer cells.
J Biol Chem. 2025 Aug 1:110531. doi: 10.1016/j.jbc.2025.110531.
Abstract
Shaping the Future of Personalized Therapy in Bladder Cancer Using Artificial
Intelligence.
Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00216-0. doi: 10.1016/j.euf.2025.
Abstract
Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic
Review.
Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00178-6. doi: 10.1016/j.euf.2025.
Abstract
The Evolving Landscape of Systemic Immunotherapy for Bacillus
Calmette-Guerin-naive High-risk Non-muscle-invasive Bladder Cancer: At the Edge
of a Tsunami?
Eur Urol Oncol. 2025 Aug 1:S2588-9311(25)00174-9. doi: 10.1016/j.euo.2025.
Abstract
Evaluating postoperative complications in radical cystectomy and ileal conduit
for bladder cancer using the clavien-dindo grading system.
J Pak Med Assoc. 2025;75:1053-1057.
Abstract
Safety of Robot-Assisted Radical Cystectomy for Muscle-Invasive Bladder Cancer: A
Real-World Analysis Using the National Clinical Database in Japan.
Cancer Med. 2025;14:e71109.
Abstract
An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer.
Urol Oncol. 2025 Jul 31:S1078-1439(25)00252.
Abstract
Assessing oncological outcomes of bladder-sparing treatments in patients with
BCG-unresponsive and BCG-exposed non-muscle-invasive bladder cancer.
Urol Oncol. 2025 Jul 31:S1078-1439(25)00253.
Abstract
Description of a cruciferous vegetable intervention trial to test the efficacy of
a maintenance component to reduce bladder cancer recurrence and progression.
Contemp Clin Trials. 2025;156:108036.
Abstract
Proteogenomic characterization unveils biomarkers associated with chemoresistance
in muscle-invasive bladder cancer.
Cell Rep Med. 2025 Jul 29:102255. doi: 10.1016/j.xcrm.2025.102255.
Abstract
Clinical utility of photodynamic diagnosis with 5-aminolevulinic acid
hydrochloride for detecting carcinoma in situ independent of urine cytology
classification.
Photodiagnosis Photodyn Ther. 2025;54:104722.
Abstract
The novel ferroptosis-inducing molecule can inhibit the progression of BC by
regulating the ubiquitination of UHRF1.
Epigenomics. 2025;17:777-791.
Abstract
Intravesical interferon-alpha2b gene therapy with nadofaragene firadenovec-vncg: a
contemporary review.
Future Oncol. 2025;21:2429-2438.
Abstract
Urinary bladder lesions of bovine enzootic hematuria in Argentina.
Res Vet Sci. 2025;193:105797.
Abstract
Risk factors of severe prolonged hypotension induced by 5-aminolevulinic acid
during photodynamic diagnosis-assisted transurethral resection of bladder tumor.
Photodiagnosis Photodyn Ther. 2025;54:104667.
Abstract
The Spectrum of Polyoma Virus and Polyoma Virus-Like Changes in Urine Cytology:
When Should an Atypical Diagnosis Be Considered.
Diagn Cytopathol. 2025;53:447-453.
Abstract
A case of irAE myositis with positive antistriational antibodies after anti-PD-L1
antibody administration: A case report.
Mod Rheumatol Case Rep. 2025;9:rxaf025.
Abstract
The role of the urinary microbiome in genitourinary cancers.
Nat Rev Urol. 2025;22:544-561.
Abstract
Antimony Exposure Induces Bladder Cancer Metastasis Via Activation of the
SUMOylation-Dependent TGF-beta/Smad2/3 Axis.
Environ Res. 2025 Aug 12:122589. doi: 10.1016/j.envres.2025.122589.
Abstract
Corrigendum to 'Development of a Technique for Diagnosis and Screening of
Superficial Bladder Cancer by Cell-Pellet DNA From Urine Sample' [Laboratory
Investigation 105 (2025) 104124].
Lab Invest. 2025;105:104225.
Abstract
Pedunculoside regulates tumor immune microenvironment and malignant
characteristics of bladder cancer by TRAF6 mediated M2 macrophage polarization.
Int Immunopharmacol. 2025;164:115301.
Abstract
Hypoxia-induced PYCR1 regulates glycolysis and histone lactylation to promote
bladder cancer progression and metastasis via SLC6A14/Glutamine metabolism.
Cancer Biol Ther. 2025;26:2546219.
Abstract
Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer.
Int J Mol Sci. 2025;26:7546.
Abstract
DNA Methylation in Bladder Cancer: Diagnostic and Therapeutic Perspectives-A
Narrative Review.
Int J Mol Sci. 2025;26:7507.
Abstract
Variations in Circulating Tumor Microenvironment-Associated Proteins in
Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment.
Int J Mol Sci. 2025;26:7413.
Abstract
Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and
Potential Therapeutic Implications.
Int J Mol Sci. 2025;26:7340.
Abstract
Growth Hormone Signaling in Bladder Cancer: Transcriptomic Profiling of Patient
Samples and In Vitro Evidence of Therapy Resistance via ABC Transporters and EMT
Activation.
Int J Mol Sci. 2025;26:7113.
Abstract
Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2025;17:2562.
Abstract
Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype
Bladder Cancer.
Cancers (Basel). 2025;17:2536.
Abstract
Evaluating Therapeutic Efficacy of Intravesical Xenogeneic Urothelial Cell
Treatment Alone and in Combination with Chemotherapy or Immune Checkpoint
Inhibition in a Mouse Non-Muscle-Invasive Bladder Cancer Model.
Cancers (Basel). 2025;17:2448.
Abstract
How Accurately Can Urologists Predict Eligible Patients for Immediate
Postoperative Intravesical Chemotherapy in Bladder Cancer?
Diagnostics (Basel). 2025;15:1856.
Abstract
Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation
and migration of bladder cancer cells mediated by CENPA.
Sci Rep. 2025;15:29679.
Abstract
Transient receptor potential vanilloid type 4 channels mediate bladder cancer
cell proliferation, migration, and chemoresistance.
J Pharmacol Exp Ther. 2025;392:103665.
Abstract
A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for
Cancer Immunology Research.
Cancer Med. 2025;14:e71150.
Abstract
Unveiling SNX10: a key player in bladder cancer progression.
Transl Androl Urol. 2025;14:1912-1924.
Abstract
Purine Nucleoside Phosphorylase (PNP) as a Biomarker and Therapeutic Target in
Muscle-Invasive Bladder Cancer.
Clin Med Insights Oncol. 2025;19:11795549251359145.
Abstract
Potential of APOBEC3B as a therapeutic target and its role in bladder cancer
onset and progression.
Eur J Med Res. 2025;30:740.
Abstract
Letter to the editor: Prognostic biomarker PSMD14 facilitates bladder cancer
tumorigenesis and progression by regulating Nucleolin-YAP1 axis.
Transl Oncol. 2025;61:102498.
Abstract
Fusobacterium nucleatum promotes bladder cancer progression and immune escape by
activating the IL22/STAT3/PD-L1 signaling cascade.
Tissue Cell. 2025;97:103065.
Abstract
Integrated photoelectrochemical/photothermal dual-mode biosensor with
simultaneous dual-signal output for detection of bladder cancer cells HT-1376.
Bioelectrochemistry. 2025;167:109075.
Abstract
Comment on "innovative logic 'AND' gate gene circuits for bladder cancer
treatment: preclinical study".
Int J Surg. 2025 Aug 11. doi: 10.1097/JS9.0000000000003080.
Abstract
Radiation-induced extracellular matrix remodelling drives prognosis and predicts
radiotherapy response in muscle-invasive bladder cancer.
Front Oncol. 2025;15:1616943.
Abstract
Identification and validation of a novel signature based on M2 macrophage
co-expressed genes in bladder cancer.
Transl Cancer Res. 2025;14:4194-4207.
Abstract
Detection of genome-wide methylation changes in bladder cancer by long-read
sequencing of urinary DNA.
Clin Epigenetics. 2025;17:141.
Abstract
Vesical perfusion volume and internal iliac pressure during double
balloon-occluded arterial infusion chemotherapy for bladder cancer.
Eur Radiol Exp. 2025;9:72.
Abstract
Extraperitoneal vs transperitoneal laparoscopic cystectomy: optimized surgical
techniques and long-term outcomes in a single-center retrospective cohort study.
World J Surg Oncol. 2025;23:310.
Abstract
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug
conjugate RC48.
J Immunother Cancer. 2025;13:e011881.
Abstract
Bladder preserving approach for treatment of primary osteogenic sarcoma of
bladder: A rare case report.
Indian J Cancer. 2025;62:305-307.
Abstract
Correction: Galactosylated silver nanoparticles as a biocompatible intrinsic SERS
probe for bladder cancer imaging and ex vivo tumor detection.
J Mater Chem B. 2025 Aug 11. doi: 10.1039/d5tb90125.
Abstract
Minimizing Blood Loss in Bladder Cancer: Efficacy of Preoperative Embolization
before Transurethral Resection of Bladder Tumor.
J Korean Soc Radiol. 2025;86:512-523.
Abstract
The Temporal Trends and Attributed Risk Burden of Kidney Cancer, Bladder Cancer,
and Prostate Cancer in China From 1990 to 2021.
Cureus. 2025;17:e87583.
Abstract
[Expressions of androgen receptor and human epidermal growth factor receptor 2 in
urinary bladder urothelial carcinoma with incidental prostate cancer and
clinicopathological features of the malignancy].
Zhonghua Nan Ke Xue. 2024;30:1081-1085.
Abstract
ASO Author Reflections: The Complex Role of 5-Alpha Reductase Inhibitors in
Bladder Cancer.
Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-18073.
Abstract
Habitat-based radiomic model for predicting muscle invasion in bladder cancer: A
multi-center study using enhanced-CT and machine learning.
Med Phys. 2025;52:e18021.
Abstract
Bacillus Calmette-Guerin (BCG) in combination with PANVAC vs. BCG alone in
adults with high-grade BCG-refractory non-muscle-invasive bladder cancer.
Urol Oncol. 2025 Aug 7:S1078-1439(25)00222-4. doi: 10.1016/j.urolonc.2025.
Abstract
HIF-independent oxygen sensing via KDM6A regulates ferroptosis.
Mol Cell. 2025;85:2973-2987.
Abstract
Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome
acquired cisplatin resistance of tumor cells.
Biochim Biophys Acta Mol Cell Res. 2025;1872:120018.
Abstract
Robot-assisted tubeless radical cystectomy: Is the absence of ureteral drainage a
mistake?
Fr J Urol. 2025;35.
Abstract
Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of
Pembrolizumab Treatment.
J Voice. 2025;39:890-895.
Abstract
Assessing the Influence of Bladder Cancer on Upper Tract Urothelial Carcinoma
Prognoses Following Radical Nephroureterectomy: A Retrospective, Propensity
Score-Based Multicenter Cohort Study.
Ann Surg Oncol. 2025 Aug 25. doi: 10.1245/s10434-025-17808.
Abstract
The clinical value of the EpCAM biomarker and its association with immune cell
infiltration in bladder cancer.
Diagn Pathol. 2025;20:96.
Abstract
PD-1 and PD-L1 expression in molecular subtypes of muscle-invasive bladder
cancer: immunohistochemical characterization and correlation with
clinicopathological features.
Diagn Pathol. 2025;20:97.
Abstract
High mobility group A2 (HMGA2) protein tissue levels and its association with
clinicopathological features in bladder cancer patients.
Discov Oncol. 2025;16:1622.
Abstract
Comparative outcomes of intracorporeal and extracorporeal urinary diversion in
robotic cystectomy: a systematic review and meta-analysis.
J Robot Surg. 2025;19:512.
Abstract
RETRACTION: SENP2 Suppresses Epithelial-Mesenchymal Transition of Bladder Cancer
Cells Through deSUMOylation of TGF-betaRI.
Mol Carcinog. 2025 Aug 25. doi: 10.1002/mc.70038.
Abstract
RETRACTION: Silencing Circular RNA VANGL1 Inhibits Progression of Bladder Cancer
by Regulating miR-1184/IGFBP2 Axis.
Cancer Med. 2025;14:e71178.
Abstract
FDA approves durvalumab for muscle-invasive bladder cancer: a new standard in
neoadjuvant and adjuvant therapy.
Ann Med Surg (Lond). 2025;87:4011-4013.
Abstract
LINC00152 knockdown exerts repressive effects on epithelial-mesenchymal
transition in bladder cancer.
Cytotechnology. 2025;77:166.
Abstract
Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier
Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.
ACS Biomater Sci Eng. 2025 Aug 24. doi: 10.1021/acsbiomaterials.5c00960.
Abstract
Advancing age- and gender-sensitive supportive care and follow-up strategies in
bladder cancer.
Urol Oncol. 2025 Aug 23:S1078-1439(25)00276.
Abstract
Reply to Hao Wang and Li Yang's Letter to the Editor re: Mariana Silva-Ferreira,
Joao A. Carvalho, Sofia Salta, et al. Diagnostic Test Accuracy of Urinary DNA
Methylation-based Biomarkers for Bladder Cancer: Considerations for Further
Research. Eur Ur
Eur Urol Focus. 2025 Aug 23:S2405-4569(25)00246.
Abstract
Role of the tumor microenvironment in promoting treatment resistance in
urothelial carcinoma (Review).
Mol Med Rep. 2025;32:293.
Abstract
Patients' experiences of a standardized care pathway for suspected bladder cancer
due to macroscopic hematuria.
BMC Urol. 2025;25:216.
Abstract
Emotional stress: a prominent factor positively related to the onset and
recurrence of bladder cancer as revealed by NHANES and a Chinese database.
Ann Med. 2025;57:2549525.
Abstract
Interaction patterns amongst risk factors for bladder cancer in adults with type
2 diabetes managed in primary care.
BJGP Open. 2025 Aug 22:BJGPO.2025.0028. doi: 10.3399/BJGPO.2025.0028.
Abstract
Evaluating surrogates for overall survival in the adjuvant treatment of bladder
cancer with chemotherapy.
Urol Oncol. 2025 Aug 21:S1078-1439(25)00269.
Abstract
Impact of the preoperative modified 5-item frailty index on the efficacy of
neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.
Urol Oncol. 2025 Aug 21:S1078-1439(25)00283.
Abstract
KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy
resistance in bladder cancer by suppressing ROS accumulation.
Urol Oncol. 2025 Aug 21:S1078-1439(25)00280.
Abstract
Global, regional, and national burden and trends of bladder cancer in individuals
Aged 55 Years and older From 1990 to 2021: Findings from the Global Burden of
Disease Study 2021.
Int J Surg. 2025 Aug 21. doi: 10.1097/JS9.0000000000003254.
Abstract
Cell Surface Proteomics Reveals Hypoxia-Regulated Pathways in Cervical and
Bladder Cancer.
Proteomes. 2025;13:36.
Abstract
IRE1alpha modulates M1 oncolytic virus sensitivity via ER stress regulation in
bladder cancer.
Cancer Drug Resist. 2025;8:41.
Abstract
Tanshinone IIA promotes METTL3/METTL14-mediated FDX1 m6A modification to induce
cuproptosis in bladder cancer.
Toxicol Res (Camb). 2025;14:tfaf123.
Abstract
Comparative efficacy of holmium laser versus plasma techniques in the surgical
management of non-muscle invasive bladder cancer: a meta-analysis.
Front Oncol. 2025;15:1625901.
Abstract
Clinical and Pathological Predictors for Occult Lymph Node Involvement in
Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical
Cystectomy.
Clin Genitourin Cancer. 2025 Jul 23:102405. doi: 10.1016/j.clgc.2025.102405.
Abstract
Re: Thomas Dreyer, Simone Brandt, Fabrin Knud, et al. Use of the Xpert Bladder
Cancer Monitor for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder
Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol
2025;88:23-30.
Eur Urol Focus. 2025 Aug 20:S2405-4569(25)00250.
Abstract
Molecular classification of nonurothelial histologic subtypes of bladder cancer.
Urol Oncol. 2025 Aug 20:S1078-1439(25)00277.
Abstract
Bladder cancer: "Breakthrough" treatment that doubles survival rates is approved
for NHS patients.
BMJ. 2025;390:r1786.
Abstract
A novel, synthesized, amphiphilic ethylene glycol squalene derivative suppresses
BBN-induced bladder carcinogenesis.
Sci Rep. 2025;15:30751.
Abstract
Role of radiotherapy in the management of bladder cancer: Recommendations of the
French Society for Radiation Oncology, 2025 update.
Cancer Radiother. 2025;29.
Abstract
Menin facilitates the cell proliferation of bladder cancer via modulating the
TFAP2C/beta-catenin axis.
Genes Dis. 2025;12:101565.
Abstract
Oncological outcome and survival predictors of widowed patients with bladder
cancer in special populations.
Sci Rep. 2025;15:30638.
Abstract
Inhibition of ELOVL6 activity impairs mitochondrial respiratory function and
inhibits tumor progression in FGFR3-mutated bladder cancer cells.
Biochim Biophys Acta Mol Basis Dis. 2025;1871:168023.
Abstract
A Sensor Solution to the Femtomolar Problem in Bladder Cancer.
ACS Sens. 2025 Aug 20. doi: 10.1021/acssensors.5c00670.
Abstract
BCG Intolerance in Nonmuscle Invasive Bladder Cancer-A Systematic Review.
ANZ J Surg. 2025 Aug 20. doi: 10.1111/ans.70281.
Abstract
Development and Validation of a Preoperative MRI Habitat Radiomics Model to
Predict Variant Histology in Bladder Cancer.
J Magn Reson Imaging. 2025 Aug 20. doi: 10.1002/jmri.70069.
Abstract
MiR-20a-5p Inhibits Bladder Cancer Proliferation and Migration by Targeting
KPNA2.
J Cell Mol Med. 2025;29:e70785.
Abstract
Copper single-atom-based flexible aptamer biochip for simultaneous monitoring of
bladder cancer-related bacteria.
Mikrochim Acta. 2025;192:602.
Abstract
Urinary bladder cancer needs more attention - recommendations for health care
professionals and politicians in the European Union.
Nat Rev Urol. 2025 Aug 19. doi: 10.1038/s41585-025-01077.
Abstract
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin
sensitivity in bladder cancer.
J Clin Invest. 2025;135:e186688.
Abstract
Prognostic value of LncRNA DLGAP1-AS2 in bladder cancer and its regulatory effect
on tumor progression.
Discov Oncol. 2025;16:1578.
Abstract
Suspected Urine-Induced Chemical Peritonitis Secondary to Invasive Bladder
Cancer: A Case Report.
Cureus. 2025;17:e90092.
Abstract
Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A
Systematic Review of Current Evidence.
Eur Urol Open Sci. 2025;79:45-59.
Abstract
Multiparametric MRI for local staging in patients with suspected muscle-invasive
bladder cancer: study protocol for a multicentre, non-inferiority randomised
controlled trial (the BladParadigm study).
BMJ Open. 2025;15:e100002.
Abstract
An interpretable CT-based deep learning model for predicting overall survival in
patients with bladder cancer: a multicenter study.
NPJ Precis Oncol. 2025;9:288.
Abstract
Integrated spatial transcriptome and metabolism study reveals metabolic
heterogeneity in human bladder cancer.
Cancer Gene Ther. 2025 Aug 16. doi: 10.1038/s41417-025-00947.
Abstract
CALD1-derived circ-0003746 targeting miR-526b promotes EMT-mediated bladder
cancer progression.
Exp Cell Res. 2025 Aug 14:114710. doi: 10.1016/j.yexcr.2025.114710.
Abstract
Genetic investigation in patients with histological variants of bladder cancer:
clinical implications.
Expert Rev Anticancer Ther. 2025 Aug 25:1-23. doi: 10.1080/14737140.2025.2548487
Abstract
The role of spectral characteristics of urine in bladder cancer diagnostics.
Sci Rep. 2025;15:29979.
Abstract
Structured MRI assessment after neoadjuvant therapy for bladder cancer: the
emerging roles of NacVI-RADS and multimodal AI.
Eur Radiol. 2025 Aug 15. doi: 10.1007/s00330-025-11934.
Abstract
Novel liquid immunocytochemistry with machine learning analysis for bladder
cancer detection.
J Histotechnol. 2025 Aug 15:1-9. doi: 10.1080/01478885.2025.2546655.
Abstract
A nomogram integrating mutation signatures and clinical features for prognostic
stratification in bladder cancer.
Discov Oncol. 2025;16:1562.
Abstract
Correction: Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1
signaling in cancer stem cells for prognosis and immunotherapeutic response in
muscle-invasive bladder cancer.
J Transl Med. 2025;23:909.
Abstract
The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by
repressing extracellular matrix deposition and mechanotransduction signaling.
Cell Death Dis. 2025;16:618.
Abstract
CBCT-based online adaptive radiotherapy of the bladder - geometrical and
dosimetrical considerations compared to conventional IGRT.
Radiat Oncol. 2025;20:128.
Abstract
Correction: LIMA1 inhibits cisplatin resistance and malignant biological behavior
of bladder cancer cells by suppressing the Wnt/beta-catenin pathway.
BMC Med Genomics. 2025;18:130.
Abstract
Do urinary bladder smooth muscle neoplasms show morphologic and immunophenotypic
features of their uterine fumarate hydratase-deficient counterparts?
Ann Diagn Pathol. 2025;79:152536.
Abstract
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers:
Implications for HER2-Targeted Therapies.
Cancer Res Commun. 2025;5:1419-1428.
Abstract
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line
maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN
Bladder Medley interim analysis.
Ann Oncol. 2025;36:1088-1095.
Abstract
Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic
urothelial carcinoma (AVETAX trial).
Urol Oncol. 2025;43:520.
Abstract
Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven
anti-tumor immunity.
Cancer Cell. 2025;43:1442-1459.
Abstract
Variability in Health Care Utilization and Perioperative Outcomes Among Urinary
Diversion Patients: Analysis of the National Surgical Quality Improvement Program
Database.
Urol Pract. 2025;12:548-556.
Abstract
Prognostic significance of pathologic response to neoadjuvant chemotherapy in
muscle-invasive urothelial carcinoma of the bladder with histologic subtype.
Urol Oncol. 2025;43:521.
Abstract
Urachal actinomycosis mimicking a urachal adenocarcinoma: case report and
systematic review.
Lancet Infect Dis. 2025;25:e533-e539.
Abstract
Risk stratification of pT1b urothelial carcinoma based on spatial relationships
between invasive tumour and muscularis propria on TURB specimens for predicting
muscle-invasive urothelial carcinoma in radical cystectomy: A new proposal.
Malays J Pathol. 2025;47:247-252.
Abstract
Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential
Chemopreventive Agent.
Cancer Genomics Proteomics. 2025;22:750-759.
Abstract
Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and
Therapeutic Target Identification.
Cancer Genomics Proteomics. 2025;22:654-682.
Abstract
Targeting GRB2-Akt-SREBP1 signaling axis by saponins from Paris polyphylla Smith
var. yunnanensis (Franch.) Hand.-Mazz to overcome cisplatin resistance in bladder
cancer.
J Ethnopharmacol. 2025 Aug 27:120502. doi: 10.1016/j.jep.2025.120502.
Abstract
Elevated C-reactive protein and D-dimer to predict venous thromboembolism in
patients with bladder cancer.
Front Immunol. 2025;16:1652139.
Abstract
Multiparametric MRI Features of Plasmacytoid Urothelial Carcinoma of the Urinary
Bladder.
Korean J Radiol. 2025;26:832-840.
Abstract
A COX-2-Targeted Platinum(lV) Prodrug Induces Apoptosis and Reduces Inflammation
in Bladder Cancer Models.
Pharmaceuticals (Basel). 2025;18:1185.
Abstract
Microbiome Shifts in Bladder Cancer: A Narrative Review of Urobiome Composition,
Progression, and Therapeutic Impact.
Medicina (Kaunas). 2025;61:1401.
Abstract
Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality
of Bladder Cancer Patients Undergoing Radical Cystectomy.
J Clin Med. 2025;14:5810.
Abstract
The Dynamic Field of Perioperative Treatment for Localized Muscle-Invasive
Bladder Cancer: A Review of the Current Research Landscape.
J Clin Med. 2025;14:5653.
Abstract
Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A
Critical Review.
Bioengineering (Basel). 2025;12:866.
Abstract
Impact of Preoperative CT-Diagnosed Sarcopenic Obesity on Outcomes After Radical
Cystectomy for Bladder Cancer.
Cancers (Basel). 2025;17:2669.
Abstract
Gene Expression in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer Cells
Exposed to Hypoxia.
Cancers (Basel). 2025;17:2624.
Abstract
Canonical correlations among symptom clusters, symptom experience, and symptom
cluster management in male patients with non-muscle invasive bladder cancer: a
cross-sectional study.
Eur J Oncol Nurs. 2025;78:102941.
Abstract
Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder
Cancer: A Retrospective Single-Center Study.
Curr Oncol. 2025;32:415.
Abstract
Clonal diversity shapes the tumour microenvironment leading to distinct
immunotherapy responses in metastatic urothelial carcinoma.
Nat Commun. 2025;16:7995.
Abstract
Clinical Predictive Factors for Reproductive Organ Involvement in Females with
Muscle Invasive Bladder Cancer: A Retrospective Review of Radical Cystectomy
Cases from Two Tertiary Centers.
Iran J Med Sci. 2025;50:530-538.
Abstract
Risk of Bladder Cancer in Patients with Chronic Indwelling Catheters: A
Real-World Data Analysis.
J Cancer. 2025;16:3464-3472.
Abstract
Emerging Role of Multiparametric MRI in the Staging of Bladder Cancer: Insights
From the BladderPath Trial.
Cureus. 2025;17:e88623.
Abstract
Evaluation of gene expression-based predictors of lymph node metastasis in
bladder cancer.
Bladder Cancer. 2025;11:23523735251370895.
Abstract
Carcinomatous leptomeningitis from bladder cancer mimicking immune-related
cerebellitis: A case report.
Neurol Sci. 2025 Aug 27. doi: 10.1007/s10072-025-08425.
Abstract
A urinary DNA methylation assay using two genes enables noninvasive detection and
prognostic prediction in urothelial carcinoma.
Sci Rep. 2025;15:31281.
Abstract
Robot-Assisted Boari-flap after Orthotopic Neobladder Using the KangDuo Surgical
Robot-01 System.
Int Braz J Urol. 2026;52:e20250341.
Abstract
Physical activity matters: prognostic impact of preoperative functioning scores
in patients undergoing radical cystectomy.
World J Urol. 2025;43:512.
Abstract
Development and landscape of maintenance therapy after first-line treatment of
advanced or metastatic urothelial carcinoma.
Front Immunol. 2025;16:1541213.
Abstract
Clinical utility of a novel perioperative quality assessment metric, trifecta,
for radical cystectomy.
Int J Clin Oncol. 2025;30:1832-1840.
Abstract
A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus
Calmette-Guerin via reprogramming granulopoiesis.
Immunity. 2025;58:1984-2001.
Abstract
Urothelial carcinoma with osteoclast-like giant cells: An expanded
immunohistochemical and molecular profile.
Am J Clin Pathol. 2025;164:257-264.
Abstract
Decoding the genetic links between substance use disorder and cancer
vulnerability.
Psychopharmacology (Berl). 2025;242:2021-2033.
Abstract
Natural lignan justicidin A-induced mitophagy as a targetable niche in bladder
cancer.
Chem Biol Interact. 2025 Sep 3:111723. doi: 10.1016/j.cbi.2025.111723.
Abstract
Is it prime time for stent-less robotic radical cystectomy? A scoping review.
J Robot Surg. 2025;19:560.
Abstract
Effects of a Dendritic Cell Vaccine Loaded With Whole Tumor Antigen on Bladder
Cancer Model in hu-PBL-SCID Mice.
Drug Dev Res. 2025;86:e70157.
Abstract
Impact of COVID-19 care reorganization on the prognosis of patients with bladder
urothelial carcinoma: a multicentric retrospective study.
Can J Urol. 2025;32:359-366.
Abstract
Construction of a gene-metabolite-microbiome regulatory network reveals novel
therapeutic targets in bladder cancer through multi-omics analysis.
Ann Med. 2025;57:2553220.
Abstract
High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic
model of bladder cancer.
Pathol Res Pract. 2025;275:156207.
Abstract
ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and
enhanced immune checkpoint inhibitor therapy in bladder cancer.
Biomaterials. 2025;326:123677.
Abstract
Non-invasive bladder cancer detection: Identification of a urinary volatile
biomarker panel using GC-MS metabolomics and machine learning.
Talanta. 2025;297.
Abstract
Prognostic Factors of Long-Term Survival in Non-Muscle-Invasive Bladder Cancer:
An 18-Year Retrospective Study from Real-Life Practice.
Chirurgia (Bucur). 2025;120:459-466.
Abstract
Bricker Urinary Diversion after Radical Cystectomy: A Comparative Analysis of
Laparoscopic vs. Robotic Approach in Terms of Quality of Life, Perioperative
Outcomes and Postoperative Complications.
Chirurgia (Bucur). 2025;120:446-458.
Abstract
Deep learning-driven whole-slide image analysis predicts chemo-resistance and
motility subtypes in muscle-invasive bladder cancer.
Genes Genomics. 2025 Sep 4. doi: 10.1007/s13258-025-01677.
Abstract
Case report: atypical anti-SAE1 autoantibody manifestation with splinter
hemorrhages as onset, and related to urothelial cancer.
Eur Rev Med Pharmacol Sci. 2025;29:398-403.
Abstract
Advances in the immunological microenvironment and immunotherapy of bladder
cancer.
Front Immunol. 2025;16:1609871.
Abstract
Agreement between transurethral resection of bladder tumor and radical cystectomy
pathology in patients with bladder cancer subtype histology: A retrospective
cohort study.
Urol Oncol. 2025 Sep 2:S1078-1439(25)00282-0. doi: 10.1016/j.urolonc.2025.
Abstract
Correction to "Clinicohistopathological implications of phosphoserine 9 glycogen
synthase kinase-3beta/ beta-catenin in urinary bladder cancer patients".
World J Clin Oncol. 2025;16:107778.
Abstract
High carbohydrate antigen 19-9 levels indicate poor prognosis in patients with
bladder cancer following radical cystectomy.
Front Oncol. 2025;15:1550203.
Abstract
Routine annual imaging does not aid in diagnosing new functional complications
more than five years after RC with ileal conduit.
World J Urol. 2025;43:539.
Abstract
Paradigm shift in the treatment of bladder cancer? The Swedish perspective.
Scand J Urol. 2025;60:186-188.
Abstract
Survival patterns after perioperative treatment escalation and cystectomy for
synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.
Scand J Urol. 2025;60:173-179.
Abstract
Synergistic nanoplatform of M1 macrophage-derived extracellular vesicles and
MoS(2) for tumor-targeted photoimmunotherapy in bladder cancer.
Nanoscale. 2025 Sep 3. doi: 10.1039/d5nr00374.
Abstract
Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by
enhancing nucleotide excision repair in bladder cancer.
J Exp Clin Cancer Res. 2025;44:265.
Abstract
The effect of neoadjuvant chemotherapy on survival outcomes subsequent to radical
cystectomy in pathological T0 bladder cancer patients: A multicenter large-scale
analysis.
Investig Clin Urol. 2025;66:395-404.
Abstract
Contemporary management of metastatic urothelial carcinoma.
Investig Clin Urol. 2025;66:375-382.
Abstract
Trends in genitourinary tumors: Academic center experience over 16 years.
Saudi Med J. 2025;46:985-991.
Abstract
Treatment approaches for non-metastatic small cell bladder cancer: a
meta-analysis of reconstructed Kaplan-Meier curves.
Clin Transl Radiat Oncol. 2025;55:101032.
Abstract
Gene and pathway analysis of genome-wide genetic associations of bladder cancer.
Curr Urol. 2025;19:321-330.
Abstract
Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in
treatment of small cell bladder cancer.
Urol Case Rep. 2025;62:103165.
Abstract
Construction and immunohistochemical validation of a necroptosis-related
prognostic signature in bladder cancer and its association with tumor immune
infiltration.
Front Genet. 2025;16:1527907.
Abstract
Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of
Neuroendocrine Bladder Cancer.
Cancer Heterog Plast. 2025;2:10.
Abstract
Unraveling bladder cancer-related circRNA biomarkers: a hybrid model combining
deep learning and statistics.
Health Inf Sci Syst. 2025;13:53.
Abstract
A population-based analysis of patterns of care in patients with de novo
muscle-invasive bladder cancer from Alberta, Canada.
Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9111.
Abstract
Testosterone replacement therapy and bladder cancer.
Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9207.
Abstract
Harnessing Nature: Computational and Experimental Insights Into Ipomoea obscura
Metabolites for Bladder Cancer Therapy.
Chem Biodivers. 2025 Sep 2:e00909. doi: 10.1002/cbdv.202500909.
Abstract
Unmasking disparities in bladder cancer outcomes in the disaggregated Asian
American population.
Expert Rev Anticancer Ther. 2025 Sep 3:1-10. doi: 10.1080/14737140.2025.2556884.
Abstract
Letter to the editor: "bladder cancer isn't BPH: why TURBT patients deserve
separate risk models for complicated UTI".
World J Urol. 2025;43:527.
Abstract
The current role of photodynamic diagnosis (PDD) in the management of non-muscle
invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper.
Minerva Urol Nephrol. 2025;77:443-450.
Abstract
Assessing cancer risk in firefighters in Northern Germany: a retrospective cohort
study.
BMC Public Health. 2025;25:2998.
Abstract
Correction: TTK promotes mitophagy by regulating ULK1 phosphorylation and
pre-mRNA splicing to inhibit mitochondrial apoptosis in bladder cancer.
Cell Death Differ. 2025 Sep 1. doi: 10.1038/s41418-025-01571.
Abstract
Investigating the relationship between peripheral blood transferrin receptor
protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.
Sci Rep. 2025;15:32197.
Abstract
Multi-DECT Image-based Interpretable Model Incorporating Habitat Radiomics and
Vision Transformer Deep Learning for Preoperative Prediction of Muscle Invasion
in Bladder Cancer.
Acad Radiol. 2025 Aug 30:S1076-6332(25)00756-1. doi: 10.1016/j.acra.2025.
Abstract
Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A
Meta-Analysis.
Clin Genitourin Cancer. 2025;23:102408.
Abstract
Cytotoxicity of (212)Pb-labeled anti-PTK7 antibody in 2D adherent and 3D
multicellular bladder cancer models.
EJNMMI Radiopharm Chem. 2025;10:58.
Abstract
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in
patients with muscle-invasive bladder cancer who are ineligible for or decline
neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a
randomised, open
Lancet Oncol. 2025 Aug 27:S1470-2045(25)00358.
Abstract
Mixed-grade papillary urothelial carcinoma with a minor high-grade component
shows a significantly worse clinical outcome than low-grade papillary urothelial
carcinoma.
Hum Pathol. 2025;163:105904.
Abstract
Invasive urothelial carcinoma with chordoid and myxoid features shows increased
RAS/RAF pathway alterations.
Hum Pathol. 2025;163:105882.
Abstract
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally
advanced or metastatic urothelial carcinoma.
Future Oncol. 2025;21:2705-2712.
Abstract
Role of 3-mercaptopyruvate sulfurtransferase in cancer.
Cell Signal. 2025;135:112020.
Abstract
Is organ preserving radical cystectomy in women oncologically safe and does it
improve quality of life?
Expert Rev Anticancer Ther. 2025;25:1075-1085.
Abstract
Deciphering the Molecular Landscape of Urothelial Carcinoma:
Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for
Cost-effective Stratification.
Appl Immunohistochem Mol Morphol. 2025;33:267-276.
Abstract
High proportion of clinically significant prostate adenocarcinomas in radical
cystoprostatectomy specimens following complete prostate sampling.
Pathology. 2025;57:708-711.
Abstract
Comparable Diagnostic Performance of 99m Tc-FAPI Scintigraphy and
Contrast-enhanced CT in Restaging a Rare Case of Metastatic Colon Adenocarcinoma
to the Urachus.
Clin Nucl Med. 2025;50:e626-e627.
Abstract
(68)Ga-FAPI and (18)F-FAPI PET/CT for detection of nodal metastases prior radical
cystectomy in high-risk urothelial carcinoma patients.
Eur J Nucl Med Mol Imaging. 2025;52:3963-3974.
Abstract
[Recurrence of urothelial bladder cancer in the upper urinary tract after radical
cystectomy: is there prevention and what are the treatment options?].
Urologiia. 2025;:59-63.
Abstract
[Review of current methods of diagnosis and treatment of locally advanced
urothelial bladder cancer].
Urologiia. 2025;:96-102.
Abstract
Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and
Challenges.
Cureus. 2025;17:e89801.
Abstract
Dissecting Causal Relationships Between Gut Microbiota, Plasma Metabolites and
Bladder Cancer: A Two-Step Mendelian Randomization Study.
Health Sci Rep. 2025;8:e71206.
Abstract
A novel prognostic biomarker DUSP6 promote the malignant progression of bladder
cancer through mTOR mediated mitophagy.
Front Oncol. 2025;15:1603069.
Abstract
Development of a radiomics and clinical feature-based nomogram for preoperative
prediction of pathological grade in bladder cancer.
Front Oncol. 2025;15:1661979.
Abstract
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder
cancer: A network meta-analysis.
Urol Oncol. 2025 Sep 10:S1078-1439(25)00333.
Abstract
Applications and future prospects of laser technologies in the treatment of
non-muscle invasive bladder cancer.
Bladder (San Franc). 2025;12:e21200050.
Abstract
Neoadjuvant therapy plus thulium laser transurethral bladder tumor resection for
muscle-invasive bladder cancer.
Bladder (San Franc). 2025;12:e21200053.
Abstract
[MASSIVE TUMOR INSIDE A GIANT BLADDER DIVERTICULUM].
Harefuah. 2025;164:529-531.
Abstract
[INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE
INVASIVE PATIENTS].
Harefuah. 2025;164:524-528.
Abstract
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment
strategies and emerging therapies.
Nat Rev Urol. 2025 Sep 10. doi: 10.1038/s41585-025-01072.
Abstract
Modulating the PPARgamma pathway upregulates NECTIN4 and enhances chimeric antigen
receptor (CAR) T cell therapy in bladder cancer.
Nat Commun. 2025;16:8215.
Abstract
Targeted hotspot profiling reveals a functionally relevant mutation in bladder
cancer.
Urol Oncol. 2025 Sep 9:S1078-1439(25)00317-5. doi: 10.1016/j.urolonc.2025.
Abstract
Corrigendum to "Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders
for the treatment of bladder cancer" [Eur. J. Med. Chem. 293 (2025) 117710].
Eur J Med Chem. 2025 Sep 10:118140. doi: 10.1016/j.ejmech.2025.118140.
Abstract
Development and analytical validation of a multiplex diagnostic qPCR-array as a
potential application in predicting the response to neoadjuvant chemotherapy in
muscle invasive bladder cancer.
Transl Oncol. 2025;61:102528.
Abstract
A commentary on "A nomogram for predicting lymph node metastases in nonmetastatic
muscle-invasive bladder cancer: a SEER-based investigation".
Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003346.
Abstract
Impact of pad wetness on health-related quality of life after radical cystectomy
and orthotopic neobladder.
World J Urol. 2025;43:548.
Abstract
An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG
to assess prognosis and immunotherapy response in bladder cancer patients.
Elife. 2025;13:RP95326.
Abstract
Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003371.
Abstract
Using epigenetics as an alternative treatment for bladder cancer: A literature
review.
Urologia. 2025 Sep 10:3915603251372377. doi: 10.1177/03915603251372377.
Abstract
Puerariae radix flavones induce apoptosis in bladder cancer T24 cells via the
FAS/TNFR1 pathway: A potential therapeutic candidate.
Biomed Rep. 2025;23:170.
Abstract
Evaluating repeat transurethral resection after en bloc resection for non-muscle
invasive bladder cancer.
Ther Adv Urol. 2025;17:17562872251367555.
Abstract
CT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the
Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two
Years after TURBT.
Curr Med Imaging. 2025 May 26. doi: 10.2174/0115734056350444250418075406.
Abstract
Long-term complications in patients with bladder-prostate rhabdomyosarcoma
treated with brachytherapy: a systematic review.
Pediatr Surg Int. 2025;41:290.
Abstract
[Primary lymphomas in urinary bladder: a clinicopathological analysis of 23
cases].
Zhonghua Bing Li Xue Za Zhi. 2025;54:925-931.
Abstract
Erratum: Risk Score Model of Aging-Related Genes for Bladder Cancer and Its
Application in Clinical Prognosis.
JCO Clin Cancer Inform. 2025;9:e2500251.
Abstract
IGHA1 and IGHG1 Expression Panel Predicts Anti-PD-L1 Response in Muscle-Invasive
Bladder Cancer.
Mol Carcinog. 2025 Sep 8. doi: 10.1002/mc.70033.
Abstract
A high stroma-tumor ratio is associated with an immunosuppressive tumor
microenvironment and a poor prognosis in bladder cancer.
Front Oncol. 2025;15:1604609.
Abstract
Cu(2)(OH)PO(4)@PAA Nanoparticles for Highly Effective Combination of
Chemodynamic, Photodynamic and Photothermal Therapies Against Bladder Cancer.
Int J Nanomedicine. 2025;20:10701-10719.
Abstract
Epigenetic regulation of bladder cancer in the context of aging.
Front Pharmacol. 2025;16:1617452.
Abstract
Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of
PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response.
Oncol Res. 2025;33:2463-2489.
Abstract
Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer
and bladder cancer using [(89)Zr]Zr-DFO-Durvalumab.
Colloids Surf A Physicochem Eng Asp. 2025;723:137332.
Abstract
Antibacterial and anticancer activity of multifunctional iron-based magnetic
nanoparticles against urinary tract infection and cystitis-related bacterial
strains and bladder cancer cells.
Biomed Eng Lett. 2025;15:903-915.
Abstract
O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor
suppressor gene PER1 via m(6)A modification.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:827-839.
Abstract
[Bladder cancer in geriatric patients].
Med Pr. 2025 Sep 1:209113. doi: 10.13075/mp.5893.01621.
Abstract
Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer:
Mechanisms and Therapeutic Targeting.
Protein Pept Lett. 2025 Sep 3. doi: 10.2174/0109298665403178250806111943.
Abstract
Prostate sparing radical cystectomy and neobladder: institutional long-standing
qualified consideration.
J Egypt Natl Canc Inst. 2025;37:58.
Abstract
Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive
non-muscle-invasive bladder cancer.
Urol Oncol. 2025 Sep 6:S1078-1439(25)00313-8. doi: 10.1016/j.urolonc.2025.
Abstract
Bisphenol A exposure promotes proliferation and invasion capabilities of bladder
cancer cells: Insights from gene expression and pathway analysis.
Toxicol Lett. 2025 Sep 5:S0378-4274(25)01577.
Abstract
MAP30 inhibits proliferation and metastasis of bladder cancer by increasing EGR1
expression and promoting the transcriptional activation of DUSP1.
Mol Immunol. 2025;187:48-60.
Abstract
Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal
Neobladder with Integrated Pelvic Fascial Structure-Sparing in Males with Bladder
Cancer.
Urol J. 2025 Sep 6. doi: 10.22037/uj.v22i.8450.
Abstract
AI-driven and Traditional Radiomic Model for Predicting Muscle Invasion in
Bladder Cancer via Multi-parametric Imaging: A Systematic Review and
Meta-analysis.
Acad Radiol. 2025 Sep 5:S1076-6332(25)00806-2. doi: 10.1016/j.acra.2025.
Abstract
Cancer-specific mortality in secondary bladder cancer after nephroureterectomy
for upper tract urothelial carcinoma.
Urol Oncol. 2025 Sep 5:S1078-1439(25)00312-6. doi: 10.1016/j.urolonc.2025.
Abstract
miR-19b-3p Affects the Proliferation and Apoptosis of Bladder Cancer Cells by
Regulating the Stability of lncRNA SNHG20.
Appl Biochem Biotechnol. 2025 Sep 6. doi: 10.1007/s12010-025-05370.
Abstract
The impact of prophylactic incisional negative pressure wound therapy on surgical
site infection following open radical cystectomy.
Urol Oncol. 2025;43:586-593.
Abstract
A label-free electrochemical immunosensor for bladder tumor marker NMP22 using
AuNPs@OMC and Thi@Gr-COOH nanocomposites.
Bioelectrochemistry. 2026;167:109074.
Abstract
Assessment of synergistic vs. independent drug activity for enfortumab vedotin
and pembrolizumab in untreated advanced urothelial carcinoma.
Urol Oncol. 2025;43:597.
Abstract
Copy number variations in urine cell-free DNA from bladder neoplasm patients.
Mol Cell Probes. 2025;83:102044.
Abstract
Early real-world utilization of avelumab switch maintenance among patients with
advanced urothelial carcinoma without progression following treatment with
first-line platinum-based chemotherapy.
Urol Oncol. 2025;43:594.
Abstract
Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on
social determinants of health.
Urol Oncol. 2025;43:596.
Abstract
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma:
A systematic review and meta-analysis.
Urol Oncol. 2025;43:595.
Abstract
The impact of early versus delayed ureteral ligation on renal function after
robot-assisted radical cystectomy.
Eur J Surg Oncol. 2025;51:110213.
Abstract
Urinary lipid production in dogs with urothelial carcinoma.
Vet J. 2025;313:106373.
Abstract
Molecular testing in urinary cytology specimens: Current status and future
directions.
Urol Oncol. 2025;43:565-578.
Abstract
Prognostic value of combined tumor regression grade and TNM stage in
muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical
cystectomy.
Arch Ital Urol Androl. 2025 Sep 17:14264. doi: 10.4081/aiua.2025.14264.
Abstract
Dioscin initiates dual roles in bladder cancer progression via
miR-195-5p/FASN/SLC3A2 axis-mediated cell death mechanisms.
Transl Oncol. 2025;61:102534.
Abstract
Real-world economic burden of disease recurrence in patients with muscle-invasive
bladder cancer: A population-level claims-based analysis.
J Manag Care Spec Pharm. 2025 Sep 17:1-11. doi: 10.18553/jmcp.2025.25106.
Abstract
Characterizing pelvic organ descent in women after radical cystectomy: an
exploratory analysis.
World J Urol. 2025;43:559.
Abstract
m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating
FOXC1 to promote PARK7 transcriptional activity.
Chin Med J (Engl). 2025 Sep 16. doi: 10.1097/CM9.0000000000003744.
Abstract
The role of focal adhesion kinase in bladder cancer: translation from in vitro to
ex vivo human urothelial carcinomas.
Radiol Oncol. 2025;59:349-367.
Abstract
FAM174B remodels the tumor microenvironment, inhibits the infiltration of
macrophage, predicts the molecular subtype and therapeutic response of bladder
cancer.
Int J Med Sci. 2025;22:3737-3748.
Abstract
Comment on "IGF2BP3 promotes the proliferation and cisplatin resistance of
bladder cancer by enhancing the mRNA stability of CDK6 in an m(6)A dependent
manner".
Int J Biol Sci. 2025;21:5284-5286.
Abstract
Dynamic changes of urinary microbiota in patients with bladder cancer after
surgery and its clinical significance.
Front Immunol. 2025;16:1638628.
Abstract
Perioperative chemotherapy use and related outcomes in muscle-invasive bladder
cancer in Australia.
BJUI Compass. 2025;6:e70083.
Abstract
The mediating effect of dyadic coping between illness perception and fear of
disease progression in bladder cancer patients: A cross-sectional survey.
Medicine (Baltimore). 2025;104:e44520.
Abstract
Causal relationships between immune cells and common urinary system tumors: A
bidirectional analysis of Mendelian randomization.
Medicine (Baltimore). 2025;104:e44297.
Abstract
A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance
in bladder cancer.
Transl Oncol. 2025;61:102537.
Abstract
Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune
Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma.
JCO Precis Oncol. 2025;9:e2500257.
Abstract
Integrated Magnetic Resonance Imaging in Muscle-Invasive Bladder Cancer: A
Comprehensive Review.
Cureus. 2025;17:e90077.
Abstract
MAIT cells promote cancer progression and regulatory T cell accumulation in
bladder tumor microenvironment.
J Immunother Cancer. 2025;13:e012496.
Abstract
Robotic Partial Cystectomy for Urachal Adenocarcinoma: Surgical Technique with
Cys-toscopic Correlation.
Int Braz J Urol. 2026;52:e20250446.
Abstract
A Multifactorial Case of Retroperitoneal Fibrosis in a Post-radiation Bladder
Cancer Patient: Diagnostic and Therapeutic Challenges.
Cureus. 2025;17:e89976.
Abstract
Alternating intravesical instillation of Bacillus Calmette-Guerin and Pseudomonas
aeruginosa effectively prevents postoperative recurrence in high-risk
non-muscle-invasive bladder cancer.
Am J Transl Res. 2025;17:6619-6629.
Abstract
Latrophilin-1 and latrophilin-2 as androgen receptor-responsive G protein-coupled
receptors promote bladder cancer progression.
Am J Transl Res. 2025;17:6403-6413.
Abstract
Upper urinary tract urothelial carcinoma patients show better overall response
rate than bladder cancer patients during enfortumab vedotin treatment following
pembrolizumab.
Transl Androl Urol. 2025;14:2279-2288.
Abstract
Angiogenesis-related gene NID2 profiling and immune infiltration in bladder
cancer: prognostic implications and immunotherapy response.
Front Immunol. 2025;16:1615173.
Abstract
Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle
Invasive Bladder Cancer.
Cancer Med. 2025;14:e71243.
Abstract
Optimizing Tissue Sampling Timing for Accurate Gene Expression Analysis.
Int J Mol Sci. 2025;26:8581.
Abstract
Distinct Metabolomic and Lipoprotein Signatures in Gall Bladder Cancer Patients
of Black African Ancestry.
Cancers (Basel). 2025;17:2925.
Abstract
Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From
Molecular Characterization to Clinical Applicability.
Cancers (Basel). 2025;17:2768.
Abstract
Demonstrating the non-inferiority of robotic radical cystectomy for cT3-cT4
urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity
score-matched analysis.
J Robot Surg. 2025;19:596.
Abstract
Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World
Multicenter Study.
Cancer Med. 2025;14:e71241.
Abstract
Long-Term Survival Obtained by Repeated Cytoreductive Surgery and S-1 Plus
Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With
Metastatic Urachal Carcinoma: A Case Report.
Cancer Rep (Hoboken). 2025;8:e70317.
Abstract
Expression and Prognostic Significance of Different Antibody-Drug Conjugate
Target Proteins in Urachal Carcinoma.
Clin Genitourin Cancer. 2025;23:102403.
Abstract
MS4A4A-positive tumor-associated macrophages associate with poor prognosis and
T-cell exhaustion in patients with urothelial carcinoma of the bladder.
J Pathol. 2025;267:225-239.
Abstract
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker
analysis of the randomized phase 3 CheckMate 274 trial.
Nat Med. 2025;31:3062-3073.
Abstract
Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A
20-Year Nationwide Center Experience.
Clin Genitourin Cancer. 2025;23:102397.
Abstract
SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma
in situ and urothelial dysplasia.
Pathol Res Pract. 2025;273:156148.
Abstract
Comparative Assessment of Chemotherapy Followed by Consolidative Radical
Cystectomy Versus Chemoradiation for Clinically Node-Positive Urothelial
Carcinoma of the Bladder.
Clin Genitourin Cancer. 2025;23:102399.
Abstract
Neuroendocrine carcinoma of the bladder: do they have a worse prognosis? A large
retrospective cohort study by propensity score matching analysis.
Int J Surg. 2025;111:6435-6440.
Abstract
Risk factors for acute kidney injury following radical cystectomy: a systematic
review and meta-analysis.
Int J Surg. 2025;111:6330-6342.
Abstract
Stromal reprogramming in urachal cancer: Fibroblast activation protein and
collagen remodeling drive immune-suppressive niches and immunotherapy resistance.
Int Immunopharmacol. 2025;163:115204.
Abstract
Synthesis and Evaluation of Trehalose-Based Mertansine Warheads for Bacillus
Calmette-Guerin Delivery of Anticancer Agents.
Chembiochem. 2025;26:e202500390.
Abstract
Genomic features of bladder neuroendocrine carcinoma with composite histology.
Histol Histopathol. 2025;40:1547-1554.
Abstract
Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or
Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients.
J Racial Ethn Health Disparities. 2025;12:3284-3293.
Abstract
Downregulated of CTGF reveals mechanism, remodels immune microenvironment,
modulates drug sensitivity in bladder cancer.
Future Sci OA. 2025;11:2560297.
Abstract
Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in
Urothelial Bladder Cancer.
Clin Genitourin Cancer. 2025 Sep 1:102421. doi: 10.1016/j.clgc.2025.102421.
Abstract
Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with
Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder
Cancer: An Analysis of the Global ANNAR Biomarker Study.
Eur Urol Oncol. 2025 Sep 22:S2588-9311(25)00201.
Abstract
Comprehensive Assessment of Tumor Stromal Heterogeneity in Bladder Cancer by Deep
Learning and Habitat Radiomics.
Acad Radiol. 2025 Sep 22:S1076-6332(25)00799-8. doi: 10.1016/j.acra.2025.
Abstract
Global Research Trends in Bladder Cancer Biomarkers: A Bibliometric Analysis.
Cureus. 2025;17:e90724.
Abstract
Circulating tumor DNA and Urinary tumor DNA: useful biomarkers for bladder cancer
detection.
Expert Rev Mol Diagn. 2025 Sep 22. doi: 10.1080/14737159.2025.2565273.
Abstract
Role of myeloid-derived suppressor cells in bladder cancer and targeted
therapeutic strategies.
Gene. 2025 Sep 20:149772. doi: 10.1016/j.gene.2025.149772.
Abstract
Applicability of the European Association of Urology 2021 Prognostic Model for
Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.
Eur Urol Open Sci. 2025;80:33-37.
Abstract
PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and
Metastasis in Bladder Urothelial Carcinoma.
Hum Mutat. 2025;2025:2227219.
Abstract
Genetic susceptibility and environmental risk factors in bladder cancer: Evidence
from the UK biobank.
Bladder Cancer. 2025;11:23523735251370863.
Abstract
Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to
bladder cancer.
Front Cell Dev Biol. 2025;13:1632101.
Abstract
The influence of immunocompromised status on recurrence and progression free
survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing
transurethral resection of bladder tumor (TURBT) and adjuvant intravesical
bacillus Calmette Guerin (BCG
Urol Oncol. 2025 Sep 19:S1078-1439(25)00254.
Abstract
Clinical applications of bladder magnetic resonance imaging: Beyond the VI-RADS(R)
classification.
Radiologia (Engl Ed). 2025;67:101668.
Abstract
Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate
bladder cancer chemoimmunotherapy.
J Control Release. 2025;387:114246.
Abstract
LncRNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2
Stability.
Cancer Res Treat. 2025 Sep 18. doi: 10.4143/crt.2025.
Abstract
Concurrent Ferroptosis and Pyroptosis Induced by a Dual-Organelle-Targeted Type
I/II AIE Photosensitizer for Bladder Cancer Immunotherapy.
Angew Chem Int Ed Engl. 2025 Sep 18:e202509783. doi: 10.1002/anie.202509783.
Abstract
Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1
non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-gamma
profiling.
Tissue Cell. 2025;98:103137.
Abstract
Hollow Dodecahedral Nanocages for Reliable Multi-Level Differentiation of
Urological Cancers through Non-Invasive Metabolic Fingerprinting.
Anal Chem. 2025;97:20622-20631.
Abstract
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab:
a path to cure?
Oncologist. 2025;30:oyaf259.
Abstract
Outcome of atypical urothelial cells (AUC) in patients without prior history of
urothelial carcinoma.
J Am Soc Cytopathol. 2025;14:334-340.
Abstract
IHC-based molecular classification in muscle-invasive urothelial bladder
carcinoma: Prognostic and predictive value toward a clinically applicable IHC
marker panel - A systematic review.
Crit Rev Oncol Hematol. 2025;214:104868.
Abstract
A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and
Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.
Target Oncol. 2025;20:743-754.
Abstract
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic
urothelial carcinoma: 2.5-year median follow-up of the phase III
EV-302/KEYNOTE-A39 trial.
Ann Oncol. 2025;36:1212-1219.
Abstract
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term
Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms
or Toxicity from the JAVELIN Bladder 100 Trial.
Eur Urol Oncol. 2025;8:941-951.
Abstract
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible
Advanced Urothelial Carcinoma: The PemCab Trial.
Eur Urol Oncol. 2025;8:952-960.
Abstract
Development and Validation of the UriMee Model: A Methylation-based Diagnostic
Tool for Early Diagnosis of Urothelial Carcinoma.
Eur Urol Oncol. 2025;8:899-908.
Abstract
Optimizing bladder magnetic resonance imaging: accelerating scan time and
improving image quality through deep learning.
Abdom Radiol (NY). 2025;50:4772-4782.
Abstract
Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic
Radical Cystectomy in Patients With Bladder Cancer.
Anticancer Res. 2025;45:1215-1224.
Abstract
Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With
Advanced Urothelial Carcinoma.
Anticancer Res. 2025;45:2185-2193.
Abstract
Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep
Learning Approaches and Graphical Data Transformation.
Anticancer Res. 2025;45:1953-1964.
Abstract
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and
Metastatic Urothelial Cancer.
Anticancer Res. 2025;45:2563-2573.
Abstract
Randomized Study of Short-time Continuous Saline Irrigation After Transurethral
Resection in Non-muscle Invasive Bladder Cancer.
Anticancer Res. 2025;45:2653-2660.
Abstract
Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive
Bladder Cancer.
Anticancer Res. 2025;45:3245-3261.
Abstract
Novel UF-5000-based Detection, Integrating Inflammatory Parameters, for
Urothelial Carcinoma of the Urinary Bladder.
Anticancer Res. 2025;45:3531-3541.
Abstract
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer:
EuroGemDoce group results.
BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645.
Abstract
Tattoos as a risk factor for bladder cancer: a call for cohort studies.
BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
Abstract
Spatial distribution and subtype-specific expression patterns of Nectin-4 in
muscle-invasive bladder cancer.
BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
Abstract
Fluid intake and recurrence and progression risk of patients with
non-muscle-invasive bladder cancer.
BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665.
Abstract
Advances in the management of high-risk localised muscle invasive bladder cancer.
BJU Int. 2025;135:364-365.
Abstract
Long-term multicentre analysis of robot-assisted radical cystectomy for
non-muscle-invasive bladder cancer.
BJU Int. 2025 Feb 20. doi: 10.1111/bju.16686.
Abstract
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive
bladder cancer.
BJU Int. 2025 Feb 18. doi: 10.1111/bju.16675.
Abstract
An international multicentre randomised controlled trial of en bloc resection of
bladder tumour vs conventional transurethral resection of bladder tumour: first
results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC)
II trial.
BJU Int. 2025;135:446-455.
Abstract
Undetectable pre-radical cystectomy circulating tumour DNA status predicts
improved oncological outcomes.
BJU Int. 2025;135:473-480.
Abstract
Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive
bladder cancer.
BJU Int. 2025 Mar 6. doi: 10.1111/bju.16697.
Abstract
Understanding patient perspectives in the management of their muscle-invasive
bladder cancer.
BJU Int. 2025 Mar 6. doi: 10.1111/bju.16695.
Abstract
Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder
cancer.
BJU Int. 2025 Mar 4. doi: 10.1111/bju.16691.
Abstract
A randomized controlled trial investigating rectus sheath catheters following
radical cystectomy.
BJU Int. 2023;132:554-559.
Abstract
Occupational incidence of bladder cancer amongst veteran ammunition technicians
of the British Army.
BJU Int. 2025 Mar 22. doi: 10.1111/bju.16678.
Abstract
Acute kidney disease after radical cystectomy for bladder cancer: a new
onco-nephrological view.
BJU Int. 2025 Mar 21. doi: 10.1111/bju.16696.
Abstract
The impact of positive surgical margins after cystectomy on oncological outcomes:
a nationwide study.
BJU Int. 2025;135:766-774.
Abstract
The impact of treatment for muscle-invasive bladder cancer on health-related
quality of life.
BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736.
Abstract
Improving the pathway to correct treatment for patients with muscle-invasive
bladder cancer: exploring the myths around the BladderPath trial.
BJU Int. 2025 Apr 14. doi: 10.1111/bju.16728.
Abstract
Indocyanine-guided ureter resection for radical cystectomy - a systematic review
and meta-analysis.
BJU Int. 2025;135:908-917.
Abstract
TYTOCARE home telemonitoring device after radical cystectomy to optimise
postoperative outcomes.
BJU Int. 2025;135:960-968.
Abstract
A study of oral metformin for the intravesical treatment of non-muscle-invasive
bladder cancer.
BJU Int. 2025 May 22. doi: 10.1111/bju.16767.
Abstract
Contemporary outcomes in non-muscle-invasive bladder cancer: a large European
multicentre study.
BJU Int. 2025 May 21. doi: 10.1111/bju.16780.
Abstract
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive
bladder cancer progression risk.
BJU Int. 2025 May 26. doi: 10.1111/bju.16793.
Abstract
Radical cystectomy mortality in older patients: a systematic review and
meta-analysis.
BJU Int. 2025;136:19-31.
Abstract
Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications
and outcomes of BCG vs gemcitabine/docetaxel.
BJU Int. 2025 Jun 15. doi: 10.1111/bju.16827.
Abstract
What spatial omics is teaching us about field cancerisation in prostate and
bladder cancer.
BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
Abstract
Enhanced prognostic value of four-tier hybrid grading system in Ta
non-muscle-invasive bladder cancer.
BJU Int. 2025 Jun 25. doi: 10.1111/bju.16828.
Abstract
Impact of timing of computed tomography staging and patient factors on the
detection of 'true' cN+ bladder cancer.
BJU Int. 2025 Jul 9. doi: 10.1111/bju.16851.
Abstract
The impact of histopathological evaluation at transurethral resection of bladder
tumour on survival in radical cystectomy candidates.
BJU Int. 2025;136:336-343.
Abstract
Immunotherapy-based neoadjuvant treatment and complication rates after radical
cystectomy.
BJU Int. 2025;136:321-328.
Abstract
Biased associations between number of BCG instillations and outcome in
non-muscle-invasive bladder cancer.
BJU Int. 2025 Jul 24. doi: 10.1111/bju.16866.
Abstract
Response to Hof et al.: spurious associations between BCG instillations and
outcomes in non-muscle-invasive bladder cancer.
BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867.
Abstract
Long-term oncological outcomes of bladder cancer: a population-based study with a
25-year follow-up.
BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883.
Abstract
The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder
cancer.
BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905.
Abstract
Carbon footprint and staff demands of surgery and chemoradiation for
muscle-invasive bladder cancer.
BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
Abstract
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate
poor long-term survival following immediate radical cystectomy.
BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
Abstract
Prospective health-related quality of life in women undergoing radical cystectomy
and urinary diversion.
BJU Int. 2025;136:728-737.
Abstract
Incidence and risk factors for postoperative vaginal events following radical
cystectomy for bladder cancer: a nationwide population-based study.
BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
Abstract
Efficacy and safety of pembrolizumab in patients with advanced urothelial
carcinoma deemed potentially ineligible for platinum-containing chemotherapy:
Post hoc analysis of KEYNOTE-052 and LEAP-011.
Cancer. 2025;131:e35601.
Abstract
FDA approves durvalumab for perioperative immunotherapy for patients with
muscle-invasive bladder cancer: In a prespecified analysis, the trial
demonstrated a statistically significant improvement in event-free survival and
overall survival.
Cancer. 2025;131:e35912.
Abstract
The current and future role of systemic therapy in non-muscle-invasive bladder
cancer.
Cancer. 2025;131:e35966.
Abstract
Top advances of the year: Bladder cancer.
Cancer. 2025;131:e70020.
Abstract
A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target
to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.
Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-3217.
Abstract
TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression.
Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-3439.
Abstract
Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive
very high-risk non-muscle-invasive bladder cancer.
Clin Cancer Res. 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321.
Abstract
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent
Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer
(IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
Clin Cancer Res. 2025;31:659-666.
Abstract
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib
in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
Clin Cancer Res. 2025;31:1644-1656.
Abstract
Impact of molecular androgen and estrogen response scores on outcomes following
neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
Clin Cancer Res. 2025 Jun 20. doi: 10.1158/1078-0432.CCR-24-4312.
Abstract
Molecular characterization of residual muscle-invasive bladder cancer identifies
a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant
therapy.
Clin Cancer Res. 2025 Jul 15. doi: 10.1158/1078-0432.CCR-24-3726.
Abstract
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus
Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
Clin Cancer Res. 2025;31:3897-3906.
Abstract
Is there a role for neoadjuvant therapies followed by radical cystectomy in
oligometastatic bladder cancer?
Curr Opin Urol. 2025 Jan 17. doi: 10.1097/MOU.0000000000001261.
Abstract
Antibody-drug conjugates in urothelial carcinoma: current status and future.
Curr Opin Urol. 2025;35:292-300.
Abstract
En bloc resection of large bladder tumor: is it feasible and reasonable?
Curr Opin Urol. 2025;35:385-389.
Abstract
Adjuvant radiotherapy following radical cystectomy in patients with
muscle-invasive bladder cancer: a narrative review.
Curr Opin Urol. 2025 Jun 23. doi: 10.1097/MOU.0000000000001310.
Abstract
Novel intravesical delivery systems for nonmuscle invasive bladder cancer.
Curr Opin Urol. 2025 Jul 17. doi: 10.1097/MOU.0000000000001326.
Abstract
Intravesical chemotherapy combination treatments for BCG-unresponsive nonmuscle
invasive bladder cancer.
Curr Opin Urol. 2025 Jul 15. doi: 10.1097/MOU.0000000000001324.
Abstract
Traditional and next-generation bacillus Calmette-Guerin based treatment
strategies for bacillus Calmette-Guerin unresponsive non-muscle-invasive bladder
cancer in the era of emerging therapies.
Curr Opin Urol. 2025 Jul 14. doi: 10.1097/MOU.0000000000001319.
Abstract
Artificial intelligence in muscle-invasive bladder cancer: opportunities,
challenges, and clinical impact.
Curr Opin Urol. 2025;35:543-548.
Abstract
Hyperthermic intravesical chemotherapy for Bacillus Calmette-Guerin-unresponsive
nonmuscle-invasive bladder cancer.
Curr Opin Urol. 2025 Aug 14. doi: 10.1097/MOU.0000000000001329.
Abstract
Antibody-drug conjugates for non-muscle invasive bladder cancer: current status
and future development.
Curr Opin Urol. 2025 Aug 25. doi: 10.1097/MOU.0000000000001330.
Abstract
Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and
future directions.
Curr Opin Urol. 2025 Sep 8. doi: 10.1097/MOU.0000000000001331.
Abstract
Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer.
Curr Opin Urol. 2025 Sep 15. doi: 10.1097/MOU.0000000000001334.
Abstract
Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer:
mechanisms, clinical evidence, and practical implementation.
Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001345.
Abstract
Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive
bladder cancer: a narrative review.
Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001343.
Abstract
Development of an artificial intelligence-generated, explainable treatment
recommendation system for urothelial carcinoma and renal cell carcinoma to
support multidisciplinary cancer conferences.
Eur J Cancer. 2025;220:115367.
Abstract
Cost-effectiveness analysis of perioperative durvalumab plus platin-based
chemotherapy in muscle invasive bladder cancer in Germany.
Eur J Cancer. 2025;227:115621.
Abstract
The Financial Burden of Localized and Metastatic Bladder Cancer.
Eur Urol. 2024 Dec 26:S0302-2838(24)02744-1. doi: 10.1016/j.eururo.2024.
Abstract
Re: Robert Huddart, Shaista Hafeez, Clare Griffin, et al. Dose-escalated Adaptive
Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomized
Controlled Trial. Eur Urol 2025;87:60-70.
Eur Urol. 2025 Jan 21:S0302-2838(25)00007-7. doi: 10.1016/j.eururo.2024.
Abstract
Bladder Cancer Recurrence Following Management of Upper Tract Urothelial
Carcinoma: Balancing Prevention and Iatrogenicity.
Eur Urol. 2025 Jan 21:S0302-2838(25)00015-6. doi: 10.1016/j.eururo.2025.
Abstract
Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive
Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
Eur Urol. 2025 Jan 17:S0302-2838(24)02785-4. doi: 10.1016/j.eururo.2024.
Abstract
The Cost of Bladder Cancer: What Can Be Done?
Eur Urol. 2025 Jan 28:S0302-2838(25)00017-X. doi: 10.1016/j.eururo.2025.
Abstract
Re: Standard or Extended Lymphadenectomy for Muscle-invasive Bladder Cancer.
Eur Urol. 2025 Jan 27:S0302-2838(25)00020-X. doi: 10.1016/j.eururo.2025.
Abstract
FGFR Inhibition in Urothelial Carcinoma.
Eur Urol. 2025;87:110-122.
Abstract
Re: Characterizing Psychological Resources and Resilience in Patients with
Bladder Cancer: Associations with Frailty and Quality of Life.
Eur Urol. 2025 Feb 3:S0302-2838(25)00022-3. doi: 10.1016/j.eururo.2025.
Abstract
Why We Need More Attention on Bladder Cancer: Establishing Policy Recommendations
for Health Care Professionals and Politicians.
Eur Urol. 2025 Feb 19:S0302-2838(25)00095-8. doi: 10.1016/j.eururo.2025.
Abstract
Re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of
Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and
Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision
of the Amer
Eur Urol. 2025 Feb 27:S0302-2838(25)00120-4. doi: 10.1016/j.eururo.2025.
Abstract
Re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of
Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In
Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49.
Eur Urol. 2025 Mar 11:S0302-2838(25)00125-3. doi: 10.1016/j.eururo.2025.
Abstract
Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia
and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle,
Otakar Capoun, et al. European Association of Urology Guidelines on
Non-muscle-invasive Bla
Eur Urol. 2025 Mar 11:S0302-2838(25)00140-X. doi: 10.1016/j.eururo.2025.
Abstract
Re: Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for
Muscle-Invasive Bladder Cancer (RETAIN 1).
Eur Urol. 2025 Mar 10:S0302-2838(25)00132-0. doi: 10.1016/j.eururo.2025.
Abstract
European Association of Urology Guidelines on Muscle-invasive and Metastatic
Bladder Cancer: Summary of the 2025 Guidelines.
Eur Urol. 2025 Mar 17:S0302-2838(25)00138-1. doi: 10.1016/j.eururo.2025.
Abstract
Reply to Alexandra Masson-Lecomte. Bladder Cancer Recurrence Following Management
of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity. Eur
Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.004.
Eur Urol. 2025 Mar 17:S0302-2838(25)00151-4. doi: 10.1016/j.eururo.2025.
Abstract
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial
Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Eur Urol. 2025;87:390-395.
Abstract
Towards Epigenetic-based Subtyping of Bladder Cancer: DNA Methylation Predicts
Molecular Subtypes of Non-muscle-invasive Bladder Cancer.
Eur Urol. 2025 Mar 7:S0302-2838(25)00126-5. doi: 10.1016/j.eururo.2025.
Abstract
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer:
Recommendations from the International Bladder Cancer Group.
Eur Urol. 2025 Apr 22:S0302-2838(25)00189-7. doi: 10.1016/j.eururo.2025.
Abstract
A Systematic Review of Novel Intravesical Approaches for the Treatment of
Patients with Non-muscle-invasive Bladder Cancer.
Eur Urol. 2025 Apr 18:S0302-2838(25)00123-X. doi: 10.1016/j.eururo.2025.
Abstract
Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be
Adapted?
Eur Urol. 2025 Apr 25:S0302-2838(25)00218-0. doi: 10.1016/j.eururo.2025.
Abstract
Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini,
and Andrea Salonia's Letter to the Editor re: Valeria Panebianco, Alberto
Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance
Imaging and t
Eur Urol. 2025 Apr 24:S0302-2838(25)00199-X. doi: 10.1016/j.eururo.2025.
Abstract
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding
Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the
Randomized Controlled DaBlaCa-15 Trial.
Eur Urol. 2025 Apr 24:S0302-2838(25)00191-5. doi: 10.1016/j.eururo.2025.
Abstract
Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al.
Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer:
Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol
2024;42:4095-102.
Eur Urol. 2025 May 3:S0302-2838(25)00250-7. doi: 10.1016/j.eururo.2025.
Abstract
Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer:
Real-World Data Challenge the Guideline Recommendation for Upfront Radical
Cystectomy.
Eur Urol. 2025 May 14:S0302-2838(25)00283-0. doi: 10.1016/j.eururo.2025.
Abstract
Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for
Patients with Non-muscle-invasive Bladder Cancer?
Eur Urol. 2025 May 10:S0302-2838(25)00268-4. doi: 10.1016/j.eururo.2025.
Abstract
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with
Atezolizumab for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive
Bladder Cancer.
Eur Urol. 2025 May 21:S0302-2838(25)00217-9. doi: 10.1016/j.eururo.2025.
Abstract
Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral
Resection for Staging New Bladder Cancers: Results from the Prospective
BladderPath Trial.
Eur Urol. 2025 May 19:S0302-2838(25)00290-8. doi: 10.1016/j.eururo.2025.
Abstract
Subtypes and Sequencing in Bladder Cancer: Powering Personalised Treatment or
Extraneous Information?
Eur Urol. 2025 May 16:S0302-2838(25)00277-5. doi: 10.1016/j.eururo.2025.
Abstract
Re: Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer:
Results from Phase II Protocol NRG Oncology/RTOG 0926.
Eur Urol. 2025 Jun 10:S0302-2838(25)00326-4. doi: 10.1016/j.eururo.2025.
Abstract
Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder
Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled
DaBlaCa-15 Trial. Eur
Eur Urol. 2025 Jun 7:S0302-2838(25)00339-2. doi: 10.1016/j.eururo.2025.
Abstract
Computational Histology Artificial Intelligence (CHAI) Enhances Risk
Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a
Multicenter Cohort: Comparison to Current European Association of Urology and
American Urological Association
Eur Urol. 2025 Jun 12:S0302-2838(25)00338-0. doi: 10.1016/j.eururo.2025.
Abstract
Reply to Xin Rui, Xiaoming Xu, and Bo Dai's Letter to the Editor re: Thomas
Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer
Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive Bladder Canc
Eur Urol. 2025 Jun 24:S0302-2838(25)00348-3. doi: 10.1016/j.eururo.2025.
Abstract
Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant
Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer
Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.
Eur Urol. 2025 Jul 1:S0302-2838(25)00342-2. doi: 10.1016/j.eururo.2025.
Abstract
Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A
Phase 1b Trial.
Eur Urol. 2025 Jul 28:S0302-2838(25)00406-3. doi: 10.1016/j.eururo.2025.
Abstract
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin,
and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder
Cancer: A Phase 2 Trial.
Eur Urol. 2025 Aug 4:S0302-2838(25)00391-4. doi: 10.1016/j.eururo.2025.
Abstract
Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of
Residual Bladder Cancer: A First-in-Human Study.
Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025.
Abstract
Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic
Subtypes of Bladder Cancer.
Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025.
Abstract
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph
Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025.
Abstract
A novel mouse model of upper tract urothelial carcinoma highlights the impact of
dietary intervention on gut microbiota and carcinogenesis prevention despite
carcinogen exposure.
Int J Cancer. 2025;156:1439-1456.
Abstract
RETRACTION: Circular RNA CEP128 Promotes Bladder Cancer Progression by Regulating
Mir-145-5p/Myd88 via MAPK Signaling Pathway.
Int J Cancer. 2025 Feb 28. doi: 10.1002/ijc.35391.
Abstract
Physical activity and risks of recurrence and progression among patients with
non-muscle invasive bladder cancer.
Int J Cancer. 2025 Jun 30. doi: 10.1002/ijc.70030.
Abstract
Loss of METTL3 m6A methyltransferase results in short-term progression and poor
treatment outcome of bladder cancer patients.
Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70147.
Abstract
Unleashing the power of urine?based biomarkers in diagnosis, prognosis and
monitoring of bladder cancer (Review).
Int J Oncol. 2025;66:18.
Abstract
Mechanism of SMYD2 promoting stemness maintenance of bladder cancer stem cells by
regulating PYCR1 expression and PINK1/Parkin mitophagy pathway.
Int J Oncol. 2025;66:41.
Abstract
alpha(1)-Blockers as a risk factor for hypotension in combination with oral
5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
Int J Urol. 2025 Jan 3. doi: 10.1111/iju.15655.
Abstract
Editorial Comment from Dr Miyake to alpha1-blockers as a risk factor for hypotension
in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in
patients with bladder cancer.
Int J Urol. 2025 Jan 28. doi: 10.1111/iju.15687.
Abstract
Stage III substaging and outcomes in patients with bladder cancer undergoing
radical cystectomy.
Int J Urol. 2025 Feb 5. doi: 10.1111/iju.70005.
Abstract
Differential Risk Factors for Early Intravesical Recurrence After Radical
Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of
Non-Muscle Invasive Bladder Cancer.
Int J Urol. 2025 Feb 13. doi: 10.1111/iju.70009.
Abstract
Editorial Comment to "Differential Risk Factors for Early Intravesical Recurrence
After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to
the History of Nonmuscle Invasive Bladder Cancer".
Int J Urol. 2025 Mar 3. doi: 10.1111/iju.70028.
Abstract
Patient Preferences for Post-Radical Cystectomy Treatment in Muscle-Invasive
Bladder Cancer: A Discrete Choice Experiment in Japan.
Int J Urol. 2025 Mar 10. doi: 10.1111/iju.70032.
Abstract
Physical, but not laboratory, treatment-related adverse events are associated
with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma:
A landmark analysis.
Int J Urol. 2025;32:270-276.
Abstract
Pathological Analysis of False-Positive Samples in Photodynamic Diagnosis of
Bladder Cancer According to a History of Intravesical Bacillus Calmette-Guerin
Therapy.
Int J Urol. 2025 Mar 26. doi: 10.1111/iju.70045.
Abstract
Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival
of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?
Int J Urol. 2025 Apr 11. doi: 10.1111/iju.70064.
Abstract
Bowel regimens before radical cystectomy: An analysis of a modern cohort.
Int J Urol. 2025;32:402-408.
Abstract
The effect of neoadjuvant chemotherapy on survival outcomes in patients with
variant histologies who underwent radical cystectomy with precystectomy
diagnostic accuracy: A multicenter study of the Turkish Urooncology Association.
Int J Urol. 2025;32:508-515.
Abstract
Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and
Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter
Retrospective Study.
Int J Urol. 2025 May 1. doi: 10.1111/iju.70087.
Abstract
Influence of best objective response to first-line treatment on survival outcomes
in advanced urothelial carcinoma in the era of sequential therapy with enfortumab
vedotin.
Int J Urol. 2025;32:524-530.
Abstract
Impact of lymph node dissection during surgery on the efficacy of pembrolizumab
in patients with metastatic urothelial carcinoma.
Int J Urol. 2025;32:593-597.
Abstract
The usefulness of transarterial embolization before transurethral resection of
bladder tumor for patients with large bladder tumors.
Int J Urol. 2025;32:488-492.
Abstract
Trends in age and antithrombotic therapy in patients who underwent transurethral
resection of bladder tumor and perioperative complications.
Int J Urol. 2025;32:516-523.
Abstract
Editorial Comment From Dr. Miyake to Effects of Robot-Assisted Radical Cystectomy
on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive
Bladder Cancer: A Multicenter Retrospective Study.
Int J Urol. 2025 May 15. doi: 10.1111/iju.70112.
Abstract
PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in
Muscle-Invasive Bladder Cancer.
Int J Urol. 2025 May 23. doi: 10.1111/iju.70122.
Abstract
Preoperative Pyuria as a Predictor of False-Positive Rates in the Photodynamic
Diagnosis of Nonmuscle-Invasive Bladder Cancer Using Oral 5-Aminolevulinic Acid.
Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70134.
Abstract
Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy
of Bacillus Calmette-Guerin Therapy for Bladder Carcinoma In Situ.
Int J Urol. 2025;32:737-746.
Abstract
Outcomes of Second Resection Following Conventional Initial Transurethral
Resection of Bladder Tumors.
Int J Urol. 2025;32:720-726.
Abstract
Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients
Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to
Receiving Enfortumab Vedotin: A Real-World Evidence Study.
Int J Urol. 2025;32:650-657.
Abstract
Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or
Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World
Multicenter Study.
Int J Urol. 2025;32:679-685.
Abstract
Recent Advances and Future Directions in Bladder Preservation Therapy for
Muscle-Invasive Bladder Cancer.
Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70164.
Abstract
Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder
Cancer.
Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70119.
Abstract
Efficacy of Metastasectomy for Metastatic Bladder Cancer: A Systematic Review and
Meta-Analysis.
Int J Urol. 2025 Jul 9. doi: 10.1111/iju.70176.
Abstract
Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous
Thromboembolism After Robot-Assisted Radical Cystectomy.
Int J Urol. 2025;32:839-847.
Abstract
Editorial Comment on "Recent Advances and Future Directions in Bladder
Preservation Therapy for Muscle-Invasive Bladder Cancer".
Int J Urol. 2025 Jul 27. doi: 10.1111/iju.70184.
Abstract
The Xing Technique for Intracorporeal Ileal Conduit: Outcomes From a Single
Center.
Int J Urol. 2025;32:1034-1038.
Abstract
Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic
Urothelial Carcinoma Is a Prognostic Factor for Avelumab Maintenance Therapy: A
Multicenter Retrospective Study.
Int J Urol. 2025;32:997-1004.
Abstract
Geriatric Nutritional Risk Index Predicts Postoperative Complications in Elderly
Patients Undergoing Robot-Assisted Radical Cystectomy.
Int J Urol. 2025;32:944-950.
Abstract
Re: Recent Advances and Future Directions in Bladder Preservation Therapy for
Muscle-Invasive Bladder Cancer.
Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70199.
Abstract
Open Versus Robotic Radical Cystectomy With Intracorporeal Neobladder: A
Decade-Long Single-Surgeon Experience.
Int J Urol. 2025;32:1234-1242.
Abstract
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in
Patients With Advanced Urothelial Carcinoma Treated With First-Line
Platinum-Based Chemotherapy: A Multicenter Collaborative Study.
Int J Urol. 2025;32:1147-1156.
Abstract
RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and
Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of
Signal Transducer and Activator of Transcription 3.
Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224.
Abstract
The effect of intravesical chemohyperthermia with mitomycin in
non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or
recur after treatment and refuse cystectomy.
Int Urol Nephrol. 2025;57:63-69.
Abstract
Clinical significance of a new early diagnostic model for bladder cancer based on
genome-wide microarray profiling of serum exosomal lncRNAs.
Int Urol Nephrol. 2025 Jan 7. doi: 10.1007/s11255-024-04360.
Abstract
Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a
retrospective multicenter European study.
Int Urol Nephrol. 2025 Feb 11. doi: 10.1007/s11255-025-04416.
Abstract
Artificial intelligence algorithms enhance urine cytology reporting confidence in
postoperative follow-up for upper urinary tract urothelial carcinoma.
Int Urol Nephrol. 2025;57:801-808.
Abstract
Intravesical gemcitabine versus anthracyclines for primary and first recurrent
non-muscle-invasive bladder cancer: a single-center retrospective study over
10 years.
Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04413.
Abstract
Exploring the impact of chronotype, chrononutrition and lifestyle on bladder
cancer.
Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04371.
Abstract
Overexpression of BMAL-1 is related to progression of urothelial carcinoma in
arsenic exposure area.
Int Urol Nephrol. 2025;57:1175-1187.
Abstract
PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the
bladder.
Int Urol Nephrol. 2025;57:1381-1388.
Abstract
The role of angiogenin in bladder cancer: where are we in 2025?
Int Urol Nephrol. 2025 Apr 22. doi: 10.1007/s11255-025-04517.
Abstract
DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11
expression by methylating its promoter.
Int Urol Nephrol. 2025 May 2. doi: 10.1007/s11255-025-04527.
Abstract
Oncological outcomes after non-surgical management versus radical cystectomy in
non-organ-confined non-urothelial bladder cancer.
Int Urol Nephrol. 2025 May 7. doi: 10.1007/s11255-025-04566.
Abstract
The nephroprotective effect of metformin with cisplatin in bladder cancer:
randomized clinical trial.
Int Urol Nephrol. 2025 May 3. doi: 10.1007/s11255-025-04505.
Abstract
Previous maximal transurethral resection of bladder tumor lead to unfavorable
perioperative outcomes following radical cystectomy.
Int Urol Nephrol. 2025;57:1817-1826.
Abstract
A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation
therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data
analysis.
Int Urol Nephrol. 2025 May 14. doi: 10.1007/s11255-025-04567.
Abstract
Comparison of microRNA-21 expression in bladder cancer tumor with
normal-appearing adjacent tissue and healthy controls.
Int Urol Nephrol. 2025 Jun 13. doi: 10.1007/s11255-025-04581.
Abstract
Prognostic factors in T1 high-grade urothelial carcinoma of the bladder with
lymphovascular invasion: a retrospective cohort study.
Int Urol Nephrol. 2025;57:2099-2105.
Abstract
Intravesical administration of highly concentrated hyaluronic acid and
chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus
Calmette-Guerin (BCG) immunotherapy.
Int Urol Nephrol. 2025;57:2033-2039.
Abstract
Artificial intelligence for rare bladder cancer variants: a new hope for
detection?
Int Urol Nephrol. 2025 Jul 4. doi: 10.1007/s11255-025-04647.
Abstract
A cross-sectional study on the effects of intravesical BCG on urinary microbiota
in bladder cancer patients.
Int Urol Nephrol. 2025 Jun 30. doi: 10.1007/s11255-025-04607.
Abstract
Assessment of quality of life in patients undergoing hyperthermic intravesical
chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24).
Int Urol Nephrol. 2025;57:2415-2423.
Abstract
High-density lectin microarray uncovers stage-specific plasma glycoprofiling
signatures for non-muscle-invasive and muscle-invasive bladder cancer.
Int Urol Nephrol. 2025 Aug 10. doi: 10.1007/s11255-025-04708.
Abstract
Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional
TURBT for NMIBC: a comparative study.
Int Urol Nephrol. 2025;57:2755-2765.
Abstract
Two different protocols in single, immediate, postoperative intravesical
chemotherapy after transurethral resection in suspected, low-risk,
non-muscle-invasive bladder cancer.
Int Urol Nephrol. 2025 Aug 28. doi: 10.1007/s11255-025-04767.
Abstract
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral
Resection for Staging New Bladder Cancers: Results From the Prospective
BladderPath Trial.
J Clin Oncol. 2025 Jan 14:JCO2302398. doi: 10.1200/JCO.23.02398.
Abstract
Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging
Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder
Cancer?
J Clin Oncol. 2025 Feb 5:JCO2402482. doi: 10.1200/JCO-24-02482.
Abstract
Errata: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral
Resection for Staging New Bladder Cancers: Results From the Prospective
BladderPath Trial.
J Clin Oncol. 2025 Apr 23:JCO2500779. doi: 10.1200/JCO-25-00779.
Abstract
TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive
Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
J Clin Oncol. 2025 Jul 30:101200JCO2501651. doi: 10.1200/JCO-25-01651.
Abstract
Muscle-Invasive Bladder Cancer: A Watershed Moment.
J Clin Oncol. 2025 Aug 5:JCO2500718. doi: 10.1200/JCO-25-00718.
Abstract
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for
Patients With Muscle-Invasive Bladder Cancer.
J Clin Oncol. 2025 Sep 11:JCO2501608. doi: 10.1200/JCO-25-01608.
Abstract
Erratum: TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk
Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
J Clin Oncol. 2025 Sep 9:JCO2502053. doi: 10.1200/JCO-25-02053.
Abstract
Artificial Intelligence-Based Assessment of Preoperative Body Composition Is
Associated With Early Complications After Radical Cystectomy.
J Urol. 2025;213:228-237.
Abstract
Letter: Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO
Guideline: 2024 Amendment.
J Urol. 2025 Feb 7:101097JU0000000000004431. doi: 10.1097/JU.0000000000004431.
Abstract
Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in
Treatment-Naive Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer.
J Urol. 2025 Feb 10:101097JU0000000000004472. doi: 10.1097/JU.0000000000004472.
Abstract
Reply: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO
Guideline: 2024 Amendment.
J Urol. 2025 Feb 10:101097JU0000000000004452. doi: 10.1097/JU.0000000000004452.
Abstract
Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted
Radical Cystectomy With Intracorporeal Ileal Conduit.
J Urol. 2025;213:437-446.
Abstract
Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding,
Thromboembolism, and Survival Outcomes.
J Urol. 2025;213:447-454.
Abstract
Perceived Impact on Patient Routines/Responsibilities for Surgery and a
Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk
Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial.
J Urol. 2025 Mar 6:101097JU0000000000004511. doi: 10.1097/JU.0000000000004511.
Abstract
Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage Of Two
Grading Systems.
J Urol. 2025 Mar 25:101097JU0000000000004542. doi: 10.1097/JU.0000000000004542.
Abstract
AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated
Non-muscle Invasive Bladder Cancer.
J Urol. 2025 Apr 16:101097JU0000000000004541. doi: 10.1097/JU.0000000000004541.
Abstract
Letter: Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage of 2
Grading Systems.
J Urol. 2025 Apr 15:101097JU0000000000004555. doi: 10.1097/JU.0000000000004555.
Abstract
Comparison of Complication and Readmission Rates Between Robot-Assisted and Open
Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.
J Urol. 2025;213:684-692.
Abstract
Non-modifiable drivers of BCG response: Considerations of age, sex and chronic
inflammation for the management of non-muscle invasive bladder cancer.
J Urol. 2025 Jun 10:101097JU0000000000004632. doi: 10.1097/JU.0000000000004632.
Abstract
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During
Intravesical Administration of Nadofaragene Firadenovec for BCG-Unresponsive
Non-Muscle-Invasive Bladder Cancer.
J Urol. 2025 Jun 26:101097JU0000000000004658. doi: 10.1097/JU.0000000000004658.
Abstract
Do Prophylactic Antibiotics Decrease the Rate of Urinary Tract Infections after
Robot-Assisted Radical Cystectomy? A Randomized Controlled Trial.
J Urol. 2025 Apr 25:101097JU0000000000004586. doi: 10.1097/JU.0000000000004586.
Abstract
IP11-07 A 3D Tumor Map for the Surgical Management of Bladder Cancer: Feasibility
and Preliminary Analysis: Erratum.
J Urol. 2025;214:458.
Abstract
Protein disulfide isomerase-enriched extracellular vesicles from bladder cancer
cells support tumor survival and malignant transformation in the bladder.
Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03380.
Abstract
Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through
destabilizing cytoplasmic KDM3A.
Oncogene. 2025 Apr 19. doi: 10.1038/s41388-025-03410.
Abstract
PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model
harboring p53 missense mutations.
Oncogene. 2025;44:1336-1349.
Abstract
Crosstalk between SUMOylation and ubiquitination controls the stability of
transcription factor zinc finger protein 24: a novel antitumor mechanism in
bladder cancer.
Oncogene. 2025 May 28. doi: 10.1038/s41388-025-03450.
Abstract
SFXN1 promotes bladder cancer metastasis by restraining PINK1-dependent
mitophagy.
Oncogene. 2025 Jun 4. doi: 10.1038/s41388-025-03460.
Abstract
ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via
53BP1 acetylation.
Oncogene. 2025 Jul 1. doi: 10.1038/s41388-025-03474.
Abstract
Retraction Note: Non-classic deubiquitinase USP13 inhibits bladder cancer
metastasis through destabilizing cytoplasmic KDM3A.
Oncogene. 2025 Jul 30. doi: 10.1038/s41388-025-03520.
Abstract
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament
network and focal adhesion.
Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03557.
Abstract
Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer
angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and
enhancing NCF2 transcription.
Oncogene. 2025 Sep 17. doi: 10.1038/s41388-025-03575.
Abstract
Prognostic Significance of Albumin-Globulin Ratio in Urachal Carcinoma.
Urol Int. 2025;109:8-17.
Abstract
Patient-Derived Bladder Cancer Organoids: Model Construction and Drug Sensitivity
Testing.
Urol Int. 2025 Feb 10:1-16. doi: 10.1159/000543983.
Abstract
The role of radical cystectomy with orthotopic neobladder reconstruction in
patients developing bladder cancer after prior radical prostatectomy, radiation
therapy or BPH surgery.
Urol Int. 2025 Mar 6:1-17. doi: 10.1159/000545103.
Abstract
Anti-Reflux Ureteroileal Anastomosis for Orthotopic Ileal Neobladder Using
Wallace Technique in a Single Trough.
Urol Int. 2025;109:182-188.
Abstract
A rare case of a plasmacytoid and sarcomatoid differentiated urothelial bladder
carcinoma with a single metastasis to the right ventricle of the heart and rapid
review of single heart metastasis in bladder cancer.
Urol Int. 2025 Apr 26:1-15. doi: 10.1159/000546149.
Abstract
The value of circulating tumor DNA in the prognostic diagnosis of bladder cancer:
a systematic review and meta-analysis.
Urol Int. 2025 May 2:1-17. doi: 10.1159/000546014.
Abstract
The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A
Single-Center Experience.
Urol Int. 2025;109:361-371.
Abstract
Does Time Matter in Early Radical Cystectomy? Comparing Outcome, Clinical, and
Pathological Characteristics of Immediate versus Deferred Radical Cystectomy.
Urol Int. 2025;109:315-322.
Abstract
Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial
Carcinoma of the Bladder: 20 Years of Experience in a Tertiary Center.
Urol Int. 2025;109:337-345.
Abstract
Gender-Specific Differences in Recurrence and Progression following Bacillus
Calmette-Guerin Instillation for Non-Muscle-Invasive Bladder Cancer.
Urol Int. 2025;109:412-424.
Abstract
A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG
in the treatment of non-muscle invasive naive urinary bladder cancer: A
systematic review and meta-analysis of oncological outcomes.
Urology. 2025 Jan 9:S0090-4295(25)00006-8. doi: 10.1016/j.urology.2025.
Abstract
Comment on "Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive
Bladder Cancer: A Systematic Review and Meta-analysis".
Urology. 2025 Jan 29:S0090-4295(25)00008-1. doi: 10.1016/j.urology.2025.
Abstract
Editorial comment on "A comparison between intravesical Gemcitabine plus
Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive
urinary bladder cancer: A systematic review and meta-analysis of oncological
outcomes".
Urology. 2025 Feb 10:S0090-4295(25)00139-6. doi: 10.1016/j.urology.2025.
Abstract
Editorial Comment on "A comparison between intravesical Gemcitabine plus
Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive
urinary bladder cancer: A systematic review and meta-analysis of oncological
outcomes".
Urology. 2025 Feb 19:S0090-4295(25)00176-1. doi: 10.1016/j.urology.2025.
Abstract
Survival outcomes and temporal trends of non-surgical management versus radical
cystectomy in non-organ-confined urothelial bladder cancer.
Urology. 2025 Mar 6:S0090-4295(25)00216-X. doi: 10.1016/j.urology.2025.
Abstract
Effect of Bacillus Calmette-Guerin Instillation Timing on Oncological Survivals
After Transurethral Resection of Bladder Tumor.
Urology. 2025;197:126-132.
Abstract
Optimizing Care for Women through Gynecologic Organ Considerations During
Cystectomy: A Pre-Operative Checklist of Important Considerations.
Urology. 2024 Nov 28:S0090-4295(24)01095-1. doi: 10.1016/j.urology.2024.
Abstract
Real-World Economic Burden and Healthcare Resource Utilization of Radical
Cystectomy and Trimodal Therapy for Bladder Cancer in the United States.
Urology. 2025 Mar 21:S0090-4295(25)00280-8. doi: 10.1016/j.urology.2025.
Abstract
Tailoring Cystoscopy Surveillance: Addressing the Needs of Frail Bladder Cancer
Patients.
Urology. 2025 Mar 21:S0090-4295(25)00253-5. doi: 10.1016/j.urology.2025.
Abstract
The (Re) evolution in the treatment of bladder cancer.
Urology. 2025 Mar 21:S0090-4295(25)00287-0. doi: 10.1016/j.urology.2025.
Abstract
Editorial Comment on "Real-World Economic Burden and Healthcare Resource
Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the
United States".
Urology. 2025 Apr 7:S0090-4295(25)00317-6. doi: 10.1016/j.urology.2025.
Abstract
Editorial comments on Survival outcomes and temporal trends of non-surgical
management versus radical cystectomy in non-organ-confined urothelial bladder
cancer.
Urology. 2025 Apr 4:S0090-4295(25)00319-X. doi: 10.1016/j.urology.2025.
Abstract
Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An
International Multi-Institutional Study Comparing Isolated Nodal Disease versus
Persistent Muscle-Invasive Disease.
Urology. 2025 Apr 16:S0090-4295(25)00345-0. doi: 10.1016/j.urology.2025.
Abstract
Reply to Editorial Comment on "Survival Outcomes And Temporal Trends Of
Non-Surgical Management Versus Radical Cystectomy In Non-Organ-Confined
Urothelial Bladder Cancer".
Urology. 2025 Apr 15:S0090-4295(25)00341-3. doi: 10.1016/j.urology.2025.
Abstract
Detection Of High-Grade Bladder Cancer In Urine Samples Using In Situ
Hybridization Of Long Non-Coding RNA UCA1.
Urology. 2025 May 13:S0090-4295(25)00468-6. doi: 10.1016/j.urology.2025.
Abstract
Letter to the Editor on "A Comparison Between Intravesical Gemcitabine Plus
Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle
Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of
Oncological O
Urology. 2025 May 29:S0090-4295(25)00513-8. doi: 10.1016/j.urology.2025.
Abstract
Inflammatory Myofibroblastic Tumor of the Bladder in Childhood: A Three Case
Series.
Urology. 2025;200:e72-e75.
Abstract
Reply to editor comment on "A Comparison Between Intravesical Gemcitabine Plus
Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle
Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of
Oncologica
Urology. 2025 Jun 16:S0090-4295(25)00600-4. doi: 10.1016/j.urology.2025.
Abstract
Disparities in Access to High Volume Centers for Muscle Invasive Bladder Cancer
and its Association With Treatment Patterns and Outcomes.
Urology. 2025 Jun 12:S0090-4295(25)00595-3. doi: 10.1016/j.urology.2025.
Abstract
Effect of Sex Differences on Cancer Outcomes after Chemo-Radiation for
Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study.
Urology. 2025 Jun 28:S0090-4295(25)00636-3. doi: 10.1016/j.urology.2025.
Abstract
Treatment Patterns for Non-Muscle Invasive Bladder Cancer during the Bacillus
Calmette-Guerin shortage.
Urology. 2025 Jul 23:S0090-4295(25)00711-3. doi: 10.1016/j.urology.2025.
Abstract
Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era:
A Patient Preference Study.
Urology. 2025 Aug 12:S0090-4295(25)00767-8. doi: 10.1016/j.urology.2025.
Abstract
Editorial Comment: Muscle-Invasive Bladder Cancer Treatment Selection in an
Emerging Treatment Era: A Patient Preference Study.
Urology. 2025 Sep 4:S0090-4295(25)00838-6. doi: 10.1016/j.urology.2025.
Abstract
Evaluation of the association between lymph node ratio and long-term survival in
patients after surgery for lymph node-positive bladder cancer: a SEER
population-based study with external validation.
BMC Cancer. 2025;25:135.
Abstract
Clinical outcomes of nephroureterectomy with bladder cuff excision or radical
cystectomy for distal ureteral carcinoma invaded muscle of the ureteral orifice.
BMC Cancer. 2025;25:221.
Abstract
Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1
inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1
multicenter, open-label, single-arm clinical trial.
BMC Cancer. 2025;25:195.
Abstract
Multi-omics analysis reveals the impact of YAP/TEAD4-mediated EIF5A1 expression
on mitochondrial apoptosis and bladder cancer progression.
BMC Cancer. 2025;25:234.
Abstract
Small non-coding RNA profiling in patients with non-muscle invasive bladder
cancer.
BMC Cancer. 2025;25:319.
Abstract
Pathology-based deep learning features for predicting basal and luminal subtypes
in bladder cancer.
BMC Cancer. 2025;25:310.
Abstract
Senescence-specific molecular subtypes stratify the hallmarks of the tumor
microenvironment and guide precision medicine in bladder cancer.
BMC Cancer. 2025;25:297.
Abstract
Urine proteomics-based analysis identifies CHI3L1 as an immune marker and
potential therapeutic target for bladder cancer.
BMC Cancer. 2025;25:271.
Abstract
Intravesical chemotherapy in BCG waiting period may prolong time to recurrence
for high-risk NMIBC patients.
BMC Cancer. 2025;25:268.
Abstract
The role of urinary microbiota in primary and recurrent bladder cancer: insights
from a propensity score matching study.
BMC Cancer. 2025;25:468.
Abstract
Risk factors for in-hospital venous thromboembolism in patients with bladder
cancer: A retrospective single-center study.
BMC Cancer. 2025;25:536.
Abstract
Single-cell sequencing combined with urinary multi-omics analysis reveals that
the non-invasive biomarker PRDX5 regulates bladder cancer progression through
ferroptosis signaling.
BMC Cancer. 2025;25:533.
Abstract
Using machine learning for predicting cancer-specific mortality in bladder cancer
patients undergoing radical cystectomy: a SEER-based study.
BMC Cancer. 2025;25:523.
Abstract
Machine learning-based characterization of stemness features and construction of
a stemness subtype classifier for bladder cancer.
BMC Cancer. 2025;25:717.
Abstract
The role of CDK8 gene polymorphisms in bladder cancer susceptibility and
prognosis: a study in the Chinese Han population.
BMC Cancer. 2025;25:714.
Abstract
Loss of chromosome Y is unrelated to the composition of the tumor
microenvironment and patient prognosis in muscle-invasive urothelial bladder
cancers.
BMC Cancer. 2025;25:677.
Abstract
ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT
signaling.
BMC Cancer. 2025;25:789.
Abstract
Clinicopathological characteristics of transcription factor-defined subtypes in
bladder small cell carcinoma.
BMC Cancer. 2025;25:766.
Abstract
Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab
Vedotin combined with Toripalimab and pelvic lymph node dissection in
muscle-invasive bladder cancer patients: study protocol of a multicenter
single-arm phase II trial.
BMC Cancer. 2025;25:868.
Abstract
Novel Gene expression-based Risk Stratification tool predicts recurrence in
Non-muscle invasive Bladder cancer.
BMC Cancer. 2025;25:916.
Abstract
Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer
analysis.
BMC Cancer. 2025;25:932.
Abstract
Effects of functional antioxidants on the expansion of gamma delta T-cells and
their cellular cytotoxicity against bladder cancer cells.
BMC Cancer. 2025;25:980.
Abstract
Multi-machine learning model based on radiomics features to predict prognosis of
muscle-invasive bladder cancer.
BMC Cancer. 2025;25:1116.
Abstract
BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
BMC Cancer. 2025;25:1057.
Abstract
Droplet digital PCR assay for precise determination of FRS2 gene copy number in
bladder cancer.
BMC Cancer. 2025;25:1211.
Abstract
Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer
immunotherapy by inhibiting CD276 expression.
BMC Cancer. 2025;25:1404.
Abstract
Notch2/3-DLL4 interaction in urothelial cancer cell lines supports a tumorigenic
role of Notch signaling pathways in bladder carcinoma.
PLoS One. 2025;20:e0317709.
Abstract
Preoperative antihypertensives and hypotension during bladder tumor resection
with oral 5-aminolevulinic acid administration.
PLoS One. 2025;20:e0319413.
Abstract
Gender disparities in bladder cancer: A population-based study on life expectancy
and health spending in Asia.
PLoS One. 2025;20:e0323803.
Abstract
Association between CYP17A1 rs743572 polymorphism and cancer risk: A
meta-analysis.
PLoS One. 2025;20:e0326843.
Abstract
Deep learning-based spatial analysis on tumor and immune cells of pathology
images predicts MIBC prognosis.
PLoS One. 2025;20:e0328816.
Abstract
CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism
contributing to therapeutic resistance in T24 cells.
PLoS One. 2025;20:e0331289.
Abstract
Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
PLoS One. 2025;20:e0332825.
Abstract
Thank you for your interest in scientific medicine.
